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THESIS ABSTRACT
Isolation, identification and characterisation of Enterococcus faecalis
isolates for the generation of multifunctional bioactive peptides from
milk
Ken Graham, B.Sc.
Enterococci are lactic acid bacteria (LAB) that have the paradoxical position of
possessing biochemical properties of technological importance, but are also considered
as opportunistic pathogens capable of causing infection in immunocompromised patients.
However, they have a long history of safe use in foods and have been evaluated in several
studies for their role as starter, adjunct, probiotic and protective cultures. They show
higher proteolytic activities than other LAB and have demonstrated the ability to produce
bioactive peptides during the fermentation of milk. The aim of this project was to identify
proteolytic Enterococcus faecalis isolates capable of generating health-promoting
bioactive peptides during the fermentation of bovine skim milk. Twenty-five E. faecalis
strains were isolated using Kanamycin Skim Milk Aesculin Azide (KSMEA) agar, a
selective and differential growth medium developed in this work for the isolation of
proteolytic enterococci. The isolates were assessed for proteolytic activity and putative
pathogenic traits to assess their suitability for use in milk fermentations. E. faecalis
DPC5154 proved the most promising strain, demonstrating the highest level of proteolytic
activity, sensitivity to all eleven antibiotics used and harboured few virulence
determinants. The DPC5154 milk fermentate displayed the highest antioxidant,
angiotensin converting enzyme inhibitory (ACEI) and α-glucosidase inhibitory (α-GI)
activity. Further analysis of the DPC5154 fermentate by RP-HPLC and mass
spectrometry resulted in the identification of three β-casein-derived peptides:
IPPLTQTPVVVPP, VLPVPQK and AVPYPQR. These peptides were chemically
synthesised for assessment of the aforementioned bioactivities in vitro. All three peptides
displayed ACEI (IC50 = 523.8, 776.9 and 387.60 µM, respectively), antioxidant and α-GI
activity (IC50 = 62.32, 61.78 and 60.77 mM, respectively). This work is the first to report
on the multifunctional bioactive properties of these three peptides which could be further
developed as food ingredients for the production of functional foods and nutraceuticals
to improve human nutrition and health.
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INTRODUCTION
Enterococci are Gram positive, facultative anaerobic, non-spore forming, lactic acid
bacteria (LAB) that predominantly reside in the gastrointestinal (GI) tract of humans and
animals but are also widely distributed in food and the environment. The genus currently
comprises 58 species with the most recent additions proposed in 2017 (Jin et al., 2017;
McLaughlin et al., 2017). For many years, enterococci were considered as harmless
commensals with no risk to human health. However, in recent times, they have emerged
as opportunistic pathogens, particularly in nosocomial settings. This is understood to be
a result of an increasing incidence of antibiotic resistance as well as the detection of
putative virulence determinants in some species (Chajęcka-Wierzchowska et al., 2017;
Franz et al., 2003). These factors can be intrinsic or acquired. Intrinsic determinants are
mediated by genes residing on the chromosome, while acquired determinants are those
residing on plasmids or transposons and are of much greater concern due to the possibility
of transfer to other enterococcal strains or species of other genera. Enterococci have also
been implicated in the aetiology of several human diseases such as bacteraemia,
endocarditis and urinary tract infections (UTI) (Franz et al., 1999; Kayser, 2003).

On the contrary, enterococci also represent a promising group of microorganisms which
possess great potential for use in food applications and have featured in the dairy industry
for decades. From a technological point of view, they play an acknowledged role in the
development of organoleptic properties of fermented dairy products when utilised as
starter or adjunct cultures owing to the possession of specific biochemical properties such
as lipolysis, proteolysis and citrate and pyruvate metabolism (Franz et al., 2011; Giraffa,
2003). They have successfully been applied as probiotics to improve human and animal
health most notably in the treatment of diarrhoea such as the commercialised probiotic
preparations Cernivet® and Cylactin® (Cerbios-Pharma SA, Barbengo, Switzerland).
Similarly, Symbioflor® 1 (SymbioPharm, Herborn, Germany), prepared with E. faecalis,
is used to treat recurring illness in the upper respiratory system. Furthermore, many
studies have been conducted to evaluate the probiotic characteristics of Enterococcus
strains and they have been shown to alleviate Irritable Bowel Syndrome (IBS), while
immunostimulatory

(Benyacoub

et

al.,

2003;

Molina

et

al.,

2015)

and

hypocholesterolaemic effects (Guo et al., 2015; Hlivak et al., 2005) have also been
observed. Their suitability as protective cultures in food bio-preservation through the
2
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production of bacteriocins is well documented (Alvarez-Cisneros et al., 2012; Bhardwaj
et al., 2008; Foulquié Moreno et al., 2006). Furthermore, the production of bioactive
peptides by enterococci is a relatively recently developed concept but studies so far have
indicated that enterococcal food-derived bioactive peptides, particularly those from milk,
may have important implications in human nutrition and health and offer new
opportunities for the development of functional food ingredients and nutraceuticals
(Graham et al. 2019c, unpublished data; Gútiez et al., 2013; Quirós et al., 2007).

Evidently, enterococci have the paradoxical position of being beneficial in dairy
fermentations, but also pose a potential risk to human and animal health. Fortunately,
modern genetic tools have enabled the differentiation of pathogenic from non-pathogenic
enterococci. The possession of virulence factors and antibiotic resistant genes appears to
be strain dependant and these traits are typically more common among isolates of clinical
origin compared to those isolated from food. Similarly, food isolates also remain largely
susceptible to clinically relevant antibiotics, thereby suggesting a lower pathogenic
potential among enterococcal strains from food (Chajęcka-Wierzchowska et al., 2017;
Gaglio et al., 2016). Nevertheless, prior to the application of enterococci in food, the
advantages of their use must be weighed against the negatives in a well contemplated
risk/benefit analysis in order to truly understand if enterococcal strains can safely be
applied in food fermentations. The safety evaluation of enterococci remains difficult
because knowledge is limited regarding the type and combination of virulence factors
which are necessary for pathogenic potential, but should typically comprise studies on
genomic data, phenotypic traits and oral toxicity (Hanchi et al., 2018). Following a
comprehensive risk assessment, interesting and safe enterococci with the potential for use
as starter, adjunct, probiotic or bio-preservative cultures can be selected. Ideally, such
strains should harbour no virulence determinants and should be susceptible to clinically
relevant antibiotics. The aim of this review is to summarise the current knowledge on the
safety aspects and technologically beneficial functionalities of enterococci in order to
determine their suitability as starter or adjunct cultures in food applications and to
underline the controversial nature of the genus.
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THE GENUS ENTEROCOCCUS
Taxonomy of enterococci
The taxonomy of enterococci has been described by several authors (Domig et al., 2003;
Franz et al., 1999, 2003; Giménez-Pereira, 2005) and dates back to 1899 when Thiercelin
first used the term ‘entérocoque’ to describe a Gram-positive diplococcus of intestinal
origin. This led to the subsequent proposal of the genus ‘Enterococcus’ by Thiercelin and
Jouhaud in 1903. However, in 1906 Andrewes and Horder renamed Thiercelin’s
enterococci as Streptococcus faecalis following the identification of a potentially
pathogenic bacterium from a patient suffering with endocarditis, coupled with the ability
of the bacteria to form short or long chains. As a consequence of its close resemblance
with strains isolated from intestinal origin, the species epithet ‘faecalis’ was suggested
(Andrewes & Horder, 1906; Domig et al., 2003).

Further difficulty pertaining to the classification of the Enterococcus genus stems from
the lack of clear phenotypic criteria when compared with other Gram-positive, catalase
negative, coccus-shaped bacterial genera. This explains why the history of enterococci
cannot be separated from that of the genus Streptococcus and also provides insight as to
why classical taxonomy of enterococci remains rather vague (Bhardwaj et al., 2008).
Nevertheless, the majority of Enterococcus species can be distinguished from other
Gram-positive, catalase-negative cocci by their ability to grow at 10 and 45 °C and
between pH 4 and 9.6, tolerate 6.5% sodium chloride and 40% bile, and survive heating
at 60 °C for 30 min (Franz et al., 1999). Furthermore, enterococci are oxidative negative,
non-sporulating facultative anaerobes and can occur in pairs or in chains and belong to
the family Enterococcaceae (Foulquié Moreno et al., 2006).

Several developments have occurred in recent years which have contributed to the
establishment of the enterococcal autonomy as a separate genus. These developments
gathered momentum in 1933, when Lancefield developed a serological typing system for
enterococci whereby those of ‘faecal origin’ possessed the group D antigen (Lancefield,
1933). This gave rise to the now renowned ‘Lancefield’s group D streptococci’
classification. Moreover, Lancefield’s findings correlated with a later study carried out
by Sherman (1937) who proposed a new taxonomic scheme for the genus Streptococcus.
4
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Sherman divided the Streptococcus genus into four groups designated as pyogenic,
viridans, lactic and enterococci (Fig. 1.1) (Sherman, 1937).

The most significant advancement materialised in 1984 when Shleifer and Klipper-Bälz
demonstrated that S. faecalis and S. faecium should be transferred to the newly established
Enterococcus genus. This proposal was put forward based on results obtained from
DNA:DNA and DNA:rRNA hybridization studies which demonstrated that S. faecalis
and S. faecium were distantly related to the non-enterococcal streptococci (S. bovis and
S. equinus) of serological group D and also to other streptococci, thereby warranting their
transfer to a separate genus (Schleifer & Kilpper-Balz, 1984).

Figure 1.1. Sherman’s classification of the Streptococcus genus including the sub-species that
fell within the D-antigen producing group of enterococci. Adapted from Giménez-Pereira, (2005).

Since Schleifer and Klipper-Bälz’s establishment of Enterococcus as an independent
genus in 1984, further chemotaxonomic and phylogenetic studies in recent years have
resulted in the addition of several new species to the genus. Currently, there are 58 species
assigned to the genus Enterococcus (Table 1.1). Some of the earliest identified
enterococci include E. faecalis and E. faecium which were discovered by the
aforementioned authors while other species identified in the same year (1984) include E.
avium, E. casseliflavus, E. durans, E. gallinarum and E. malodoratus (Collins et al., 1984;
Schleifer & Kilpper-Balz, 1984). It is quite possible that the phylogenetic system of the
genus Enterococcus has not been completely elucidated. Recently, new species have been
proposed by several authors such as E. alcedinis (Frolková et al., 2013), E. olivae
(Lucena-Padrós et al., 2014) and E. bulliens (Kadri et al., 2015). The most recent
5

Chapter I

contributions to the Enterococcus genus were made by Jin et al. and McLaughlin et al. in
2017 who isolated E. wangshanyuanii (from faeces of yaks) and E. crotali (from the
faecal material of a timber rattlesnake), respectively. Therefore, because new species have
been identified as recently as 2017, it is likely that the genus Enterococcus has not been
completely elucidated and thus may be further re-classified in the future.
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Table 1.1. Species of the genus Enterococcus and their associated habitats.
Species
E. alcedinis
E. aquimarinus

Habitat(s)
Animal (bird)
Sea water

Reference(s)
(Frolková et al., 2013)
(Svec, Vancanneyt, Devriese, et
al., 2005)
(de Vaux et al., 1998)

Species
E. malodoratus
E. moraviensis

Habitat(s)
Animal (pig)
Surface water

Reference(s)
(Collins et al., 1984)
(Svec et al., 2001)

E. asini

Animal (donkey)

E. mundtii

Soil, plant

(Collins et al., 1984)
(Kadri et al., 2015)
(Carvalho et al., 2006)
(Sukontasing et al., 2007)
(Naser et al., 2005)
(De Graef et al., 2003)
(Collins et al., 1984)

E. olivae
E. pallens
E. phoeniculicola
E. plantarum
E. porcinus c
E. pseudoavium
E. quebecensis

Plant
Human
Animal (bird)
Plant
Animal (pig)
Human
Well water

(Collins et al., 1986; Muller et
al., 2001)
(Lucena-Padrós et al., 2014)
(Tyrrell et al., 2002)
(Law-Brown & Meyers, 2003)
(Svec et al., 2012)
(Teixeira et al., 2001)
(Collins et al., 1989)
(Sistek et al., 2012)

E. avium
E. bulliens
E. caccae
E. camelliae
E. canintestini
E. canis
E. casseliflavus a

E. devriesei

Animal (bird)
Animal (camel)
Human
Plant
Animal (dog)
Animal (dog)
Human, animal,
plant
Animal
(chickens)
Animal (pigeon)
Animal (timber
rattlesnake)
Animal (cattle)

(Devriese et al., 1983; Williams
et al., 1989)
(Devriese et al., 1990)
(McLaughlin et al., 2017)

E. raffinosus

Human

(Collins et al., 1989)

E. ratti
E. rivorum

Animal (rat)
Water (brook)

(Teixeira et al., 2001)
(Niemi et al., 2012)

(Svec, Vancanneyt, Koort, et al.,
2005)
(Kim et al., 2013)

E. rotai

(Sedláček et al., 2013)

E. saccharominimus b
E. saigonensis

Animal (pig)
Human, animal
(multiple), plant,
insect
Human, animal
(multiple), plant,
insect
Human

(Collins et al., 1991)
(Collins et al., 1984; Cox &
Gilmore, 2007; Layton et al.,
2010)
(Cotta et al., 2013)
(Cox & Gilmore, 2007; Layton et
al., 2010; Muller et al., 2001;
Schleifer & Kilpper-Balz, 1984)
(Cox & Gilmore, 2007; Layton et
al., 2010; Muller et al., 2001;
Schleifer & Kilpper-Balz, 1984)
(Pompei et al., 1992)

Water, insect
(mosquito), plant
Animal (cattle),
sewage
Animal (cattle)
Animal (chicken)

E. diestrammenae

Insect

E. dispar
E. durans

Human
Human, Animal
(multiple), insect

E. eurekensis
E. faecalis

E. seriolicida
E. silesiacus

Animal (fish)
Surface water

(Kusuda et al., 1991)
(Svec et al., 2006)

E. solitarius

Human

(Collins et al., 1989)

E. sulfureus

Plant

(Cox & Gilmore, 2007; Layton et
al., 2010; Muller et al., 2001)
(Tyrrell et al., 2002)

E. termitis

Insect (termite)

E. gilvus

Human, animal
(multiple), insect
Human

(Martinez-Murcia & Collins,
1991; Muller et al., 2001)
(Svec et al., 2006)

E. thailandicus

Human

E. haemoperoxidus
E. hermanniensis
E. hirae

Surface water
Animal (dog)
Animal (multiple)

(Svec et al., 2001)
(Koort et al., 2004)
(Farrow & Collins, 1985)

E. ureasiticus
E. ureilyticus
E. viikkiensis

E. italicus b
E. lactis
E. lemanii

Animal (cattle)
Animal (multiple)
Animal (pig)

(Fortina et al., 2004)
(Morandi et al., 2012)
(Cotta et al., 2013)

E. villorum c
E. wangshanyuanii
E. xiangfangensis

Well water
Water, plant
Animal (broiler
plant)
Animal (pig)
Animal (yak)
Plant

E. cecorum
E. columbae
E. crotali

E. faecium

E. flavescens a
E. gallinarum

E. saccharolyticus

a

(Layton et al., 2010; Rodrigues
& Collins, 1990)
(Vancanneyt et al., 2004)
(Harada et al., 2016)

(Carvalho et al., 2008;
Shewmaker et al., 2011;
Tanasupawat et al., 2008)
(Sistek et al., 2012)
(Sedláček et al., 2013)
(Rahkila et al., 2011)
(Vancanneyt et al., 2001)
(Jin et al., 2017)
(Li et al., 2014)

E. flavescens is a later heterotypic synonym of E. casseliflavus (Naser et al., 2006).
E. saccharominimus is a later heterotypic synonym of E. italicus (Naser et al., 2006).
c
E. porcinus is a synonym of E. villorum (De Graef et al., 2003).
b
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Isolation and identification of enterococci
The correct isolation and identification of bacteria is of considerable importance,
particularly in medical and food microbiology. Precise identification is important in the
food industry, for example when applying correct preservation techniques, during food
testing or when selecting a starter strain for food fermentation. Similarly, accurate
identification of bacteria is also useful in the clinical field, for example when selecting
the most appropriate antibiotic therapy or when identifying a pathogen from an infected
patient. Enterococci are ubiquitous microbes commonly found in the GI tract of humans,
animals and insects, in the environment and in various food samples (Fig. 2).

Figure 1.2. Common sources of enterococci.

Sources
Gastrointestinal (GI) tract
It is believed that the primary habitat of enterococci is the intestines of warm-blooded
animals and that they are then introduced into secondary sources when released from the
GI tract (Byappanahalli et al., 2012). Their presence in the intestines of several animals
has been reported, including pigs, donkeys, chickens, dogs (de Vaux et al., 1998; Klein,
2003; Naser et al., 2005). However, the intestines of cold-blooded animals, such as insects
and birds, constitute other important habitats (Devriese et al., 1990). Although 58
Enterococcus species are now recognised, E. faecalis and E. faecium remain the two most
prominent species, particularly in the GI tract of humans where they play a likely role in
8
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digestion and other gut metabolic pathways. E. faecium has been reported as the most
prevalent species in faecal samples from production animals (Klein, 2003), while other
species also occur in high numbers like E. cecorum and E. durans. However, not all
species are prevalent in the GI tract. E. mundtii and E. casseliflavus are typically of plant
origin, thereby indicating a great diversity in the ecology of the Enterococcus genus
(Klein, 2003).
Environment
Research has also shown that enterococci prevail in extra-enteric environments, even
when there is little or no input from human and/or animal faecal sources (Byappanahalli
et al., 2012). This is likely due to their robust nature, enabling them to adapt and survive
in sub-optimal conditions such as temperature and pH extremes, as well as in areas with
high salinity such as marine waters. This can enable enterococci to outcompete
environmental bacteria of other genera for nutrients and space, thereby enhancing their
survival. Enterococci have been isolated from a number of environmental sources
including soil (Graham et al., 2017), beach sand, vegetation, fresh water, surface water,
farmland and urban sewage (Byappanahalli et al., 2012; Kühn et al., 2003). In fact, in the
study performed by Kühn et al. in 2003 which compared enterococcal populations from
a range of samples of human, animal and environmental origin, enterococci were present
in most sample types, thereby reinforcing their status as ubiquitous microorganims (Kühn
et al., 2003).

Food
The presence of enterococci in foods, especially those of animal origin, is often attributed
to their presence in the GI tract of animals and that the isolation of E. faecalis and E.
faecium in foods is an indication of poor hygiene and primary contamination with faeces.
However, their presence in foods has often been shown to be unrelated to direct faecal
contamination. It is also possible for enterococci to enter food indirectly from
contaminated water sources or from the exterior of the animal (Giraffa, 2002). Therefore,
because their presence in food may not be related to faecal contamination and as a result
of their ubiquitous occurrence, enterococci may now be considered normal components
of animal derived food microflora, and not necessarily as indicators of inadequate sanitary
conditions or faecal contamination (Giraffa, 2003). Furthermore, enterococci have several
9
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important applications in food which are discussed later in this review. As mentioned,
enterococci are present in foods of animal origin and have been isolated from pork,
turkey, beef and chicken (Graham et al., 2019a), but their presence in milk and dairy
products, and applications therein, are reported much more frequently (Bhardwaj et al.,
2008; Giménez-Pereira, 2005; Giraffa, 2003; Muguerza et al., 2006). They are also found
in plant based foods such as fruits and vegetables, although the source of enterococci in
these foods, whether endogenous or as a result of environmental contamination, is not
clearly defined (Abriouel et al., 2008; Hanchi et al., 2018).

Growth media utilised for the isolation of enterococci
Due to their significance in food, environmental and clinical samples, enterococcal
detection, enumeration and identification have become important issues in current
research activities. Several media have been employed for the isolation and quantitation
of enterococci, yet no single method has been established that meets all necessary
requirements. Factors to consider prior to selecting a medium for isolating and
enumerating enterococci include the source of isolation and the form they exist in i.e.,
whether they are single components or part of a mixed microflora (Domig et al., 2003).
Although noted for their ability to survive and prevail in harsh conditions, propagation of
enterococci in synthetic media can prove challenging due to their requirements for several
vitamins and amino acids.

Commonly employed complex media for the propagation of enterococci include De Man,
Rogosa and Sharpe (MRS) and Trypticase Soy (TS) media (Domig et al., 2003), while,
throughout our work, we frequently utilised Brain Heart Infusion (BHI) medium to
achieve rapid and profuse growth of Enterococcus isolates (Graham et al., 2019a; Graham
et al., 2019b, under review; Graham et al., 2019c, unpublished data; Graham et al., 2017).
These media are advantageously applied only if enterococci are present as the single
microbial component of a product. However, like other members of LAB, enterococci are
often found associated with a microflora of considerable diversity, for example in a food
matrix or from an environmental source.

Recovery of enterococci becomes more complex when a sample consists of a mixed
microbial population. Consequently, to isolate enterococci from a diverse microflora,
10
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several selective and/or differential media have been proposed. These are typically
prepared with selective chromogenic dyes or inhibitory agents (e.g. antibiotics) and are
designed to enable the differential enumeration of enterococci (Domig et al., 2003).
However, as with all selective and differential media, those proposed for isolation of
enterococci have various advantages and drawbacks in terms of selectivity and recovery.
In any case, the media and methods selected should be based on good selective and
differential ability, quantitative recovery, and ease of use. The choice of a particular
selective medium chosen for isolation of enterococci usually depends on the source of
enterococci, whether they are to be enumerated and whether or not the source is likely to
be highly contaminated.

Two of the most common selective culture media employed to propagate enterococci are
Slanetz-Bartley (SB) agar and Kanamycin Aesculin Azide (KAA) agar, which are
typically utilised to estimate enterococcal counts in water, food, feed and clinical
specimens (Domig et al., 2003). Other commonly used media for the isolation and
detection of enterococci have been reviewed elsewhere (Domig et al., 2003). These media
are summarised in Table 1.2., with a particular focus on those which have been
recommended for enterococcal enumeration in dairy foods.

Table 1.2. Media commonly used for the isolation and enumeration of enterococci from various
sources.
Source
Medium

Abbreviation

Azide Blood Agar Base
Azide Dextrose Broth
Bile Aesculin
Bile Aesculin Azide
Bromocresol Purple Azide Broth
Citrate Azide Medium
Citrate Azide Tween Carbonate
Enterococcus Selective Differential Medium
Kanamycin Aesculin Azide Agar
KF Streptococcal Medium
Membrane Filter Enterococcus Agar
Slanetz-Bartley Agar

ABAB
AD
BA
BEA
BB
CAM
CATC
ESD
KAA
KF
mE
SB

+ Media used; - Not mentioned.
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Dairy
foods
+
+
+
+
+
+
+
+
+
+
+
+

Other
foods
+
+
+
+
+
+
+

Sewage

Water

+
+
+
+

+
+
+
+
+
+
+

Intestinal,
clinical
+
+
+
+
+
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Following an extensive screening of published methods for culturing and enumerating
enterococci, Weiss et al. (2005) compared twelve commercially available selective media
for the detection, isolation and enumeration of enterococci present in probiotic animal
feed, either as a single component or in combination with other microbes. Citrate Azide
Tween Carbonate (CATC) inhibited the growth of all non-enterococcal strains used in the
study, subsequently displaying the best selectivity. However, the colour of enterococcal
colonies varied from rosy to dark red, while the growth of several enterococci was also
inhibited to the extent where only pinpoint colonies were formed. The author’s concluded
that, based on their study, Bile Aesculin Azide (BEA) medium was best suited for
selective enumeration of probiotic enterococci since it demonstrated good selectivity and
reproducibility and pronounced growth of most enterococcal strains. Bacteria of other
genera such as Lactobacillus and Pediococcus did grow on BEA, but colonies were
pinpoint, and most were easily distinguished from enterococcal colonies. However, L.
plantarum could not be macroscopically distinguished from enterococci due to its ability
to hydrolyse aesculin and its small colony size, thereby reinforcing the fact that there is
no single ‘ideal’ medium for the enumeration of enterococci and each has its drawbacks
in terms of selectivity and recovery (Weiss et al., 2005).

Throughout our work, we routinely used Kanamycin Aesculin Azide (KAA), a
commercial medium for the selective and differential isolation of enterococci, particularly
from foods. KAA contains the selective inhibitory components sodium azide and the
antibiotic kanamycin and makes use of an indicator system involving aesculin and ferric
iron. The selective components inhibit the growth of the majority of non-enterococcal
microbes, while aesculin is hydrolysed by enterococci during growth, thereby releasing
aesculetin. This reacts with ferric iron in the medium to give colonies which are
accompanied by distinct black haloes. KAA proved effective at detecting and
enumerating enterococci in our work, where no significant difference was observed in
colony counts when compared with BHI (Graham et al., 2017). However, similar to the
observation of Weiss et al. (2005), the growth of some non-enterococcal isolates was
observed and coincides with that observed on BEA and other selective media for
enterococci, which also permitted the growth of non-enterococcal isolates (Weiss et al.,
2005).
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What is particularly interesting are the efforts being made to improve the selection of
desired isolates from a mixed microflora by the manipulation of commercially available
media. Audicana et al. (1995) modified KAA in an attempt to improve the selectivity of
the medium for the enumeration of faecal streptococci from water samples. The authors
increased the concentration of sodium azide and replaced kanamycin with oxolinic acid.
When the newly formed medium was compared to SB and KF agars, higher specificity,
selectivity and recovery efficiencies were observed (Audicana et al., 1995). Similarly,
because our work is concerned with enterococci which display proteolytic activity, we
also modified KAA to develop Kanamycin Skim Milk Aesculin Azide Agar (KSMEA).
KSMEA combines KAA with bovine skim milk (BSM) to combine the selective
properties of KAA and the proteolytic identifying properties of skim milk for the isolation
of proteolytic enterococci in one step as opposed to the routinely employed two step
method. KSMEA reduces screening time and associated costs, thereby providing a
quicker and effective method for the isolation of presumptive proteolytic enterococci
(Graham et al., 2017).

The isolation and detection of microbes of interest using selective and/or differential
media should only be considered presumptive until further techniques, such as phenotypic
and genotypic methods, are applied to confirm their true identity (Domig et al., 2003).
Nevertheless, due to their importance in food, environmental and clinical microbiology,
the rapid isolation and detection of enterococci is vitally important. Thus, the use of
selective and/or differential media can be utilised as a quick and convenient method for
the isolation of enterococcal strains, particularly when present in a mixed microbial
population.
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SAFETY ASPECTS OF ENTEROCOCCI
Implications in disease development
The recent paradigm shift in the consideration of enterococci as harmless commensals
with low pathogenic potential to ubiquitous opportunistic pathogens capable of causing
infection is exemplified in the findings of many authors (Abriouel et al., 2008; ChajęckaWierzchowska et al., 2016, 2017; Eaton & Gasson, 2001; Franz et al., 2001; Furumura et
al., 2006; Reviriego et al., 2005). Increasing concerns are being raised regarding the
apparent role that enterococci are suggested to have in nosocomial infections. Enterococci
have been associated with the development of several human diseases such as
endocarditis, bacteraemia and urinary tract, central nervous system and neonatal
infections (Franz et al., 1999; Kayser, 2003; Murray, 1990). For some of these, other
microorganisms are frequently isolated from the same site, thereby often making it
difficult to determine whether the manifestations of infection are due to enterococci or
the presence other pathogenic microbes. However, in the case of bacteraemia and
endocarditis, enterococci have clearly been implicated in the development of disease. In
fact, enterococci are the second leading cause of Gram-positive healthcare associated
bacteraemia (Weiner et al., 2016), an increase from the sixth most common cause in the
1980’s, while endocarditis is one of the most serious enterococcal infections (Agudelo
Higuita & Huycke, 2014). Enterococcal infections are predominantly caused by E.
faecalis and, to a lesser extent, E. faecium, which account for up to 80% and 20% of
clinical isolates, respectively. Other enterococcal species such as E. durans, E. avium and
E. hirae are less frequently isolated and therefore are rarely associated with enterococcal
infections in humans (Kayser, 2003; Ogier & Serror, 2008; Reynolds et al., 2004).

Risk factors of enterococci that may contribute to pathogenesis
Pathogenesis of infectious processes results from an interplay between determinants of
pathogenicity and virulence of the invading organism and the host response trying to
prevent the occurrence of disease. Major risk factors associated with the host for acquiring
nosocomial enterococcal infections include severe underlying disease, a prolonged
hospital stay, presence of urinary or vascular catheters, and preceding antibiotic therapies
for other infectious diseases (Franz et al., 1999, 2003; Kayser, 2003; Majhenič, 2006).
Furthermore, co-existence of many of these factors could influence enterococcal
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colonisation in a patient. Immunocompromised individuals are at greatest risk of
developing Enterococcus associated infections, while the morbidity of healthy humans
resulting from enterococcal infections appears to be low (EFSA, 2012; Franz et al., 2003).
Although knowledge regarding the risk factors that contribute to the suggested virulence
of enterococci is lacking, advancements have been made in recent years which attempt to
explain their pathogenic role (Chajęcka-Wierzchowska et al., 2017; Franz et al., 2011;
Franz et al., 2001; Hosseini et al., 2016). The emergence of enterococci as opportunistic
pathogens has mostly been attributed to an increasing incidence of antibiotic resistance
as well as the possession of several virulence determinants. This is reflected in the
literature whereby several authors have examined the antibiotic resistant profiles and
virulence factors of enterococci from various habitats (Aspri et al., 2017; Cariolato et al.,
2008; Kayser, 2003; Lins et al., 2013; Martin et al., 2005; Reviriego et al., 2005).

Virulence determinants
Virulence determinants are genetically encoded factors found in some strains of
enterococci that may confer pathogenic effects on host tissue and/or resistance against the
host’s defence system. Although the virulence mechanisms of enterococci are not
completely known, considerable efforts have been made in recent years to determine the
presence of virulence determinants in enterococcal isolates and the implications of these
traits in the aetiology of disease. In the past, due to subtle differences, identification of
virulence factors was somewhat challenging. However, in recent years, the progress made
in detecting virulence factors in enterococci of clinical origin has made it possible to
detect these traits in strains isolated from food. This has enabled the assessment of
differences in the pathogenic potential of food and clinical isolates, an important
advancement required to facilitate the safety evaluation of strains intended for use in
foods as starter, adjunct, probiotic or protective cultures.

Virulence determinants may be intrinsic within an organism, but they are of much greater
concern when they are present on mobile genetic elements that can be transferred between
microorganisms. Several enterococcal virulence factors have been described and are
broadly classified by the observed effects in the host (Table 1.3). They include those
associated with adherence to host tissue and extracellular matrix proteins (agg, esp, efaA),
resistance to and evasion of the host immune system (agg, esp), cell and tissue damage
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(cyl, gelE, hyl) and the production of sex pheromones that facilitate conjugation of
pheromone responsive plasmids between cells.

Table 1.3. Enterococcus virulence determinants.
Enterococcal virulence
factor
Aggregation substance

Gene(s)

Putative role

Reference

agg

Adherence to host cells, cell
aggregation and conjugation

(Chajęcka-Wierzchowska et
al., 2017)

Enterococcal surface protein

esp

Adhesion and colonisation

(Koort et al., 2004)

Endocarditis specific antigen

efaAfs, efaAfm

Cell wall adhesin expressed in
serum

(Chajęcka-Wierzchowska et
al., 2017)

Cytolysin

cylR1, cylR2, cylLL,
cylLS, cylM, cylB,
cylA, cylI

Haemolytic activity, cell lysis

(Eaton & Gasson, 2001; Van
Tyne et al., 2013)

Gelatinase

gelE

Hydrolyses gelatin, collagen,
haemoglobin and casein

(Chajęcka-Wierzchowska et
al., 2017; Gútiez et al., 2014)

Hyaluronidase

hyl

Plays a role in destroying
mucopolysaccharides of the
connective tissue and cartilage

(Chajęcka-Wierzchowska et
al., 2017)

Sex pheromones

cob, cad, ccf, cpd

Facilitate conjugation, chemotactic
for human neutrophils

(Bhardwaj et al., 2008)

Aggregation substance (agg)
This is an enterococcal surface protein understood to play a role in the adherence of
enterococci to host tissue, the first step in many cases of infection and subsequent disease
development (Chajęcka-Wierzchowska et al., 2017). The aggregation substance (AS) is
encoded by a pheromone responsive plasmid and induces cell clumping of E. faecalis
cells, thereby facilitating the efficient transfer of the plasmid on which the AS gene (agg)
is encoded. AS was also suggested to play a role in invasion of host cells. In cell culture
experiments, the expression of AS enhanced the adherence of E. faecalis to eukaryotic
cells, while numbers of AS producing cells were internalised by enterocytes to a greater
degree compared to their non-expressing counterparts (Olmsted et al., 1994). Therefore,
AS is an important virulence factor which can be implicated in multiple stages of
infection, most notably in adhesion and invasion. Moreover, because AS causes cell
clumping, which subsequently facilitates the transfer of plasmids, expression of AS has
potential implications in the transfer of plasmids containing antibiotic resistant genes and
other virulence factors.
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Enterococcal surface protein (esp)
The enterococcal surface protein (ESP) is an enterococcal adhesin which is
chromosomally encoded and was first described in 1999 (Shankar et al., 1999). Similar
to AS, it is also suggested to play a role in the adherence of enterococcal cells to host
tissue. Furthermore, ESP may also promote colonisation and assist in evading the host’s
immune system, thereby enabling enterococci to persist in the host (ChajęckaWierzchowska et al., 2017; Foulquié Moreno et al., 2006). Biofilm formation and
adherence to abiotic surfaces have also been attributed to the expression of ESP which
may have important implications for patients with medical implants (Franz et al., 2003).
The pathology of ESP is yet to be fully elucidated but advancements have been made
since 2001 when Shankar et al. reported that ESP could not influence histopathological
changes in an animal model (Shankar et al., 2001). In a study carried out by Leendertse
et al. (2009) that examined the role of ESP in UTI and peritonitis, E. faecium cells
expressing ESP outgrew ESP-deficient mutants in the bladder and kidneys of mice. This
facilitated the onset of bloodstream infection and the induction of higher levels of proinflammatory cytokines in kidney tissue. However, the authors concluded that the effect
of ESP was transient in their model as the presence of ESP only influenced the initial
course of UTI. Furthermore, ESP had no effect on the course of E. faecium peritonitis
(Leendertse et al., 2009). Moreover, Zou and Shankar (2016) demonstrated that ESP can
modulate inflammation during infection in a murine model and has important
implications for enterococcal pathogenesis (Zou & Shankar, 2016).

E. faecalis and E. faecium endocarditis antigens (efaAfs, efaAfm)
The Enterococcus endocarditis antigen is a protein encoded by the efaAfs gene in E.
faecalis strains, and by the efaAfm gene in E. faecium (Eaton & Gasson, 2001). These are
considered to be potential virulence determinants also thought to play a role in adherence
of enterococci to host cells. Little is known regarding the implication of the E. faecium
endocarditis antigen in enterococcal infection. However, the efaAfs antigen was suggested
to play a role in adhesion in endocarditis and to influence pathogenicity in animal models
(Franz et al., 2003; Singh et al., 1998).
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Cytolysin (cyl)
Cytolysin is a pore-forming exotoxin which belongs to a large class of lanthioninecontaining bacteriocins and is one of the best characterised enterococcal virulence factors
(Van Tyne et al., 2013). Production of cytolysin is mediated by an operon comprising
eight genes: cylR1, cylR2, cylLL, cylLS, cylM, cylB, cylA, cylI. This operon can exist on a
pheromone-dependant plasmid or within the bacterial chromosome on a pathogenicity
island near other virulence determinants such as ESP and AS (Chajęcka-Wierzchowska
et al., 2017; Eaton & Gasson, 2001). Expression of the cylLL, cylLS, cylM, cylB and cylA
genes are required for the production of active cytolysin which lyses a broad range of
eukaryotic and Gram-positive cells. CylLL and cylLS encode the structural subunits of
cytolysin which are then subject to post-translational modification, extracellular transport
and final activation of cytolysin by the cylM, cylB and cylA genes, respectively. The cylR1,
and cylR2 genes encode proteins involved in the regulation of cytolysin expression, while
the cylI determinant encodes a surface protein that protects the cytolysin-producing cells
from lysis following excretion (Chajęcka-Wierzchowska et al., 2017). Cytolytic activity
is mostly observed by haemolytic activity in vitro and is subsequently thought to be the
most frequently involved virulence trait in haemolytic activities (Franz et al., 2003).
Moreover, a study was carried out by Jett et al., (1992) to examine the effect of cytolysin
on tissue damage in rabbits. After three days, rabbits exposed to strains expressing
cytolysin had lost 99% of retinal function, while those inoculated with non-cytolytic
isolates showed little or no signs of retinal destruction (Jett et al., 1992).

Gelatinase (gelE)
Gelatinase is an extracellular zinc metalloprotease capable of hydrolysing gelatin, elastin,
collagen and haemoglobin. Gelatinase is encoded by the gelE gene which is found on an
operon together with the sprE gene which encodes a serine protease. The gelE-sprE
operon resides on the chromosome and is controlled by the fsr (E. faecalis regulator)
operon, a two-component quorum sensing-dependant regulatory system which encodes
the fsrA, fsrB, fsrC and fsrD genes. The fsrA gene undergoes monocistronic transcription
into a response regulator, while fsrB and fsrC are contranscribed and encode a processing
enzyme and sensor kinase, respectively. The fsrD gene encodes an auto-inducing cyclic
peptide termed gelatinase biosynthesis activating pheromone (GBAP). FsrD is processed
into mature GBAP by the processing enzyme (FsrB) and then exported out of the cell.
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Accumulated GBAP outside the cell is sensed by the FsrC histidine kinase which, in turn,
activates the FsrA response regulator by phosphorylation. This upregulates the expression
of the fsrBDC genes which boosts GBAP signalling and induces the gelE-sprE operon.
Therefore, the expression of both gelatinase and serine protease is controlled by the fsr
regulatory system (Fig. 1.3) (Dundar et al., 2015; Teixeira et al., 2012). Moreover,
deletions within the fsr operon and/or the presence of a nonsense codon in the FsrC
protein, can produce mutants which, despite having the gelE gene, do not produce
gelatinase and thus, may be less virulent (Nakayama et al., 2002; Teixeira et al., 2012).
Gelatinase, most frequently found in E. faecalis, is understood to play a role in virulence
and was suggested to increase pathogenicity in a murine model (Chajęcka-Wierzchowska
et al., 2017; Singh et al., 1998). However, Singh et al. could not determine that gelE alone
was directly responsible for infection. Similarly, although the presence of functional
gelatinase has been associated with virulence, it is not required for enterococci to cause
disease (Galloway-Peña et al., 2011). Furthermore, the gelE gene is present in
enterococcal isolates from different ecological environments and also in species not
typically associated with infection such as E. hirae and E. durans (Lopes et al., 2006),
thereby suggesting that the gelatinase protein may play a role in the biology of E. faecalis
not exclusively associated with virulence. This was further evidenced by Gútiez et al.
(2014) who demonstrated that gelatinase was responsible for casein degradation and
subsequent generation of bioactive peptides with human health connotations. Proteolytic
activity during milk fermentation also has important effects on the development of the
flavour and texture of cheese (Foulquié Moreno et al., 2006). Therefore, proteolytic
enterococci expressing gelatinase may have a useful role in food biotechnology
applications.
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Figure 1.3. Schematic representation of the fsrABCD and gelE-sprE operons responsible for
gelatinase production in enterococci. Modified from Teixeira et al., (2012).

Hyaluronidase (hyl)
Hyaluronidase is also considered a toxin and is a protein which plays a role in destroying
the mucopolysaccharides of connective tissue and cartilage. This increases bacterial
invasiveness and facilitates the spread of enterococci within the host’s tissue, which may
have serious implications if the cells harbour other virulence determinants (Araújo &
Ferreira, 2013; Chajęcka-Wierzchowska et al., 2017). Hyaluronidase is encoded by the
hyl gene and is mostly associated with the genome of E. faecium strains, while it is rarely
found in E. faecalis (Vankerckhoven et al., 2004). Hyaluronidase is homologous with
hyaluronidases found in other pathogenic microorganisms, such as Staphylococcus
aureus and Streptococcus pyogenes, which provides an indirect basis for speculating that
this enzyme may contribute to enterococcal virulence. However, although its presence in
enterococcal strains has been shown (Hammad et al., 2015; Hosseini et al., 2016),
hyaluronidase has yet to be implicated in enterococcal disease.

Sex pheromones (cpd, cob, ccf, cad)
Some enterococci possess a plasmid accumulation mechanism which is based on the
production of chromosomally encoded genes of sex pheromones. These are small linear
peptides of 7-8 amino acids which facilitate the conjugative transfer of plasmids between
cells (Bhardwaj et al., 2008; Chajęcka-Wierzchowska et al., 2017). Interestingly,
recipient cells, which do not contain plasmids, can produce pheromones which bind to
receptors on donor cells, subsequently inducing plasmid encoded AS-producing genes in
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the donor cells. As previously discussed, expression of AS promotes clumping of cells
and subsequent formation of mating aggregates between donor and recipient cells,
thereby enhancing the possibility of the conjugative transfer of sex-pheromone plasmids
between cells. Moreover, a recipient cell which harbours a newly acquired sex pheromone
plasmid will no longer secrete the corresponding pheromone for that plasmid. However,
it may still secrete pheromones specific for other sex-pheromone plasmids which it does
not possess but may subsequently acquire. Therefore, it is possible for enterococci to
harbour multiple sex pheromone plasmids (Franz et al., 1999). These sex pheromone
plasmids can carry one or more antibiotic resistance genes and/or the previously discussed
virulence determinants. This becomes particularly problematic when enterococci, which
do not normally harbour genes for known virulence factors, accumulate plasmids which
contain virulence and/or antibiotic resistant genes. Furthermore, the sex pheromones can
also serve as chemo-attractive agents for human neutrophils and initiate inflammatory
responses as well as the production of superoxides (mutagenic substances), and are thus
considered virulence factors (Bhardwaj et al., 2008; Chajęcka-Wierzchowska et al.,
2017).

Prevalence of virulence factors among enterococci
The lack of knowledge regarding the type and combinations of virulence factors required
for enterococci to cause infection makes it difficult to carry out a risk assessment on the
safety of enterococcal strains. It may be argued that strains which possess multiple
virulence

determinants

associated

with

various

stages

of

infection

(adherence/colonisation, evasion of immune response and induction of pathological
changes) pose a higher risk than strains which harbour only a single virulence
determinant. Studies on the presence of virulence factors in enterococci have typically
involved the use of molecular based methods to identify genes with a putative role in
enterococcal virulence. Although present in enterococcal strains isolated from various
habitats, the general consensus among authors is that virulence factors are detected most
frequently among clinical isolates, while food isolates possess fewer virulence
determinants, thereby suggesting that food isolates have a lower potential for
pathogenicity. Even more interesting is the observation that the lowest prevalence of
virulence factors was detected among starter isolates (Eaton & Gasson, 2001).
Furthermore, virulence factors among E. faecalis isolates are reported more often and in
much higher frequencies than E. faecium.
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Regarding the occurrence of specific virulence factors among species, those which play
a role in the adherence of enterococci to host cells appear to be common among E. faecalis
isolates. Elsewhere in our work, when 25 E. faecalis isolates were examined for the
presence of putative virulence factors, the efaAfs and agg genes were found in 96 and 76%,
respectively (Graham et al. 2019b, under review). This was similar to the findings of
several authors who also reported a high incidence of these determinants amongst E.
faecalis isolates (Čanžek Majhenič et al., 2005; Cariolato et al., 2008; Eaton & Gasson,
2001; Landete et al., 2018; Martín-Platero et al., 2009; Martin et al., 2005). The incidence
of esp, encoding an enterococcal surface protein, was lower both in our findings and also
in the work of Cariolato et al. (2008) where the gene was detected in 44 and 42% of
isolates, respectively. These observations also correlated well with the findings of Eaton
and Gasson (2001) and Franz et al. (2001), particularly among E. faecalis isolates of food
origin, where esp was detected in 33 and 36.2% of strains in the respective studies (Eaton
& Gasson, 2001; Franz et al., 2001).

In our work, we also examined the incidence of the cylA, cylB and cylM determinants
involved in the expression of cytolysin and found that these genes were present in 36%
of isolates, occurring concomitantly in all cases. Eaton and Gasson (2001) reported
similar levels among E. faecalis isolates of food origin (44%), where each of the three cyl
determinants also occurred simultaneously. However, none of the E. faecium strains
examined in that study, whether a starter, food or medical isolate, harboured any of the
cyl determinants. This observation was in agreement with the findings of Landete et al.
(2018), who reported the presence of these determinants in 26.9% of E. faecalis isolates,
while none of the E. faecium isolates examined in the study contained any of the cyl
determinants (Landete et al., 2018). Production of cytolysin is most commonly observed
as haemolytic activity. However, in the Landete et al. (2018) study, none of the isolates
showed haemolysin activity in vitro despite 26.9% harbouring the cyl determinants. This
was also observed by Eaton and Gasson (2001) in some cases. Therefore, to further
understand the role of cytolysin in enterococcal virulence, in vivo studies should
accompany phenotypic and genotypic screening in vitro.

Gelatinase is also frequently detected in E. faecalis strains but rarely in E. faecium. In a
study by Martin et al. (2005) that examined enterococci from slightly fermented sausages,
gelE was only detected in 5.5% of E. faecium isolates but was found in all the E. faecalis
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isolates used in the study (Martin et al., 2005). Similarly, Eaton and Gasson reported the
presence of gelE in 67% of E. faecalis isolates of food origin, but none of the E. faecium
isolates harboured the gene. This phenomenon was further corroborated in the findings
of Franz et al., (2001) and Cariolato et al., (2008) where the incidence of gelE among E.
faecalis was much higher than that of E. faecium (50% v 0%, and 70% v 1% in the
respective studies). More recently, in a study that examined the presence of virulence
factors among enterococci isolated from the faeces of healthy breastfed infants in China,
the incidence of gelE was also higher in E. faecalis strains (41%) compared to E. faecium
(10%) (Zhang et al., 2016). However, the generally agreed consensus that gelE is
prevalent among E. faecalis but rarely found in E. faecium isolates was contradicted in
the works of Landete et al., (2018) who also examined the presence of virulence factors
among enterococcal isolates from the faeces of breastfed infants, albeit from a different
geographical location (Spain). The gelE determinant was found in 80.8 and 60% of E.
faecalis and E. faecium isolates, respectively (Landete et al., 2018). This somewhat
aberrant report may allude to genetic variation among enterococcal strains from different
geographical locations.

The presence of the sex pheromone determinants among enterococcal isolates appears to
be less frequently reported in the literature, perhaps due to their vaguely established direct
role in enterococcal virulence. Although some authors report their potential role as
chemo-attractants for human neutrophils, the greatest concern associated with sex
pheromones is the conjugative transfer of sex pheromone responsive plasmids which may
harbour antibiotic resistant and/or virulence genes. Similar to the trend observed with
other virulence determinants, the sex pheromones are frequently identified among E.
faecalis isolates (Eaton & Gasson, 2001) but have also been reported in E. faecium strains
from various sources (Abriouel et al., 2008). Landete et al., (2018) reported the presence
of cob, cad, ccf, and cpd in both E. faecalis and E. faecium isolates but the incidence of
each sex-pheromone determinant was higher in E. faecalis in all cases (84.6 v 0%, 84.6 v
20%, 92.3 v 80% and 76.9 v 14.4%, respectively) (Landete et al., 2018). In the study by
Eaton and Gasson who examined the presence of virulence factors among starter, food
and medical E. faecalis and E. faecium isolates, the sex pheromone determinants were
detected exclusively in E. faecalis, regardless of the source (Eaton & Gasson, 2001). In
contrast, in a recent study on enterococci isolates from retail shrimp, the cob, ccf and cpd
determinants were detected at a similarly high level in both E. faecalis and E. faecium
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isolates (Chajęcka-Wierzchowska et al., 2016). The disparate reports in the literature
regarding the prevalence of virulence factors among enterococcal isolates, particularly
for gelE and the sex pheromone determinants, reaffirms the requirement for further
research in order to fully elucidate the incidence of virulence factors among enterococci.

In most cases in the literature, species exhibiting virulence traits were not necessarily
positive for all traits, thereby strengthening the argument that the presence of virulence
factors among enterococci is very much strain-specific (Abriouel et al., 2008; Eaton &
Gasson, 2001; Franz et al., 2001; Lepage et al., 2006; Martín-Platero et al., 2009).
Therefore, although virulence factors have been detected among Enterococcus isolates
from several sources, including food, it may be equally possible to identify strains which
do not harbour virulence genes and may be considered ‘safe’ and suitable for use in food
and/or food fermentations. Furthermore, although the presence of virulence genes
suggests a putative role in pathogenesis, food-borne enterococcal infections have never
been reported (Chajęcka-Wierzchowska et al., 2017; Ogier & Serror, 2008).
Nevertheless, the presence of virulence factors alone cannot fully explain the role of
enterococci in disease development. Resistance to a wide range of antibiotics, particularly
those of clinical importance, has also been associated with the pathogenesis of
enterococci. Therefore, due to the importance of enterococci as opportunistic pathogens,
the incidence of Antibiotic Resistant Enterococci (ARE) is an important area of
investigation.

Antibiotic resistance
Overuse and misuse of antibiotics to treat infections represents a public health risk as it
can result in the emergence of resistant forms of disease-causing bacteria. Resistance to
a wide variety of antibiotics is a contributing factor to pathogenicity and impedes medical
treatment of enterococcal infections as therapeutic options become limited. Virulence of
enterococci is strongly enhanced by their frequent resistance to antibiotics and, although
typically associated with clinical environments, antibiotic resistant enterococci are
widespread in food and have been found in meat, dairy products and ready-to-eat foods
(Franz et al., 2001; Giraffa et al., 1997; Hosseini et al., 2016). Like other Gram-positive
bacteria, enterococci can display ‘intrinsic’ (natural) resistance to a number of antibiotics,
mediated by the presence of antibiotic resistance genes on the chromosome. In some
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strains, particularly of clinical origin, antibiotic resistance can also be ‘acquired’
(transferable), and is typically mediated by genes residing on plasmids or transposons
(Majhenič, 2006).
Enterococci are intrinsically resistant to several antibiotics including cephalosporins, βlactams, sulphonamides and semi-synthetic penicillins such as oxacillin (Bhardwaj et al.,
2008; Klare et al., 2003). Furthermore, E. faecalis is intrinsically resistant to
streptogramins, while other species such as E. gallinarum and E. flavescens show low
level intrinsic resistance to aminoglycosides and vancomycin. Nevertheless, low levels
of resistance to aminoglycosides can be overcome by the synergistic effect observed by
combining penicillin with an aminoglycoside such as gentamicin or ampicillin (Foulquié
Moreno et al., 2006; Klare et al., 2003). Acquired resistance is of greater concern as it
may lead to the development and persistence of multidrug-resistant enterococci not
naturally found within an environment. The acquisition of resistance genes often occurs
by conjugation using pheromone-responsive plasmids, conjugative plasmids, or
conjugative transposons with the potential to carry multiple antibiotic resistance genes
(Arias & Murray, 2012). Examples of acquired resistance include resistance to
chloramphenicol, erythromycin, clindamycin, tetracycline, aminoglycosides such as
gentamicin and streptomycin, fluoroquinolones such as ciprofloxacin, and glycopeptides
such as teicoplanin and vancomycin (Bhardwaj et al., 2008; Klare et al., 2003).

Vancomycin Resistant Enterococci (VRE)
VRE are a major cause for concern as vancomycin is often one of the last options for
antimicrobial therapy in enterococcal infections. Thus, if multi-drug resistance is
observed in pathogenic enterococci, including resistance to vancomycin, resulting
infections are then difficult to cure since the bacteria do not respond to treatment with
conventional antibiotic therapy. Furthermore, VRE are typically resistant to all standard
anti-enterococcal drugs, thereby constituting a serious risk group (Foulquié Moreno et
al., 2006). Consequently, new drugs are being evaluated in order to replace vancomycin.
Examples include semi-synthetic glycopeptides, everninomycins and daptomycin
(Giraffa, 2002). Originally, six identified gene clusters were considered to be responsible
for mediating vancomycin resistance in enterococci: vanA, vanB, vanC, vanD, vanE, and
vanG. However, more recently, the vanL, vanM, and vanN gene clusters have been
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described and have also been shown to confer resistance to the glycopeptides vancomycin
and teicoplanin in enterococci (Table 1.4). The vanA and vanB gene clusters are
considered the most clinically important regarding glycopeptide resistance as they are
most frequently observed in E. faecalis and E. faecium and can be transferred horizontally
and vertically (Araújo & Ferreira, 2013; Bhardwaj et al., 2008; Kayser, 2003; Klare et
al., 2003). Elsewhere in our work, we screened 25 E. faecalis strains, isolated mostly
from foods, for the presence of the vanA and vanB determinants. None of the 25 isolates
harboured either of these genes and were completely susceptible to vancomycin when
assayed using the disc diffusion method for antibiotic resistance. These results show that
our isolates, which are mostly from foods, do not contain the important gene clusters
associated with acquired vancomycin resistance, while phenotypic sensitivity of the
isolates to vancomycin was also demonstrated (Graham et al. 2019b, under review).

26

Chapter I

Table 1.4. Glycopeptide resistant gene clusters in enterococci.
Gene cluster
vanA

Resistance mediated
Vancomycin: High level
Teicoplanin: High level

MIC (µg/ml)
64-1000
16-512

Species
E. faecium, E. faecalis

Genetic determinant
Acquired

Transferable
Yes

Reference
(Cetinkaya et al., 2000)

vanB

Vancomycin: Variable
Teicoplanin: Susceptible

4-1024
≤0.5

E. faecium, E. faecalis

Acquired

Yes

(Cetinkaya et al., 2000)

vanC

Vancomycin: Low level
Teicoplanin: Sensitive

2-32
≤0.5

E. gallinarum, E.
casseliflavus

Intrinsic

No

(Cetinkaya et al., 2000)

vanD

Vancomycin: Intermediate
Teicoplanin: Low level

128
4

E. faecium

Acquired

No

(Perichon et al., 1997)

vanE

Vancomycin: Low level
Teicoplanin: Susceptible

16
0.5

E. faecalis

Acquired

No

(Fines et al., 1999)

vanG

Vancomycin: Intermediate
Teicoplanin: Susceptible

16
≤0.5

E. faecalis

Acquired

No

(Depardieu et al., 2003;
McKessar et al., 2000)

vanL

Vancomycin: Low level
Teicoplanin: Susceptible

8
≤0.5

E. faecalis

Acquired

No

(Boyd et al., 2008)

vanM

Vancomycin: High level
Teicoplanin: high level

>256
96

E. faecium

Acquired

Yes

(Xu et al., 2010)

vanN

Vancomycin: Low level
Teicoplanin: Susceptible

16
≤0.5

E. faecium

Acquired

Yes

(Lebreton et al., 2011)

MIC: Minimum Inhibitory Concentration.
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Antibiotic Resistant Enterococci (ARE) in food
The principle concern regarding the use of enterococci in food is their pathogenic
potential based on the transfer and/or acquisition of virulence and antibiotic resistant
genes. The increasing incidence of antibiotic resistance among clinical isolates poses the
question whether isolates of food origin could also possess antibiotic resistance traits.
Several studies carried out on antibiotic resistance among enterococcal isolates from food
have demonstrated that, although resistance to one or more antibiotics has been observed,
isolates of food origin still remain largely susceptible to clinically relevant antibiotics.
(Cariolato et al., 2008; Franz et al., 2001; Giraffa & Sisto, 1997; Hosseini et al., 2016;
Mannu et al., 2003; Teuber et al., 1999). In 2001, Franz et al. investigated the antibiotic
susceptibility of E. faecalis and E. faecium isolates from foods. Antibiotics utilised in the
study included ciprofloxacin, penicillin, erythromycin, chloramphenicol, tetracycline,
streptomycin, gentamicin, ampicillin and vancomycin. None of the tested strains were
resistant to all the antibiotics used in the study, while the incidence of resistance to
clinically relevant antibiotics such as ampicillin and vancomycin was low. This coincides
with the findings of Teuber et al. (1999) who also reported a low incidence of vancomycin
resistant enterococci in European cheeses (Teuber et al., 1999). More recently, ARE were
isolated from ready-to-eat salads, retail cheese, ham and raw meat but resistance to
vancomycin was low among the isolates (Pesavento et al., 2014). The low incidence of
resistance to clinically relevant antibiotics by enterococcal food isolates was also
observed in our work. We examined the antibiotic resistance profile of 25 E. faecalis
isolates, mainly of meat and dairy foods, and all 25 isolates were completely susceptible
to clinically relevant antibiotics including ampicillin, penicillin, the high-level
aminoglycoside gentamicin and the glycopeptides teicoplanin and vancomycin (Graham
et al. 2019b, under review). Similar to the incidence of virulence determinants among
enterococci, the occurrence of antibiotic resistance also varies between studies and
appears to be strain and region dependent.

Biogenic amines
Other potential risk factors that play a role in the pathogenesis of enterococci are biogenic
amines. These are organic basic compounds that occur in many foods such as fruit,
vegetables, cheese, eggs, wine, beer, fermented sausages and fish products. The most
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important biogenic amines occurring in foods are tyramine, histamine, putrescine,
tryptamine, p-phenylethylamine, spermine, spermidine and cadaverine (Giraffa, 2002;
Kučerová et al., 2009). Food intoxication caused by ingestion of biogenic amines may be
of clinical concern and is characterised by symptoms of increased blood pressure,
vomiting, allergic reactions and headaches. Biogenic amines are commonly found in
fermented foods due to the action of amino acid decarboxylases of microbial agents
included as starter cultures or present as part of contaminating microflora. The ability of
enterococci to form biogenic amines during growth in dairy products has been reported,
particularly in the case of tyramine, which is often considered to be the only biogenic
amine formed by enterococci (Aspri et al., 2017). However, this was disproved by the
findings of several authors who demonstrated the production of other biogenic amines
through histidine and tyrosine decarboxylase activities by enterococci during growth in
milk and other dairy products (Kučerová et al., 2009; Martín-Platero et al., 2009).
Nevertheless, the production of biogenic amines is dependent on the extent of
enterococcal growth and enterococci rarely reach sufficient cell numbers in cheese and
milk to be considered a threat regarding the production of biogenic amines (GiménezPereira, 2005). Furthermore, although production of biogenic amines by enterococci has
been reported, they have yet to be implicated in enterococcal disease. Therefore, although
an important consideration, it would seem judicious to evaluate these capacities in
enterococci isolated from foods and also in those used as starter cultures of probiotics.
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ENTEROCOCCI IN FOOD
Despite the consideration of certain enterococcal species as opportunistic pathogens, they
have a long history of safe use in foods and there are undeniable advantages associated
with their use in food, particularly in milk and other dairy products. Their applicability as
starter or adjunct cultures and associated benefits, pertaining to the improvement of the
organoleptic properties of milk and dairy products as well as the production of
bacteriocins, is frequently reported (Alvarez-Cisneros et al., 2012; Aymerich et al., 2000;
Franz et al., 2011; Giraffa, 2003). As probiotics, they contribute to the improvement of
microbial balance and can be used in the treatment of various diseases in humans and
animals (Benyacoub et al., 2003; Enck et al., 2008; Hlivak et al., 2005). Furthermore,
enterococci have also demonstrated the ability to generate bioactive milk hydrolysates
during fermentation, a phenomenon which has received considerable attention in
scientific literature in recent years (Miguel et al., 2006; Quirós et al., 2007).

Starter/adjunct cultures
The genus Enterococcus includes a wide range of strains suitable for use as starter
cultures where they positively contribute to the development of the organoleptic
properties of fermented foods, including meat, dairy and vegetable products. (Franz et al.,
2011). Although perceived in some cases as opportunistic pathogens, the inclusion of
enterococci in foods as starter cultures is possible. The Advisory Committee on Novel
Foods and Processes (ACNFP) permitted the use of E. faecium strain K77D as a starter
culture in dairy products (ACNFP, 1995). However, enterococci are generally perceived
to possess weak acidifying activities and are thus considered of minor importance as
primary starter cultures in dairy fermentations, particularly for cheese production. They
are of much greater benefit when applied as adjunct cultures (non-starter) for purposes
other than acid formation, which is the sole responsibility of the starter culture. Adjunct
cultures are typically added to improve the organoleptic properties of dairy products and
to accelerate ripening (Giraffa, 2003). They may also function as effective probiotics
(Bhardwaj et al., 2008). The technological functionality of enterococci in dairy products
was studied by several authors who assessed the suitability of certain enterococcal species
as starter/adjunct cultures in cheeses (Table 1.5).
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Table 1.5. Cheese products in which the technological functionality of enterococci has been
studied.
Origin

Cheese product

Reference

France

Venaco

(Casalta et al., 1997)

Greece

Feta

(Sarantinopoulos et al., 2002)

Iran

Lighvan

(Pirouzian et al., 2010)

Italy

Mozzarella

(Villani & Coppola, 1994)

Spain

Hispanico

(Oumer et al., 2001)

Spain

Cabreiro

(Centeno et al., 1999)

Enterococci as probiotics
The World Health Organisation (WHO) defines probiotics as “live microorganisms which
when administered in adequate amounts confer health benefits on the host” (FAO/WHO,
2002). Enterococci are natural inhabitants of the human and animal GI tract where they
contribute to digestion and have thus been considered for their potential role as probiotics
(Bhardwaj et al., 2008). Certain enterococcal species have successfully been applied as
probiotics to improve human and animal health. Perhaps the most common and best
researched Enterococcus probiotic strain is E. faecium SF68 (strain NCIMB 10415;
commercialised as Cernivet® and Cylactin®, Cerbios-Pharma SA, Barbengo,
Switzerland). In a double-blind, placebo-controlled clinical trial, SF68 proved effective
in reducing the incidence of antibiotic associated diarrhoea (Wunderlich et al., 1989). The
efficacy of E. faecium SF68 as a probiotic supplement was also demonstrated in feed and
has been used in dry dog food where it significantly enhanced immune function in young
dogs (Benyacoub et al., 2003). Similarly, E. faecalis Symbioflor 1 (SymbioPharm,
Herborn, Germany) is also a well-established probiotic for human health and is used to
treat recurring illness in the upper respiratory system. Likewise, in a one year human trial,
administration of probiotic E. faecium M-74 reduced serum cholesterol levels by 12%
(Hlivak et al., 2005).

Products containing probiotic organisms for human consumption are most often sold as
infant foods, fermented and non-fermented milks, and pharmaceutical preparations.
Gardiner et al. (1999) assessed the use of cheese as a delivery system of probiotic strains
to the GI tract of humans. E. faecium PR88, which is non-pathogenic, of intestinal origin,
acid and bile tolerant and has the ability to relieve irritable bowel syndrome i.e. properties
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required of a probiotic microorganism, was used as an adjunct culture in the production
of cheddar cheese. Not only did the strain lead to improvements in the texture and flavour
of the cheese, it also remained viable throughout the 9-month ripening period. Therefore,
the evidence suggested that cheddar cheese was a good carrier for the probiotic E. faecium
PR88 and that the strain would not only be beneficial for human health, but would also
improve the intrinsic properties of cheddar cheese (Gardiner et al., 1999). However,
enterococcal probiotics are usually not incorporated as starter or adjunct cultures, but are
rather used as food supplements in the form of pharmaceuticals (Franz et al., 2011).
Probiotic enterococci have been utilised in the treatment of irritable bowel syndrome
(Enck et al., 2008) and diarrhoea (Wunderlich et al., 1989), while health-promoting
properties such as hypocholesterolaemic (Guo et al., 2015) and immunostimulatory
(Habermann et al., 2002) effects have also been observed. Probiotic enterococci have also
been administered in animals such as poultry, pigs and cattle for competitive exclusion
of gastrointestinal pathogens and for immunostimulation (Franz et al., 2011).

Functionality of enterococci in milk and dairy products
Biochemical properties of technological interest
As previously mentioned, enterococci play a role in the development of the flavour, aroma
and texture of dairy products during fermentation. This can be attributed to the possession
of several biochemical properties of technological interest including acidifying, lipolytic
and proteolytic activities, as well as metabolism of carbohydrates and production of
volatile compounds (Bhardwaj et al., 2008; Foulquié Moreno et al., 2006). Although not
directly involved in the flavour development of fermented dairy products, bacteriocin
production is also an important biochemical trait of enterococci that is frequently reported
in the literature for its role in bio-preservation such as the prevention of food spoilage and
contamination (Achemchem et al., 2006; Alvarez-Cisneros et al., 2012). Evaluation of
these biochemical properties is important when considering the use of enterococcal
strains in food fermentations.

Acid production
Acid production is an important characteristic in dairy fermentations, particularly during
cheese manufacture, where it has an important role in the development of sensory
characteristics of the fermented products and exclusion of undesirable microorganisms.
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Milk has a pH of approximately 6.6 which must be reduced to <6.0 at the end of ripening
during cheese production. A rapid decrease in pH during cheese production (6.6 to 5.3 in
6 hours at 30 °C) is advantageous as it is essential for coagulation and flavour and aroma
development. It may also prevent the growth of accompanying microflora, which may be
particularly beneficial if spoilage and/or pathogenic microbes are present (Aspri et al.,
2017). In general, enterococci exhibit low milk acidifying ability, although data in the
literature is somewhat conflicting. In a study which assessed the biochemical properties
of enterococcal strains relevant to their technological performance in fermented dairy
foods, only 3 of 129 strains examined reduced the pH of milk below 5.9 in 6 hours, while
after 16 hours of growth, only 16.3% of strains decreased the pH below 5.0, thereby
demonstrating the slow and weak acidifying ability of enterococci (Sarantinopoulos et
al., 2001). Therefore, enterococcal isolates examined in this study would be of little
benefit as starter cultures. The authors also concluded that the most acidifying strains
belonged to the E. faecalis strains of food origin. The high acidifying potential of E.
faecalis compared to other enterococcal species was corroborated in the findings of other
authors (Giraffa, 2003; Suzzi et al., 2000). However, when enterococci from Turkish
Tulum cheese were examined for their technological properties, E. faecium strains
showed higher acidifying ability than E. faecalis (Tuncer, 2009). In agreement with the
majority of other studies, Jaouani et al. (2015) also reported that enterococcal strains
examined in their study were slow and weak acid producers. However, in contrast to the
findings of the aforementioned studies, the authors did not find differences in acidifying
activity between E. faecalis and E. faecium strains after 24 hours (Jaouani et al., 2015).
Similar observations were made in a more recent study by Aspri et al. (2017) who also
concluded that enterococci were considered slow and weak acidifiers. However, they did
not indicate if differences in acidifying activity were observed between different
enterococcal species (Aspri et al., 2017). Therefore, while authors agree that enterococci
are poor acidifiers, it is not completely clear whether acid production by enterococci is
species specific. Therefore, further studies are required to fully establish to which species
the most acidifying strains belong.

Lipolytic and esterolytic activity
Lipases are enzymes which hydrolyse substrates in emulsion, while esterases are enzymes
classified by the hydrolysis of substrates in solution (Giraffa, 2003). Lipases and esterases
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are understood to contribute to cheese flavour and texture through the hydrolysis of milk
fat followed by further conversion of released fatty acids into methylketones and
thioesters, which are compounds with implications in the development of cheese flavour.
In general, LAB (including enterococci) are only weakly lipolytic, although data is
limited and often contradictory. Sarantinopoulos et al. (2001) reported that lipolytic
activity was highest among E. faecalis strains, followed by E. durans while E. faecium
displayed the weakest lipolytic activity. However, on observation of esterolytic activity,
E. faecium displayed the highest level of esterase activity, while there were no significant
differences in esterase activity observed for E. faecalis and E. durans (Sarantinopoulos et
al., 2001). Furthermore, esterolytic activity among enterococci is considered higher than
most LAB (Tsakalidou et al., 1994). The contradictory data regarding the lipolytic
activities of enterococci is reflected in the findings of Durlu-Ozkaya et al. (2001), who
concluded that enterococci showed pronounced lipolytic activity, and Villani and
Coppola (1994), who reported that enterococci exhibit low lipolytic activity (DurluOzkaya et al., 2001; Villani & Coppola, 1994). Therefore, lipolytic and esterase activity
among enterococci appears to be strain and/or region specific.

Proteolytic activity
Data in the literature regarding the proteolytic activities of enterococci is perhaps the most
conflicting regarding the biochemical properties of the genus. Some authors have reported
high levels of proteolytic activity (Durlu-Ozkaya et al., 2001; Fabricio L Tulini et al.,
2016; Tuncer, 2009; Wessels et al., 1990), while others suggest that enterococci typically
display weak proteolytic activities (Morandi et al., 2006; Sarantinopoulos et al., 2002).
What authors do seem to agree on is that the most proteolytic strains belong to the species
E. faecalis, particularly of food origin (Dagdemir & Ozdemir, 2008; Morandi et al., 2006;
Sarantinopoulos et al., 2001; Tuncer, 2009; Villani & Coppola, 1994). This coincides
with the observation that the gelE gene conferring casein hydrolysis during enterococcal
growth in milk is more prevalent among E. faecalis than other species. Furthermore,
although E. faecalis are reported to be the most proteolytic species, there appears to be a
marked strain-to-strain variation of this phenotypic trait. This was observed elsewhere in
our work where 25 E. faecalis isolates displayed varying levels of proteolytic activity
(Graham et al., 2019b, under review). Even more interesting is the observation that
enterococci show higher proteolytic activities than other LAB, which makes them of
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particular importance for use in milk fermentations (Bhardwaj et al., 2008; Centeno et
al., 1996; Monika et al., 2017; Fabrício Luiz Tulini et al., 2015). Casein degradation by
proteolytic activity plays a significant role in cheese ripening and in the texture and
flavour development of fermented milk products, while proteolytic enterococci have also
demonstrated the ability to generate milk hydrolysates with biological activity,
particularly in the form of bioactive peptides (Gútiez et al., 2014; Miguel et al., 2006;
Quirós et al., 2007). Therefore, evaluation of proteolytic activity among enterococcal
isolates is important for their use in further applications in the food industry.

Influence of citrate and pyruvate metabolism on the production of volatile compounds
Data on citrate and pyruvate metabolism by enterococci is reported less often than the
previously discussed biochemical properties. Nevertheless, metabolism of these organic
acids is an important consideration from a technological viewpoint as they are broken
down into a number of volatile compounds including acetaldehyde, ethanol, diacetyl,
acetone and acetoin, which contribute to the flavour and aroma of fermented dairy
products (Giraffa, 2003). The ability of E. faecalis, E. faecium and E. durans strains to
utilise citrate and pyruvate as the sole carbon sources was demonstrated by
Sarantinopoulos et al., (2001) although strain to strain variation existed and E. faecalis
utilised these organic acids at a quicker rate compared to the other two species
(Sarantinopoulos et al., 2001). Nevertheless, all species were shown to produce varying
concentrations of aldehyde, ethanol and acetoin, which were expertly summarised in
tabular format by Giménez-Pereira (2005). Therefore, it appears that enterococci have the
metabolic potential to actively contribute to the aroma and flavour development in cheese
and further confirms their significance in the development of the organoleptic properties
of fermented dairy products.
Bacteriocin production
Enterococci and their enterocins
The contribution of enterococci to food is not limited in their ability to influence the
rheological and organoleptic properties of fermented products. They also produce several
enzymes that promote other important biochemical transformations linked to food biopreservation. Numerous enterococcal isolates, mainly E. faecalis and E. faecium, produce
bacteriocins, called enterocins. These are small, ribosomally synthesised, extracellularly
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released antimicrobial peptides that have demonstrated inhibitory activity towards
spoilage bacteria and food-borne pathogens such as Listeria monocytogenes
(Achemchem et al., 2006), Escherichia coli (Gálvez et al., 1989), Vibrio cholerae
(Simonetta et al., 1997), Campylobacter spp., Salmonella spp. (Line et al., 2008),
Staphylococcus aureus and Clostridium spp. (Cintas et al., 1997). Enterocins typically
belong to class II bacteriocins which are regarded as small, heat stable non-lantibiotics.
Bacteriocin-producing enterococci have been isolated from several foods including
fermented meats (Aymerich et al., 1996; Casaus et al., 1997; Cintas et al., 1998), dairy
products (Tarelli et al., 1994) and vegetables (Franz et al., 1996). Even more promising
is the observation that some strains can simultaneously harbour multiple bacteriocinrelated genes (Hanchi et al., 2018). For example, E. faecium L50, a producer of enterocin
L50A and L50B, also produces enterocin P and enterocin Q (Cintas et al., 2000). This
provides such strains with a strong competitive advantage over other microbial species in
food applications and other ecological niches. Some of the well-established bacteriocins
produced by enterococci are outlined in Table 1.6.

Table 1.6. Well-characterised bacteriocins produced by enterococci.
Bacteriocin

Producer strain

Source

Target microorganisms*

Reference

Enterocin A

E. faecium CTC492

Fermented sausage

Listeria spp.

(Aymerich et al., 1996)

Enterocin B

E. faecium T136

Fermented sausage

Listeria spp.

(Casaus et al., 1997)

Enterocin P

E. faecium P13

Fermented sausage

L. monocytogenes, S. aureus,

(Cintas et al., 1997)

C. perfringens, C. botulinum
Enterocin L50A and L50B

E. faecium L50

Fermented sausage

L. monocytogenes

(Cintas et al., 1998)

Bacteriocin 31

E. faecalis YI717

Human origin

L. monocytogenes

(Tomita et al., 1996)

Enterocin AS-48

E. faecalis S-48

Human origin

L. monocytogenes, Bacillus

(Gálvez et al., 1989,

spp., S. aureus, E. coli,

1986)

Pseudomonas spp.
Enterocin E-760

E. durans, E. faecium

Chicken ceca

Campylobacter spp.,

or E. hirae

(Line et al., 2008)

Salmonella spp., E. coli,
broad range of Gram-positive

Cytolysin (CylLL, CylLs)

E. faecalis DS16

Clinical origin

Broad range of Gram-positive

(Gilmore et al., 1994)

bacteria
*

Where information pertaining to the target organisms was not obtained from the reference provided in the
table, the data was obtained from BACTIBASE, a database for bacteriocin characterisation (Hammami et
al., 2007).
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Application of enterococcal enterocins in food
Enterocins possess great potential for application in the dairy industry as they exhibit
desirable dairy-grade traits such as strong antilisterial effects, production and stability in
milk at 30-37 °C, are compatible with other starter LAB species, and have stability over
a wide range of pH values (Giraffa, 2003). Two main application methods concerning
bacteriocins are possible: the inclusion of the antibacterial peptide as a food additive, or
by directly including the bacteriocin-producing strain(s) in the food system as starter or
antimicrobial cultures. The latter appears favourable in many cases as certain strains may
also provide additional benefits such as the development of flavour and aroma,
improvements in the ripening process, probiotic characteristics, and production of
bioactive hydrolysates during fermentation. However, in the case where an enterococcal
strain produces an enterocin with a broad inhibitory spectrum but is also in possession of
putative pathogenic traits, the inclusion of the purified peptide as a food additive may be
considered the safer, more practical approach. The applicability of bacteriocin-producing
enterococci and/or the enterocins they produce has been studied in a variety of fermented
foods. For example, in dairy products, the strain E. faecium 7C5 (produces enterocin 7C5)
was shown to inhibit the growth of Listeria innocua when included as a co-culture in milk
(Giraffa et al., 1995), while, in a different study, enterocin CCM 4231 was used to control
the growth of L. monocytogenes and S. aureus in soy milk (Lauková & Czikková, 1999).
The applicability of enterocins either through fermentation with enterocin-producing
strains or as food additives has also been demonstrated in meat. E. faecium RZS C13
(producing enterocin RZS C13) strongly inhibited the growth of Listeria spp. during the
fermentation of sausage meat (Callewaert et al., 2000), while purified enterocins A and
B had an antilisterial effect in meat products such as cooked ham, raw pork and chicken
(Aymerich et al., 2000). Therefore, regardless of the method or food system in which they
are applied, enterococcal enterocins possess great potential for use as bio-preservatives
in fermented food applications (Foulquié Moreno et al., 2006).
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PRODUCTION OF BIOACTIVE PEPTIDES
Isolation and characterisation of bioactive peptides
In addition to the aforementioned biochemical properties of technological benefit,
enterococci have also demonstrated the ability to produce bioactive peptides during
fermentation, particularly in milk. Bioactive peptides are typically short protein fragments
(2-20 amino acid residues) with hormone- or drug-like activity. Research on bioactive
peptides provides insightful information on the impact of dietary proteins on health. In
addition to their nutritional value, they exert positive physiological effects in the body
and may thus influence health (Fitzgerald & Murray, 2006; Korhonen, 2009). Bioactive
peptides have been isolated from a variety of foods including animal products such as
dairy foods, meat and fish, and plant sources such fruits, vegetables and cereals (Iwaniak
et al., 2018). They are often encrypted within the parent protein molecule and require
release to unlock their true potential. This can be achieved using digestive enzymes, by
hydrolysis in vitro with specific proteolytic enzymes or by the proteolytic activity of
microorganisms during fermentation. The industrial scale production of bioactive
peptides is still limited by high costs associated with enzymes used for protein hydrolysis
and the lack of suitable large-scale technologies. Therefore, food fermentation with
proteolytic microorganisms provides an alternative, cost-effective approach for the
derivatisation of peptides with biological activity and is already widely applied in the
dairy industry (Ryan et al., 2011; Walther & Sieber, 2011).

Following the hydrolysis of the protein substrate, several steps are employed to identify
and characterise bioactive peptides (Fig. 1.4). Subsequent to hydrolysis, the crude protein
hydrolysates are assayed for bioactivities of interest. Following the detection of activity,
the hydrolysates are fractionated based on peptide size, which is typically performed
using ultrafiltration through filter units of desirable molecular weight cut off points. The
permeate is then subjected to further purification to separate individual peptides which
can be achieved using Reversed-Phase High Performance Liquid Chromatography (RPHPLC). Peptide fractions are then assayed for bioactivity once again following RP-HPLC
and those displaying bioactivity are selected for further analysis. Peptides within these
fractions are identified using the combined techniques of mass spectrometry and amino
acid sequence determination. Finally, identified peptides are chemically synthesised to
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obtain them in their pure forms. The chemically synthesised peptides are subjected to
further characterisation which includes repeating relevant bioassays to verify the
bioactivity which was initially observed in the RP-HPLC fractions. The inhibition
potential of synthesised peptides is commonly measured as percentage inhibition or IC50
(the concentration of peptide required to inhibit 50% of the enzymatic reaction) where
appropriate (Hayes et al., 2007; Kehinde & Sharma, 2018; Ryan et al., 2011).

Figure 1.4. Typical work flow for the isolation and identification of bioactive peptides in food
proteins.

Milk-derived bioactive peptides
To date, milk proteins provide the greatest source of biologically active peptides which
exert a wide range of physiological functions upon release including antioxidant,
antihypertensive, immunomodulatory, antimicrobial and hypocholesterolaemic effects
(Fitzgerald & Meisel, 2003; Park & Nam, 2015). Subsequently, the liberation of bioactive
peptides from milk is currently the subject of intensive research, particularly by the
proteolytic activities of fermenting microorganisms. Several LAB species have
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demonstrated the ability to generate milk hydrolysates during fermentation which have
biological activity (Apostolidis, Kwon, Ghaedian, et al., 2007; Gobbetti et al., 2000;
Regazzo et al., 2010). Although bacteria of the genera Lactobacillus, Bifidobacteria and
Lactococcus are commonly used for this purpose, there is merit in exploring the benefits
of other genera of LAB. Enterococci are leading microbes in fermentation processes of
traditional foods, are commonly isolated from dairy products and show higher proteolytic
activities compared to other LAB (Bhardwaj et al., 2008; Centeno et al., 1996; Monika
et al., 2017; Fabrício Luiz Tulini et al., 2015). Furthermore, the proteolytic activity of
enterococci is exerted in a strain- and species-dependent manner leading to a large variety
of proteolytic activities. This underlines the high potential of enterococci to generate
novel bioactive peptides and strengthens the argument that they are indeed suitable
candidates for the liberation of bioactive peptides from food, particularly from milk and
other dairy products.

Production of bioactive peptides by enterococci
The generation of Enterococcus-derived food hydrolysates with biological activity is a
recently developed concept and thus, data in the literature regarding this topic is
somewhat limited compared to the extensive information available on the applicability of
enterococci as starter/adjunct, probiotic or bio-preservative cultures. Nevertheless, it is an
interesting and important area of investigation. Angiotensin Converting Enzyme
Inhibitory (ACEI) and antihypertensive peptides, particularly those derived from milk
proteins, are the most frequently studied bioactive peptides to date and coincides with the
high prevalence of hypertension worldwide (Gútiez et al., 2013; Hayes et al., 2007;
Martínez-Maqueda et al., 2012; Phelan et al., 2014). Their effectiveness has been
demonstrated in vitro (Gútiez et al., 2013; Phelan et al., 2014; Pihlanto, 2006), in vivo
(Miguel et al., 2006; Quirós et al., 2007) and in clinical studies (Hata et al., 1996; Mizuno
et al., 2005; Townsend et al., 2004). Hypertension is a chronic degenerative disease
characterised by high blood pressure. The Renin-Angiotensin System (RAS) is a
signalling pathway that is partially responsible for regulating blood pressure (Fig 1.5).
The body secretes a proteolytic enzyme called renin from the kidneys as a defensive
mechanism to reduce blood pressure. Renin catalyses the conversion of angiotensinogen,
which is continuously secreted from the liver, to angiotensin I, an inactive decapeptide.
Angiotensin Converting Enzyme (ACE) catalyses the cleavage of the biologically
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inactive angiotensin I to its potent vasoconstrictor, angiotensin II (octapeptide), a process
which is considered one of the main components of the RAS. Furthermore, ACE degrades
bradykinin, a hormone which exerts important vasodilation activity (Ryan et al., 2011).
Therefore, peptides which exert antihypertensive effects by inhibiting the activity of ACE
may play a crucial role in minimising the risk factors and alleviating the symptoms of
hypertension. Although food derived ACE inhibitors tend to have lower ACEI activity in
vitro compared to ACEI drugs like captopril, they do not display harmful side effects,
such as dry cough and angioedema, which are often associated with chemically
synthesised drugs (Riordan, 2003).

Figure 1.5. The renin-angiotensin system showing Angiotensin Converting Enzyme Inhibitory
(ACEI) activity.

The suitability of milk as an abundant source of ACEI and antihypertensive peptides has
been documented by several authors (FitzGerald et al., 2004; Fitzgerald & Murray, 2006;
Korhonen, 2009; Ricci et al., 2010). Accordingly, the majority of information in the
literature regarding the production of bioactive milk hydrolysates by enterococci is based
on those which exhibit ACEI activity. Elsewhere in our work, we demonstrated that milk
fermented with E. faecalis isolates, primarily of food origin, displayed high ACEI activity
(Graham et al., 2019a). In later studies by our group, we identified, purified and
chemically synthesised the bioactive peptides responsible for the observed ACEI activity
in milk fermented with E. faecalis DPC5154, a fontina cheese isolate (Graham et al.
2019c, unpublished data). The ACEI and/or antihypertensive activity of milk fermented
with enterococci has also been reported by several other authors (Martinez-Villaluenga
et al., 2012; Muguerza et al., 2006; Regazzo et al., 2010), while the bioactive peptides
responsible for ACEI activity in Enterococcus fermented milk were also shown (Gútiez
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et al., 2014, 2013). The antihypertensive activity of E. faecalis milk-derived peptides has
also been demonstrated in vivo in rats (Miguel et al., 2006). Therefore, there is merit in
exploring the benefits of Enterococcus milk-derived ACEI peptides as they may prove
useful as an effective therapeutic approach in the treatment of hypertension.

Although less often reported, other activities have been observed for Enterococcusderived milk hydrolysates and include immunomodulatory (Molina et al., 2015), antiinflammatory (Martinez-Villaluenga et al., 2012) and antioxidant activity (Gútiez et al.,
2013; Martinez-Villaluenga et al., 2012). In our work, when we fermented BSM with E.
faecalis isolates, we also observed antioxidant activity in the fermentates (Graham et al.,
2019a). We later identified the peptides which contributed to the antioxidant effects in
the fermentate of E. faecalis DPC5154, the strain which generated the milk fermentate
with the highest antioxidant activity (Graham et al., 2019a, Graham et al., 2019c,
unpublished data). Even more interesting was the observation of anti-hyperglycaemic
activity of the E. faecalis milk fermentates, which was measured by the inhibition of the
α-glucosidase enzyme in vitro (Graham et al., 2019a). Similar to the works on ACEI and
antioxidant activity, we also identified the peptides in the milk fermentate of DPC5154
(generated the fermentate with the highest α-glucosidase inhibitory activity) which
contributed to the α-glucosidase inhibitory activity (Graham et al. 2019c, unpublished
data). α-Glucosidase inhibitory peptides are found in a wide range of foods including
milk, eggs, fish and plant-based foods (Patil et al., 2015) and, although α-glucosidase
inhibitory activity has previously been observed in milk fermented with other LAB
species (Apostolidis, Kwon, Ghaedian, et al., 2007; Ayyash et al., 2018), to our best
knowledge, we are the first to have reported on E. faecalis milk-derived peptides
conferring α-glucosidase inhibitory activity. Particularly promising in our work is the
observation that three peptides were identified in the DPC5154 fermented milk which
were responsible for conferring the ACEI, antioxidant and α-glucosidase inhibitory
activity discussed above. Thus, we are also the first group to report on the multifunctional
bioactivities of the E. faecalis DPC5154 milk derived peptides. The liberation of bioactive
peptides which exhibit multiple biological effects is an important area of investigation as
they may simultaneously elicit multiple health benefits thereby offering significant
advantages over peptides which only confer a single biological effect. This may prove
particularly beneficial in the case where interrelated disorders exist, such as type 2
diabetes and hypertension. Therefore, peptides displaying more than one biological
42

Chapter I

function may be useful as multifunctional ingredients in functional foods or as
nutraceuticals for the treatment of relevant health implications.

Limitations, challenges and commercial applications
The optimal exploitation of bioactive peptides for human nutrition and health represents
an exciting scientific and technological challenge, while at the same time offering
potential for commercially successful applications. The desirable health benefits of
bioactive peptides make them suitable for use as ingredients in functional foods and
nutraceuticals. Although several studies have demonstrated the potential human health
connotations of bioactive peptides in vitro and in vivo, much remains to be done before
their widespread application as functional food ingredients. There are several limitations
associated with their production and commercialisation ranging from their initial
identification to their observed physiological effect in the body. One of the biggest
challenges relates to the bioavailability of bioactive peptides. In order to exert a
physiological effect, the peptide(s) must reach its target site in the bioactive form. Several
factors influence the bioavailability of peptides such as their structure and composition,
technological aspects such as oral delivery systems, individual aspects such as diet and
gut microbiota, and mechanistic factors such as the mechanism by which bioactive
peptides exert their physiological effect in the body (Iwaniak et al., 2018). Furthermore,
if the bioactive peptides are intended for oral ingestion, a series of processes must be
considered. The peptides must resist the action of gastrointestinal and brush border
peptidases, be transported through the intestinal wall into the blood, and display resistance
and stability towards the action of peptidases therein (Kehinde & Sharma, 2018;
Vermeirssen et al., 2004). Evidently, bioactive peptides must overcome several hurdles
in the body when ingested in order to reach their target site in the active form and it is
highly unlikely that the amino acid sequences are not subjected to any alterations before
eliciting their activity. Therefore, several approaches have been designed to improve oral
administration including chemical modifications to the peptide, genetically engineering a
microorganism to express the peptide followed by the subsequent delivery of the peptide
in situ, and microencapsulation to control the release of functional peptides (Vermeirssen
et al., 2004). In any case, detailed clinical trials involving double-blind placebocontrolled studies are necessary to validate the efficacy of bioactive peptides intended for
human consumption. Nevertheless, several food products contain bioactive peptides that
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are known to reach the cardiovascular system intact, thereby exerting their associated
biological effect. A few commercial developments have been launched on the market and
this trend is likely to continue with the ever-increasing knowledge regarding the
functionality of bioactive peptides. They are utilised in several commercialised
nutraceutical products such as Calpis®, Ameal S® (Calpis Co., Tokyo, Japan) and
Evolus® (Valio Ltd., Helsinki, Finland), all of which contain the well-established
antihypertensive peptide sequences Val-Pro-Pro and Ile-Pro-Pro (Korhonen, 2009). Other
commercial dairy products contain peptides with anti-cariogenic, mineral-binding, stressrelieving and anxiety reducing properties and examples are provided in Table 1.7. Further
research on the bioavailability and structure-activity relationship of bioactive peptides
can improve isolation and production. With careful consideration of regulatory aspects
surrounding the development of functional foods and nutraceuticals and their associated
health claims, Enterococcus milk-derived bioactive peptides, particularly those which
exhibit multiple functionalities, can play an important role in human nutrition and health.

Table 1.7. Commercial products containing bioactive peptides derived from milk products.
Product
Ameal S®

Product type
Fermented milk

Active peptide
VPP, IPP

Health claim
Anti-hypertensive

Manufacturer
Calpis Co., Japan

BioPURE-GMP

Whey protein isolate

Κ-casein f(106-169)

Prevention of dental
caries

Davisco, USA

BioZate ®

Whey protein isolate

Β-lactoglobulin
fragments

Anti-hypertensive

Davisco, USA

C12 Peptide®

Bovine milk protein
hydrolysate

FFVAPFEVFGK

Anti-hypertensive

DMV International,
the Netherlands

Calpis®

Sour milk

VPP, IPP

Anti-hypertensive

Calpis Co., Japan

Casein DP®

Casein hydrolysate

FFVAPFPEVFGK

Anti-hypertensive

Kanebo Ltd., Japan

Evolus®

Fermented milk

VPP, IPP

Anti-hypertensive

Valio Ltd., Finland

Lactium®

Flavoured milk drink,
tablets, confectionary

YLGYLEQLLR

Anti-stress, modulate
anxiety

Ingredia, France

PeptoPro®

Ingredient/hydrolysate

Casein derived peptides

Improves athletic
performance and muscle
recovery

DSM Food
Specialities, the
Netherlands

Vivinal® Alpha

Whey protein
hydrolysate

Whey derived peptide

Aids relaxation and sleep

Borculo Domo
Ingredients (BDI),
the Netherlands
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CONCLUSIONS AND PERSPECTIVES REGARDING THE USE OF
ENTEROCOCCI IN FOOD
Despite a long history of safe use in foods, the question of whether enterococci can be
used as starter, adjunct or probiotic cultures for the development of new food products
remains controversial and difficult to answer. The principle concern regarding the use of
enterococci in foods is associated with their status as opportunistic pathogens, capable of
causing infection in immunocompromised patients in nosocomial settings. The
possession of putative virulence factors and an increasing incidence of antibiotic
resistance in some species is impeding the progression of these microbes as important
cultures in food technology applications. However, the presence of virulence factors does
not explicitly infer that the strains will cause disease, but rather that they have pathogenic
potential. For example, virulence determinants associated with adhesion and colonisation
were detected in E. faecalis Symbioflor 1, a strain that has successfully been used as a
probiotic for more than 20 years without any reports of infection (Domann et al., 2007;
Franz et al., 2011; Fritzenwanker et al., 2013). It is noteworthy that the presence of
virulence genes does not necessarily imply that they are functional. For example, isolates
carrying the gelE gene may not produce gelatinase. Furthermore, the ability to cause
infection is considered a more intricate process than the sole possession of virulence
determinants (Chajęcka-Wierzchowska et al., 2017; Franz et al., 2011).

Moreover, although particular strains may be considered opportunistic pathogens, it is
doubtful they would cause disease in healthy individuals. Enterococci strains from food
that harbour single or multiple virulence determinants have been reported but despite this,
the morbidity of healthy humans resulting from enterococcal infections appears to be very
low (EFSA, 2012; Franz et al., 2003). Similarly, there is no data showing a direct
relationship between the consumption of foods containing virulent enterococci and illness
(Chajęcka-Wierzchowska et al., 2017; Ogier & Serror, 2008). In addition, enterococcal
isolates from food are generally susceptible to antibiotics of clinical relevance such as
ampicillin, penicillin, high-level aminoglycosides and the glycopeptides teicoplanin and
vancomycin. Likewise, genomic studies, and those pertaining to the occurrence of
virulence factors among enterococci from foods, have demonstrated that the incidence of
virulence factors is strain specific and that isolates from starter cultures harbour fewer
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virulence determinants than food isolates, which, in turn, possess less than strains of
clinical origin. Therefore, starter cultures and food isolates have a lower potential for
pathogenicity (Eaton & Gasson, 2001; Franz et al., 2001; Lepage et al., 2006).

Promisingly, recent advances in molecular epidemiology and establishment of modern
genetic tools have enabled the differentiation of pathogenic from non-pathogenic
enterococci. However, despite these recent advances in scientific knowledge,
Enterococcus species neither have Generally Recognised as Safe (GRAS) status nor have
they been included in the Qualified Presumption of Safety (QPS) list (Hanchi et al., 2018).
However, in some cases, it appears certain enterococcal strains can be safely applied in
food systems. Organisations such as EFSA and the ACNFP permitted the use of certain
enterococcal strains as foods additives and supplements based on a careful case-by-case
assessment (ACNFP, 1995; EFSA, 2012). Similarly, a safety assessment carried out by
several authors enabled the identification of enterococcal strains which could be
considered safe and which were in possession of beneficial features for application in
food (Li et al., 2018; Nascimento et al., 2019). Enterococci have also been used as
probiotics in the production of feed additives to prevent diarrhoea or to improve growth
in animals (Franz et al., 2011). Thus, there seems to be positive evidence that enterococci
can find application in food. As discussed previously, enterococci provide several
benefits when included as starter or adjunct cultures in food fermentation, particularly in
milk. Therefore, a careful and balanced evaluation of both the beneficial and undesirable
traits of each particular enterococcal strain may enable the selection and subsequent
utilisation of certain strains in food applications. Ideally, any strains considered for use
in food should not harbour any of the known virulence determinants, display
susceptibility to clinically relevant antibiotics and should not produce toxins or biogenic
amines (Fig. 1.6).
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Figure 1.6. Proposed decision scheme for the safety assessment of enterococci for use in food
applications. Modified from (Hanchi et al., 2018).

One area that requires particular attention is the ability of enterococci to transfer or
acquire virulence and/or antibiotic resistant genes through mobile genetic elements.
Enterococci are in possession of highly efficient gene transfer mechanisms enabling them
to transfer acquired determinants to other enterococcal strains or species of other genera,
including both pathogenic and non-pathogenic bacteria. Therefore, of particular concern
is that the consumption of food harbouring large numbers of enterococci creates a
population of potential donor and recipient cells in the human gut, where safe strains may
become pathogenic by the acquisition of virulence and/or antibiotic resistant genes.
Indeed, future safety assessment should include careful examination of the transferability
of virulence and antibiotic resistant genes between enterococci and to other
microorganisms. Studies are urgently needed to further improve our understanding of the
mechanisms of enterococcal pathogenesis, and to reconcile the disparate reports in the
literature regarding both their technological and safety features. We propose that the use
of enterococci in foods, as starter, adjunct, probiotic or bio-preservative cultures should
be possible on a case-by-case basis establishing their innocuity or at least the absence of
virulence determinants and acquired antibiotic resistance genes. Any strain considered
safe for use should be continuously monitored for genetic change.
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In conclusion, this review provides an update on the potential application of Enterococcus
species in food with a consideration for associated pathogenic traits pertaining to
antibiotic resistance and virulence factors and the implications they may have in disease
development. Modern scientific techniques, up-to-date knowledge of enterococci and
their biochemical properties of technological interest, implementation of adequate
guidelines and consideration for appropriate legislation and regulatory aspects may help
industry, health-staff and consumers accept enterococci, like other LAB, as potential
candidates for useful and beneficial applications in food.
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Chapter II

Development of a rapid, one-step screening
method for the isolation of presumptive
proteolytic enterococci

Published in the Journal of Microbiological Methods
Graham, K., Rea, R., Simpson, P., Stack, H. (2017). Development of a rapid, one-step
screening method for the isolation of presumptive proteolytic enterococci. Journal of
Microbiological Methods 132, 99–105.
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ABSTRACT
Individual strains of enterococci can show higher proteolytic activities than other lactic
acid bacteria and thus have received considerable attention in scientific literature in recent
years. Proteolytic enzymes of enterococci have warranted the use of some species as
starter, adjuncts or protective cultures and as probiotics, while in some strains they have
also been linked with virulence. Consequently, the isolation and identification of
proteolytic enterococci is becoming of increasing interest and importance. However,
current screening methods for proteolytic enterococci can be time consuming, requiring
a two-step procedure which may take up to 96 hours. This study describes a method,
utilising Kanamycin Skim Milk Aesculin Azide (KSMEA) agar, for the isolation of
proteolytic enterococci in one-step, thereby significantly reducing screening time.
KSMEA combines the selective properties of Kanamycin Aesculin Azide Agar (KAA)
with skim milk powder for the detection of proteolytic enterococci. Enterococci produced
colonies with a black halo on KSMEA which were accompanied by a zone of clearing in
the media when enterococci were proteolytic. KSMEA medium retained the selectivity
of KAA, while proteolytic enterococci were easily distinguished from non-proteolytic
enterococci when two known strains were propagated on KSMEA. KSMEA also proved
effective at isolating and detecting enterococci in raw milk, faeces and soil. Thirty-three
isolates recovered from the screen were confirmed as enterococci using genus-specific
primers. Proteolytic enterococci were present in the raw milk sample only and were easily
distinguishable from non-proteolytic enterococci and other microorganisms. Therefore,
KSMEA provides a rapid, one-step screening method for the isolation of presumptive
proteolytic enterococci.
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INTRODUCTION
Enterococci are ubiquitous lactic acid bacteria (LAB) that constitute an important part of
environmental, food and clinical microbiology. Enterococci represent an emerging pool
of opportunistic pathogens owing to the possession of virulence factors and an association
with an increasing incidence of antibiotic resistance and subsequent disease development.
These traits are particularly attributed to E. faecalis and E. faecium species of clinical
origin (Abriouel et al., 2008; Bhardwaj et al., 2008; Kayser, 2003). However, enterococci
have also been used as starter or adjuncts cultures whereby they improve the organoleptic
properties of food while also proven to release natural antimicrobials, known as
enterocins, shown to inhibit the growth of foodborne pathogens (Achemchem et al., 2006;
Aymerich et al., 2000a; Foulquié Moreno et al., 2006; Franz et al., 1999).

Certain enterococcal species have also successfully been applied as probiotics to improve
human and animal health. However, enterococcal probiotics are usually not incorporated
as starter or adjunct cultures, but are rather used as food supplements in the form of
pharmaceutical preparations (Franz et al., 2011). Perhaps the best known and best
researched probiotic Enterococcus strain is E. faecium SF68 (commercialised as
Cernivet® and Cylactin®, strain NCIMB 10415, produced by Cerbios-Pharma SA,
Barbengo, Switzerland). Therefore, enterococci can be ingested in high numbers to
provide health benefits most notably in the treatment of common diseases such as irritable
bowel syndrome (Enck et al., 2008) and diarrhoea (Wunderlich et al., 1989), while healthpromoting properties such as hypocholesterolaemic (Guo et al., 2015) and
immunostimulatory (Molina et al., 2015) effects have also been observed.

Moreover, enterococci have also demonstrated the ability to generate bioactive peptides
during milk fermentations owing to the possession of highly proteolytic extracellular
enzymes. E. faecalis secretes two dominant proteases; gelatinase and serine protease
(Thomas et al., 2008). Current literature suggests that gelatinase (gelE) is responsible for
casein hydrolysis, while serine protease (sprE) does not appear to play a role in the
hydrolysis of casein (Gútiez et al., 2014; Maharshak et al., 2015). Gútiez et al. also
showed that enterococcal strains expressing gelatinase generated peptides when grown in
bovine skim milk (BSM) which had Angiotensin-Converting Enzyme Inhibitory (ACEI)
activity (Gútiez et al., 2014). Therefore, these peptides have the potential to be used as
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food additives as they contribute to the maintenance of normal blood pressure by
preventing hypertension, thereby improving the health of the consumer (Gútiez et al.,
2013). Contrastingly, it is now understood that proteases can also play a role in the
virulence of enterococci, particularly gelatinase which has been shown to increase
pathogenicity in an animal model (Franz et al., 2003; Kayser, 2003; Singh et al., 1998).
Enterococci are now considered among the most proteolytic bacteria to date and show
higher proteolytic activities than other LAB (Bhardwaj et al., 2008; Centeno et al., 1996;
Tsakalidou et al., 1994). Consequently, the isolation and identification of proteolytic
enterococci is becoming of increasing importance and interest.

Current microbiological practices require a two-step procedure when screening for
presumptive proteolytic enterococci. First, enterococci must be isolated from a chosen
environmental niche. Several selective and/or differential media have been developed for
this purpose and are extensively reviewed in the literature (Domig et al., 2003; Weiss et
al., 2005). Among others, Kanamycin Aesculin Azide Agar (KAA) is commonly utilised,
particularly for the isolation and enumeration of enterococci from dairy and other foods.
The selective pressures of the medium, coupled with aesculin hydrolysis, enable the
effective enumeration of enterococci while supressing the growth of the majority of other
microbes (Domig et al., 2003). Following isolation of enterococci, assays are applied to
assess the proteolytic ability of isolates. The conventional method for initially
determining the proteolytic activity of a microorganism has employed cultivation on skim
milk agar (SMA). Proteolytic bacteria hydrolyse casein to form soluble nitrogenous
compounds which is indicated by a clear zone in the agar surrounding the colonies
(Frazier & Rupp, 1928). Therefore, current screening practices can be time consuming,
requiring initial isolation of enterococci using KAA followed by an assessment of
proteolytic activity using SMA.

Recognizing the limits of currently used screening methods and the increasing interest in
enterococci which display proteolytic capabilities, it is desirable to develop a quicker,
more convenient and cost-effective method to isolate proteolytic enterococci. This study
aimed to develop a method, utilising Kanamycin Skim Milk Aesculin Azide Agar
(KSMEA), for the isolation of presumptive proteolytic enterococci in one-step and to
ensure that the selectivity of commercialised selective/differential media for enterococci
was retained while proteolysis was clearly identifiable.
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MATERIALS AND METHODS
Bacterial strains and growth conditions
The bacterial strains used in this study (Table 2.1) were obtained from the American Type
Culture Collection (ATCC), the Dairy Products Research Centre (DPC) culture collection
(Teagasc Food and Research Centre, Moorepark, Fermoy, Co. Cork) and the Cork
Institute of Technology (CIT) Culture Collection (CITCC, Cork Institute of Technology,
Bishopstown, Co. Cork). Bacterial strains were recovered from -80oC stocks and
routinely cultured in Brain Heart Infusion (BHI) medium (LabM, Heywood, Lancashire,
United Kingdom) aerobically at 37 °C. Lactococcus lactis and Lactobacillus brevis were
propagated aerobically at 30 °C.

Table 2.1. Bacterial strains used in this study.
Species

Source

Aesculin Hydrolysis

Protein Hydrolysis

Escherichia coli
Pseudomonas aeruginosa
Salmonella enterica
Bacillus subtilis
Staphylococcus aureus
Lactococcus lactis
Streptococcus bovis
Lactobacillus brevis
Enterococcus faecalis
Enterococcus faecalis
Enterococcus faecium
Enterococcus faecalis
Enterococcus faecalis
Enterococcus faecalis
Enterococcus casseliflavus
Enterococcus casseliflavus
Enterococcus faecalis

ATCC25922
CITCCK01
CITCCK02
ATCC6633
CITCCK03
CITCCK04
CITCCK05
CITCCK06
ATCC29212
DPC5203
DPC4983
DPC3891
DPC5186
DPC1144
DPC4993
DPC4960
DPC5209

Negative
Negative
Negative
Positive
Negative
Negative
Positive
Negative
Positive
Positive
Positive
Positive
Positive
Positive
Positive
Positive
Positive

N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Positive

ATCC: American Type Culture Collection; CITCC: Cork Institute of Technology Culture Collection;
DPC: Dairy Products Research Centre culture collection, Teagasc.
N/A: Not applicable, strains used for assessment of selectivity only.

Media preparation
BHI Agar (LabM; a general-purpose complex medium to support the growth of all
strains) and Kanamycin Aesculin Azide Agar (KAA, Merck KGaA, Darmstadt,
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Germany; selective medium for enterococcus; concentration of Kanamycin – 20 mg/L)
were prepared according to manufacturer’s instructions.

To prepare Skim Milk Agar (SMA), 20% (w/v) Reconstituted Skim Milk Powder (RSM,
Glanbia, Fermoy, Cork, Ireland) was sterilized at 110 °C for 10 min and aseptically added
to 3% (w/v) sterile agar (LabM) held at 50 °C in a 1:1 ratio. The solution was gently
mixed to homogeneity ensuring that the formation of air bubbles was avoided and then
poured into sterile petri dishes.

Kanamycin Skim Milk Aesculin Azide Agar (KSMEA) was prepared by combining KAA
with RSM. Double strength KAA was sterilized at 121 °C for 15 min and mixed with
sterile 20% (w/v) RSM in a 1:1 ratio.

Evaluation of the selective properties of KSMEA
To evaluate the selective properties of KSMEA, eight Enterococcus strains and eight nonEnterococcus strains were selected in accordance with control strains used for
commercialised KAA (Table 2.1). The latter consisted of Escherichia coli, Salmonella
enterica,

Pseudomonas

aeruginosa,

Bacillus

subtilis,

Staphylococcus

aureus,

Lactococcus lactis, Streptococcus bovis and Lactobacillus brevis. 1 μl of overnight
cultures in BHI broth were spot inoculated onto BHI agar, KAA agar and KSMEA agar
and incubated at 37 °C for 24 h. Following incubation, the media were analysed for
growth and aesculin hydrolysis by the bacterial strains. Proteolysis was not of concern
when evaluating the selective performance of KSMEA relative to KAA therefore the
enterococcal strains used were non-proteolytic (Simpson et al, un-published data). The
selective and differential properties of KSMEA were further evaluated as described in
Appendix I.

Assessment of proteolysis and recovery of enterococci on KSMEA
To evaluate the capability of KSMEA to isolate and distinguish between proteolytic and
non-proteolytic enterococci, E. faecalis DPC5209 (DPC, Teagasc – confirmed as
proteolytic by observation of growth and zone of hydrolysis on SMA and also by the ophthalaldehyde assay - Simpson et al., unpublished data) and E. faecalis ATCC29212
(confirmed non-proteolytic Enterococcus) were used. Both strains were grown in BHI
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broth at 37 °C for 18 h. The cultures were serially diluted 10-fold in sterile ringers (LabM)
and spread plated onto BHI agar, SMA, KAA and KSMEA. This was performed in
triplicate and average results reported. Growth, proteolysis and aesculin hydrolysis, was
assessed following incubation at 37 °C for 48 h. Colony counts were recorded for both
cultures on all media after the incubation period to assess the recovery of enterococci on
KSMEA.

Analysis of KSMEA for the isolation of enterococci from selected
environmental samples
Three common sources of enterococci (Giménez-Pereira, 2005) were chosen to assess the
efficacy of KSMEA for isolating enterococci from the environment.

Bovine Raw Milk
Bovine raw milk was obtained from a dairy farm in Southern Ireland. Raw milk was
obtained from the holding tank immediately after the milking process using a sterile 100
ml disposable cup. The raw milk sample was serially diluted 10-fold in sterile ringers,
spread plated on KAA and KSMEA and incubated aerobically at 37 °C for 48 h.

Bovine Faeces
Bovine faeces were obtained from grassland of a dairy farm in Southern Ireland
immediately post defecation using a sterile 100 ml disposable cup. 1 g of bovine faeces
was added to 10 ml of sterile ringers in a faecal extraction hood and mixed vigorously by
vortexing. The faeces solution was serially diluted 10-fold in sterile ringers, spread plated
on KAA and KSMEA and incubated at 37 °C for 48 h.

Soil
Garden soil (obtained from Southern Ireland) was utilised in this study and was obtained
by removing the overlying grass layer and 1inch of topsoil before collecting a soil sample
in a sterile disposable 100 ml cup using a small sterile spade. 1g of the soil sample was
added to 10 ml of sterile ringers and mixed vigorously by vortexing. The soil solution
was serially diluted 10-fold in sterile ringers, spread plated on KAA and KSMEA and
incubated at 37 °C for 72 h.
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Selection and PCR confirmation of enterococcal isolates
Following the propagation of bacteria from each of the environmental samples,
presumptive positive enterococcal colonies on KSMEA (colonies displaying black halo
with and also without a zone of proteolysis) were selected for further analysis using the
following strategy: 50% of the colonies were selected if there were between 25 to 50
colonies on KSMEA, 75% of the colonies were selected if there were between 15-25
colonies and 100% of colonies were selected where the number of colonies on KSMEA
was less than 15. Selected isolates were confirmed as enterococci by PCR amplification
of bacterial DNA with enterococcus specific primers (E1; 5' TCAACCGGGGAGGGT 3'
and E2; 5' ATTACTAGCGATTCCGG 3') using the procedure described by Deasy et al.,
2000 (expected product size: 733 bp) (Deasy et al., 2000). Briefly, following an initial
denaturation at 94 °C for 1 min, products were amplified by 25 cycles of denaturation at
94 °C for 1 min, annealing at 60 °C for 1 min, elongation at 72 °C for 1 min and a final
extension at 72 °C for 5 min in a Thermal Cycler (Biometra, GmbH, Göttingen,
Germany).

Sequence determination and identification of isolates using 16S rRNA
sequencing
A selection of isolates were chosen for 16S rRNA sequencing by amplification of
bacterial DNA with the 27F (5’-AGAGTTTGATCMTGGCTCAG-3’) and 1492R (5’ACCTTGTTACGACTT-3’) universal primers using the procedure described by Lane,
1991 (Lane, 1991). Following an initial denaturation at 94 °C for 2 min, products were
amplified by 30 cycles of denaturation at 94 °C for 1 min, annealing at 50 °C for 1 min
and elongation at 72 °C for 1 min. Amplification was followed by a final extension at 72
°C for 5 min. Amplified PCR products were purified using a High Pure PCR Product
Purification kit (Roche Diagnostics Ltd., West Sussex, United Kingdom). Purified PCR
product sequences were determined by Sanger sequencing from the forward and reverse
ends (GATC Biotech AG, Cologne, Germany) using the 27F and 1492R primers. A
consensus sequence was produced from the overlapping reads for the 16S rRNA gene of
each isolate using Unipro UGENE software. To determine strain identity, obtained
sequences were compared against the GenBank database using the Basic Local
Alignment Search Tool (BLAST, NCBI).
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Statistical Analysis
The significance of differences in colony counts on KAA and KSMEA was calculated
using the one-way Analysis of Variance (ANOVA) test, with a significance level of P <
0.05 using Statistical Package for Social Sciences (SPSS v.22).
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RESULTS
Evaluation of the selective properties of KSMEA
All bacterial strains (Table 2.1) grew on BHI agar (Fig. 2.1A). Three out of the eight nonenterococcal strains (E. coli, S. aureus and S. bovis) grew on KAA and KSMEA agar
(Fig. 2.1B & C). Of these three cultures, growth of E. coli and S. aureus was inhibited
but not prevented while neither culture hydrolysed aesculin. S. bovis was the only nonenterococcal culture that showed growth consistent across all three media while also
exhibiting aesculin hydrolysis on KAA and KSMEA to produce colonies with a black
halo. No growth was observed for the remaining five non-enterococcal cultures on either
KAA or KSMEA despite growth observed on BHI. All (100%) Enterococcus cultures
grew on all three media and hydrolysed aesculin on both KAA and KSMEA to produce
colonies with a black halo (Fig. 1). Growth and colony morphology for all sixteen isolates
on KSMEA was consistent with that of KAA. The selective and differential properties of
KSMEA were studied further by examining the effect of different preparatory methods
on the medium as outlined in Appendix 1.
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Figure 2.1. Colonies produced by test bacteria on (A) Brain Heart Infusion Agar, (B) Kanamycin
Aesculin Azide Agar and (C) Kanamycin Skim Milk Aesculin Azide Agar after 24 h incubation
at 37 °C. From left to right: Row 1: E. coli ATCC25922, S. aureus CITCCK03, E. faecalis
ATCC29212, E. faecalis DPC5203; Row 2: P. aeruginosa CITCCK01, L. lactis CITCCK04, E.
casseliflavus DPC4993, E. faecalis DPC1144; Row 3: S. enterica CITCCK02, S. bovis
CITCCK05, E. faecium DPC4983, E. faecalis DPC5186; Row 4: B subtilis ATCC6633, L. brevis
CITCCK06, E. faecalis DPC3891, E. casseliflavus DPC4960.

Assessment of proteolysis
Both E. faecalis DPC5209 and E. faecalis ATCC29212 displayed growth on BHI agar,
SMA, KAA and KSMEA. DPC5209 produced colonies characterised by zones of
58

Chapter II

clearing on SMA. Additionally, DPC5209 also hydrolysed aesculin on KAA and KSMEA
noted by the presence of black halos surrounding the colonies. Moreover, proteolytic
activity was evident on KSMEA for DPC5209 which was determined by the presence of
colonies encompassed by a zone of clearing in the media accompanied by a black halo
(Fig. 2.2A). ATCC29212 also grew on SMA but zones of clearing were not present in the
agar following propagation. Similarly, ATCC29212 hydrolysed aesculin on KAA and
KSMEA to produce colonies surrounded by black halos but did not produce zones of
clearing on KSMEA (Fig. 2.2B).
BHI

KAA

SMA

KSMEA

Figure 2.2. Colonies of (A) E. faecalis ATCC29212 (non-proteolytic) and (B) E. faecalis
DPC5209 (proteolytic) on BHI Agar (BHI), Skim Milk Agar (SMA), Kanamycin Aesculin Azide
Agar (KAA) and Kanamycin Skim Milk Aesculin Azide Agar (KSMEA) after 48 h incubation at
37 °C. Figure is representative of a single experiment which was performed in triplicate.

Recovery of enterococci on KSMEA
Bacterial counts for E. faecalis DPC5209 and E. faecalis ATCC29212 on KSMEA were
not significantly different (P > 0.05) from those on BHI, SMA and KAA (data not shown).
After 48 h growth, both strains developed typical colony morphology on KSMEA (Fig.
2.2; colonies with a black halo with a zone of clearing and colonies with a black halo
without a zone of clearing for DPC5209 and ATCC29212, respectively).
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Analysis of KSMEA for the isolation of enterococci from selected
environmental samples
Presumptive enterococci were recovered from bovine raw milk, bovine faeces and soil on
KAA and KSMEA, both giving approximate cell counts of 8 x 103 CFU/ml, 2 x 103
CFU/ml and 8 x 102 CFU/ml, respectively (Fig. 2.3). Given that the selectivity of KSMEA
is comparable to KAA, isolates for further analyses were only selected from KSMEA.
Presumptive non-proteolytic enterococci were recovered from all three samples indicated
by the presence of colonies with a black halo but no zone of clearing on KSMEA.
Presumptive proteolytic enterococci were recovered from the raw milk sample only. This
was based on the presence of colonies surrounded by a zone of proteolysis accompanied
by a black halo on KSMEA. Ninety-six percent of isolates recovered from raw milk were
considered proteolytic while 4% were non-proteolytic. All (100%) isolates recovered
from the faeces and soil samples did not produce a zone of proteolysis on KSMEA. A
total of 44 isolates were chosen for further analysis based on desired colony morphology.
This included 21, 15 and 8 colonies from the raw milk, faeces and soil samples,
respectively (Table 2.2).

KAA

Non-proteolytic
Enterococcus

KSMEA

Raw Milk

Faeces

Soil

Figure 2.3. Colonies isolated from bovine raw milk, bovine faeces, and soil and cultured on
Kanamycin Aesculin Azide Agar (KAA) and Kanamycin Skim Milk Aesculin Azide Agar
(KSMEA) at 37 °C for 48 h, 48 h and 72 h, respectively. On KAA, growth of presumptive
enterococci is indicated by the presence of colonies surrounded by a black halo. On KSMEA,
growth of presumptive proteolytic and/or non-proteolytic enterococci is evident by the presence
of colonies surrounded by a black halo with or without an accompanying zone of proteolysis.
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Confirmation of identity of enterococcal isolates
Of the 44 isolates selected from the screen, 33 (75%) were confirmed as enterococci by
amplification of bacterial DNA with Enterococcus specific primers and subsequent gel
electrophoresis (Table 2.2). All 21 of the milk isolates gave desired PCR product when
DNA was amplified with enterococcus specific primers. 11 out of 44 selected isolates
(25%) gave desired colony morphology on KSMEA but did not generate the
Enterococcus specific PCR product (Fig. 2.4). Of these 11 isolates, 7 (64%) were
originally isolated from bovine faeces while 4 (36%) were isolated from soil. The 16S
rRNA gene of these 11 isolates were sequenced by Sanger sequencing (GATC Biotech
AG) and all 11 isolates were confirmed as non-enterococci (Table 2.2). As a control
measure, the 16S rRNA gene of 2 milk isolates (M12 and M16) were also sequenced and
both isolates were confirmed as E. faecalis.

Figure 2.4. Agarose gel electrophoresis of amplicons generated from the environmental isolates
using enterococcal primers. L1: Blank; L2: L. lactis CITCCK04 (negative control); L3: E.
faecalis DPC4996 (positive control) L4-L24: M01-M21 (milk isolates); L25-L39: F01-F15
(faeces isolates); L40-L47: S01-S08 (soil isolates).
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Table 2.2. Confirmation of the identity of milk, faeces and soil isolates.
Milk
isolates

Genus

Species

Faeces
isolates

Genus

Species

Soil
isolates

Genus

Species

M01

Enterococcus

ND

F01

Enterococcus

ND

S01

Enterococcus

ND

M02

Enterococcus

ND

F02

Bacillus

Safensis

S02

Enterococcus

ND

M03

Enterococcus

ND

F03

Enterococcus

ND

S03

Brachybacterium

Phenoliresistens

M04

Enterococcus

ND

F04

Bacillus

Safensis

S04

Brachybacterium

Phenoliresistens

M05

Enterococcus

ND

F05

Streptococcus

Equinus

S05

Enterococcus

ND

M06

Enterococcus

ND

F06

Enterococcus

ND

S06

Brachybacterium

Phenoliresistens

M07

Enterococcus

ND

F07

Streptococcus

Equinus

S07

Enterococcus

ND

M08

Enterococcus

ND

F08

Streptococcus

Equinus

S08

Bacillus

Galactosidilyticus

M09

Enterococcus

ND

F09

Streptococcus

Equinus

M10

Enterococcus

ND

F10

Enterococcus

ND

M11

Enterococcus

ND

F11

Streptococcus

Equinus

M12

Enterococcus

Faecalis

F12

Enterococcus

ND

M13

Enterococcus

ND

F13

Enterococcus

ND

M14

Enterococcus

ND

F14

Enterococcus

ND

M15

Enterococcus

ND

F15

Enterococcus

ND

M16

Enterococcus

Faecalis

M17

Enterococcus

ND

M18

Enterococcus

ND

M19

Enterococcus

ND

M20

Enterococcus

ND

M21

Enterococcus

ND

ND: Not determined – DNA was not sequenced by GATC.
Only isolates which were not confirmed as Enterococcus were subjected to sequence analysis for
identification. E. faecalis M12 and M16 were included as control measures.
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DISCUSSION
The emergence of enterococci as one of the most proteolytic lactic acid bacteria (LAB)
has resulted in the growing interest in enterococci displaying proteolytic properties
(Bhardwaj et al., 2008; Centeno et al., 1996). This, coupled with the limitations of current
screening practices, were the primary stimulants for the development of this rapid, onestep screening method. The currently employed two-step method can be time consuming,
potentially requiring up to 96 hours for the isolation of proteolytic enterococci. The
objective of this study was to develop a method, utilising Kanamycin Skim Milk Aesculin
Azide Agar (KSMEA), to select for proteolytic enterococci in one-step, thereby
significantly reducing screening time and associated costs.

KSMEA combines the selective properties of KAA with reconstituted skim milk (RSM)
to effectively detect the presence of presumptive proteolytic enterococci. To date, little is
known about the effectiveness of combining skim milk with selective media. Although it
was not the primary purpose of the study, Peck et al. utilised reinforced clostridial agar
supplemented with skim milk to assess proteolytic activity of clostridia (Peck et al.,
2010). Similarly, Süle et al. prepared an agar containing skim milk powder as well as
several other selective ingredients. However, this medium was not used for the detection
of proteolytic strains but rather for the selective enumeration of bifidobacteria and other
LAB (Süle et al., 2014). Moreover, studies which alter and/or combine KAA with other
media or reagents are also limited. One study did seek to modify KAA to improve the
selectivity of the medium for the enumeration of faecal streptococci from water samples
(Audicana et al., 1995). Therefore, while information is limited, evidence exists which
suggests that both skim milk and KAA can be successfully combined with other
ingredients and/or media for desired purpose. However, to the author’s best knowledge,
skim milk has never been combined with KAA.

In this study, the selectivity of KSMEA was compared with KAA using eight
Enterococcus strains and eight non-Enterococcus strains (Table 2.1; Fig 2.1). Given that
the main focus was to ensure that the selectivity of KSMEA was consistent with that of
KAA, all Enterococcus strains used were non-proteolytic (Simpson et al., unpublished
data). Both KSMEA and KAA completely supressed the growth of five of the eight nonenterococcal strains. This included Gram-positive and Gram-negative bacteria such as P.
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aeruginosa, S. enterica, B. subtilis and two lactic acid bacteria (LAB), L. lactis and L.
brevis. The growth of E. coli and S. aureus was inhibited but not prevented on KAA and
KSMEA. Colonies of these two cultures were much smaller on KSMEA and KAA
compared to BHI, thereby showing inhibition due to the selective pressures of the media.
S. bovis grew on KSMEA and hydrolysed aesculin to give colony morphology consistent
with that observed on KAA (good growth with black halo), while the same was also
observed for all eight Enterococcus strains which produced colonies characterised by a
black halo on both media. Therefore, KSMEA successfully retained the selectivity and
colony morphology observed on KAA for all sixteen strains (Fig 2.1).

The efficacy of KSMEA to detect and distinguish between proteolytic and nonproteolytic enterococci was also assessed (Fig. 2.2). Proteolytic colonies of E. faecalis
DPC 5209 were detected by the presence of colonies surrounded by both a zone of
clearing and a black halo. These were easily differentiated from the non-proteolytic
colonies of E. faecalis ATCC29212 which failed to hydrolyse casein and were therefore
characterised by a black halo only, while proteolytic zones were non-existent (Fig. 2.2).
Moreover, colony counts for both strains were consistent across all four media (BHI,
SMA, KAA and KSMEA) with no significant statistical difference between the counts (P
> 0.05). Subsequently, the recovery of enterococcal cells on KSMEA was not
compromised by the selective pressures of the medium.

This study also demonstrated the effectiveness of KSMEA at isolating both proteolytic
and non-proteolytic enterococci from different environmental niches. Presumptive
proteolytic and non-proteolytic colonies were recovered from raw milk, although the
incidence of proteolytic species was much higher (96%). Despite the low incidence of
non-proteolytic enterococci, proteolytic enterococcal colonies were easily differentiated
from non-proteolytic enterococci in the raw milk sample on KSMEA (Fig. 2.3.A.ii). The
ability to detect and distinguish between proteolytic and non-proteolytic enterococcal
colonies is an important advantage of KSMEA medium. Interestingly, no proteolytic
enterococci were recovered from either the bovine faeces or the soil sample, while total
enterococcal counts were highest in bovine raw milk, followed by the bovine faeces
sample and then soil. Although the natural habitat of enterococci is the intestinal tract of
humans and animals, they are less prevalent in bovine faeces (Gelsomino et al., 2001),
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while Byappanahalli demonstrated that lower incidence of enterococci in soil is likely
due to competition from other soil microorganisms (Byappanahalli, 2000).

Eleven out of 44 isolates recovered from the environmental sampling gave desired colony
morphology on KSMEA but did not generate the Enterococcus specific PCR product
(Fig. 2.4, Table 2.2). These were expected to be group D streptococci based on quality
control recommendations for KAA. However, only 5 isolates were confirmed as S.
equinus (a group D Streptococcus) by 16S rRNA sequencing. The remaining nonenterococcal isolates included 2 species from the Bacillus genus while Brachybacterium
phenoliresistens, a known aesculin hydrolyser which can also grow in 7% NaCl (Chou et
al., 2007), was also recovered. Non-enterococcal isolates which grew and hydrolysed
aesculin on KSMEA were subsequently confirmed to grow and hydrolyse aesculin on
KAA (data not shown). Therefore, when utilised for environmental sampling, KSMEA
retains the selective properties of KAA.
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CONCLUSION
With the considered limitations of current screening methods for the isolation of
proteolytic enterococci, it was necessary to develop an alternative method whereby
presumptive proteolytic enterococci can be isolated in one-step, thereby significantly
reducing screening time. KSMEA proved effective at isolating, detecting and
distinguishing between proteolytic and non-proteolytic enterococci while retaining the
selectivity of KAA. KSMEA is also very useful and advantageous when the incidence of
proteolytic enterococci in a sample is low and secondary screening of colonies on SMA
would be laborious and time consuming. KSMEA may not always indicate the presence
of new proteolytic enterococcal products, particularly from those species which lack
caseinolytic enzymes. However, KSMEA retains the properties of the widely employed
method of cultivation on SMA for the detection of proteolytic bacteria, which may also
exclude bacteria with proteolytic enzymes specific for a protein source other than casein.
Therefore, KSMEA provides an alternative, quicker and effective method for the isolation
of presumptive proteolytic enterococci and, for this purpose, is suitable for routine
laboratory use.
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ABSTRACT
The beneficial technological application of enterococci in foods, particularly in the dairy
industry, is overshadowed by the consideration of some species as opportunistic
pathogens, typically in nosocomial environments. In this study, the proteolytic activity
and safety aspects relating to antibiotic resistance and presence of virulence genes in 25
E. faecalis strains isolated from food and other sources were studied, in order to determine
their potential to be used as starter or adjunct cultures in food fermentations. Isolates
displayed varying levels of proteolytic activity when analysed using the ophthaldialdehyde method. E. faecalis DPC5154 demonstrated the greatest degree of
hydrolysis of milk proteins (8.86%). The presence of 12 putative virulence genes were
examined by PCR. The sex pheromones (cob, cpd, cad and ccf) were detected most
frequently, while DPC4784 was the only strain that did not harbour the efaAfs gene
(encoding a cell wall adhesin). Thirty-six percent of isolates possessed the genes involved
in cytolysin biosynthesis (cylA, cylB, cylM) which occurred concomitantly in all cases,
while the agg and esp genes were detected in 76% and 44% of strains, respectively. No
strain contained all of the virulence determinants investigated. Sensitivity of each strain
to 11 antibiotics was determined by the disc diffusion method. Levels of resistance to
tetracycline were highest (64% of isolates), while susceptibility levels to
chloramphenicol, ciprofloxacin, rifampicin and streptomycin were high with at least 64%
of strains proving sensitive to each of the antimicrobials. All 25 strains were completely
susceptible to the clinically relevant antibiotics ampicillin, penicillin, the high-level
aminoglycoside gentamicin and the glycopeptides (vancomycin and teicoplanin).
Recently established phenotypic methods and modern genetic tools have enabled the
differentiation of pathogenic from non-pathogenic enterococci, thereby permitting the
safe use of certain strains of enterococci in food. Therefore, we suggest that the use of
enterococcal strains in foods should be possible on the basis of a case-by-case evaluation
of individual strains. In that regard, strains displaying high levels of proteolytic activity,
antibiotic susceptibility and harbouring few putative virulence determinants in this work,
should be further examined as they could prove important candidates for the development
of new functional fermented food products.
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INTRODUCTION
Enterococci are ubiquitous lactic acid bacteria (LAB) that constitute an important part of
environmental, food and clinical microbiology. They occur in large numbers in dairy
products and other foods, and represent the most controversial group of LAB owing to
the possession of virulence traits and an increasing incidence of antibiotic resistance
(Bhardwaj et al., 2008; Foulquié Moreno et al., 2006; Giraffa, 2003). However, they have
featured in the dairy industry for decades due to their well characterised biochemical and
technological properties. They have been utilised as starter or adjunct cultures where traits
such as lipolysis, citrate breakdown, and proteolysis have contributed to the overall
improvement of the organoleptic properties of food, particularly dairy products (Foulquié
Moreno et al., 2006; Giraffa, 2003). Furthermore, some strains release natural
antimicrobials, known as enterocins, which inhibit the growth of foodborne pathogens
such as Listeria monocytogenes (Achemchem et al., 2006), Clostridium spp. (Cintas et
al., 1997), E. coli (Gálvez et al., 1989), Salmonella spp. and Campylobacter spp. (Line
et al., 2008). Certain enterococcal species have also successfully been applied as
probiotics to improve human and animal health. Perhaps the most common and best
researched Enterococcus probiotic strain is E. faecium SF68 (strain NCIMB 10415;
commercialised as Cernivet® and Cylactin®), a strain which is used in the treatment of
diarrhoea. Similarly, E. faecalis Symbioflor 1 (SymbioPharm, Herborn, Germany) is also
well established and is used to treat recurring illness in the upper respiratory system.

Enterococcal strains displaying proteolytic activity have received considerable interest in
scientific literature in recent years. Not only is proteolysis a desired trait in the dairy
industry for its contribution to texture and flavour development, proteolytic enterococci
have also demonstrated the ability to generate bioactive peptides during milk
fermentation (Foulquié Moreno et al., 2006; Gútiez et al., 2014; Quirós et al., 2007).
Similarly, we have demonstrated that milk fermented with the proteolytic E. faecalis
isolates used in this study generated fermentates with antioxidant, ACEI and
antihyperglycaemic activity (Graham et al., 2019a). Enterococci are now considered
among the most proteolytic bacteria to date and show higher proteolytic activities than
other LAB (Bhardwaj et al., 2008; Monika et al., 2017).
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On the contrary, several risk factors are also associated with enterococci and some strains,
particularly of E. faecalis and E. faecium species, are viewed as opportunistic pathogens
which can cause infections in immunocompromised patients or in those with underlying
disease (Abriouel et al., 2008; Bhardwaj et al., 2008; Kayser, 2003). This dualistic nature
raises concerns regarding their use in the food industry. They have been implicated as an
important cause of endocarditis, bacteraemia and urinary tract infections and have
demonstrated resistance to multiple antibiotics (Franz et al., 2011; Kayser, 2003).
Resistance to a wide variety of antibiotics is a contributing factor to pathogenicity and
impedes medical treatment of enterococcal infections as therapeutic options become
limited. Vancomycin resistant enterococci (VRE) are a major cause for concern as
vancomycin is often one of the last options for antimicrobial therapy in enterococcal
infections. However, antibiotic resistance alone cannot explain the virulence of
enterococci. Therefore, due to the importance of Enterococcus species as opportunistic
pathogens, the identification of virulence factors associated with enterococcal disease is
an important area of investigation.

Although the virulence mechanisms of enterococci are not completely known,
enterococcal virulence factors including adherence to host tissue, where aggregation
substance (agg), enterococcal surface protein (esp) and adhesin-like endocarditis antigen
(efaAfs) play a major role, secretion of toxic products such as cytolysin (cyl), gelatinase
(gelE) and hyaluronidase (hyl), and the production of plasmid-encoded sex pheromones
(cob, cpd, cad and ccf), have all been reported (Chajęcka-Wierzchowska et al., 2017;
Eaton & Gasson, 2001). Gelatinase (gelE) is somewhat controversial because, although
it is recognised as a virulence factor in enterococci, it is also required for casein hydrolysis
during milk fermentation which has benefits both for the liberation of potential bioactive
peptides, and for the development of the flavour and texture of cheese (Foulquié Moreno
et al., 2006; Gútiez et al., 2014).

Despite their considered status as opportunistic pathogens, enterococci have a long
history of safe use in foods. The presence of virulence factors does not necessarily mean
the strains will cause disease, but rather that they may have pathogenic potential. For
example, virulence determinants associated with adhesion and colonization, including the
agg gene, were detected in E. faecalis Symbioflor 1, a strain that has been used as a
probiotic for more than 50 years without any reports of infection (Domann et al., 2007;
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Fritzenwanker et al., 2013). The ability to cause infection is considered a more intricate
process than just possessing virulence determinants alone (Chajęcka-Wierzchowska et
al., 2017; Franz et al., 2011). Genomic studies, and those pertaining to the occurrence of
virulence factors among enterococci from foods, have shown that the presence and
incidence of virulence factors is strain specific. Furthermore, factors of virulence are less
frequent in isolates from food than in those of clinical origin, thereby suggesting that food
isolates have a lower potential for pathogenicity (Eaton & Gasson, 2001; Franz et al.,
2001; Lepage et al., 2006). Moreover, although particular strains may be considered
opportunistic pathogens, it is doubtful they would cause disease in healthy humans. Food
enterococcal strains that harbour single or multiple virulence factors have been described
but despite this, the morbidity of healthy humans resulting from enterococcal infections
appears to be very low (EFSA, 2012; Franz et al., 2003).

Despite recent advances in scientific knowledge allowing the differentiation of
pathogenic from non-pathogenic strains, Enterococcus species do not have Generally
Recognised as Safe (GRAS) status nor have they been included in the Qualified
Presumption of Safety (QPS) list (EFSA, 2017; Hanchi et al., 2018). However,
organisations such as the European Food Safety Authority (EFSA) and the Advisory
Committee on Novel Foods and Processes (ACNFP) permitted the use of certain strains
of enterococci as a food additive and supplement based on a careful case-by-case
assessment (ACNFP, 1995; EFSA, 2012). Similarly, safety assessment carried out on
enterococci by several authors enabled the identification of enterococcal strains which
could be considered safe and which were in possession of beneficial features for
application in food (Li et al., 2018; Nascimento et al., 2019).

Therefore, a careful and balanced evaluation of both the beneficial and undesirable traits
of each particular enterococcal strain may enable the selection and subsequent utilisation
of certain enterococcal strains in food. Ideally, any strain considered for use in food
should harbour no virulence determinants and should be sensitive to clinically relevant
antibiotics. The aim of this study was to evaluate proteolytic activity, incidence of
virulence factors and antibiotic resistance in E. faecalis strains, isolated mostly from
foods, to obtain further data regarding the distribution of pathogenic traits and to identify
strains which may be considered safe for use in food biotechnology, particularly in milk
fermentations.
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MATERIALS AND METHODS
Isolation, selection and confirmation of enterococcal isolates
Enterococci were isolated from various food samples (Table 3.1) as previously described
(Graham et al., 2019a). Briefly, food samples were subject to pre-enrichment in
Kanamycin Aesculin Azide (KAA, Merck KGaA, Darmstadt, Germany) broth at 37 °C
for 24 h. Samples were then serially diluted in sterile ringers, spread plated on Kanamycin
Skim Milk Aesculin Azide agar (KSMEA) and incubated aerobically at 37 °C for 24 h
(Graham et al., 2017). Following the propagation of presumptive proteolytic enterococci
from each of the food samples on KSMEA, isolates were confirmed as members of the
genus Enterococcus by Polymerase Chain Reaction (PCR) of bacterial DNA with the E1
and E2 Enterococcus specific primers described previously (Deasy et al., 2000).
Following isolation and confirmation of enterococci, all isolates were routinely
maintained on Brain Heart Infusion (BHI) agar (LabM, Heywood, Lancashire, United
Kingdom) or in BHI broth at 37 °C for 24 h for further use.
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Table 3.1. Bacterial strains used in this study.
Genus

Species

Strain

Source

Reference

Enterococcus
Enterococcus
Enterococcus
Enterococcus
Enterococcus
Enterococcus
Enterococcus
Enterococcus
Enterococcus
Enterococcus
Enterococcus
Enterococcus
Enterococcus
Enterococcus
Enterococcus
Enterococcus
Enterococcus
Enterococcus
Enterococcus
Enterococcus
Enterococcus
Enterococcus
Enterococcus
Enterococcus
Enterococcus

Faecalis
Faecalis
Faecalis
Faecalis
Faecalis
Faecalis
Faecalis
Faecalis
Faecalis
Faecalis
Faecalis
Faecalis
Faecalis
Faecalis
Faecalis
Faecalis
Faecalis
Faecalis
Faecalis
Faecalis
Faecalis
Faecalis
Faecalis
Faecalis
Faecalis

M10
M14
BR01
RC01
RC11
RC17
ST01
ST02
BF02
CK01
PK02
PK07
TK01
TK02
DPC810
DPC4996
DPC5173
DPC5154
DPC5083
DPC4995
DPC5237
DPC5209
DPC5802
DPC4784
DPC4787

Raw milk
Raw milk
Brie cheese
Roquefort cheese
Roquefort cheese
Roquefort cheese
Goat’s cheese
Goat’s cheese
Beef
Chicken
Pork
Pork
Turkey
Turkey
Cheddar cheese
Washed rind cheese
Italian cheese
Fontina cheese
Goat’s cheese
Raw milk
Horse
Human faeces
Farm water
Unknown
Unknown

This work
This work
This work
This work
This work
This work
This work
This work
This work
This work
This work
This work
This work
This work
DPC Collection
DPC Collection
DPC Collection
DPC Collection
DPC Collection
DPC Collection
DPC Collection
DPC Collection
DPC Collection
DPC Collection
DPC Collection

DPC: Dairy Products Research Centre culture collection, Teagasc, Moorepark, Fermoy, Co. Cork,
Ireland.

Random amplified polymorphic DNA (RAPD) PCR analysis and
species determination
RAPD-PCR was performed on isolated enterococci to reduce the number of strains
utilised in the study. Two random primers were used: M13R2 (Martin et al., 2005) and
OPD-05 (Eissa et al., 2016) which have both previously been used in RAPD-PCR
analysis of enterococci (Table 3.3). Following RAPD analysis, selected isolates were
determined to species level by 16S rRNA sequencing by amplification of bacterial DNA
with the 27F and 1492R universal primers (Lane, 1991). Amplified PCR products were
determined by Sanger sequencing (Eurofins GATC Biotech, 78467 Constance,
Germany). To determine strain identity, sequences were compared against the GenBank
database using the Basic Local Alignment Search Tool (BLAST, NCBI).
74

Chapter III

Confirmation of proteolysis
Overnight cultures of enterococci in BHI broth were cultured on skim milk agar (SMA)
plates and incubated at 37 °C for 48 h. A clear zone of hydrolysis around colonies on
SMA was deemed positive for proteolytic activity.

Gelatinase activity
All enterococcal isolates were screened for the presence of the gelatinase phenotype and
genotype. To detect the presence of the gelatinase phenotype, isolates were grown on BHI
agar containing 3% (w/v) gelatin (BHI-GEL) and incubated at 37 °C for 24 h. Following
incubation, agar plates were placed at 4 °C for 5 h before examination of zones of turbidity
around the colonies. The presence of the gelatinase genotype was determined by PCR
amplification of enterococcal DNA using gelE specific primers (GelE1 and GelE2; Table
3.3) as previously described (Eaton & Gasson, 2001).

Preparation of fermented milk
Milk fermentates were generated by propagation of the E. faecalis isolates in Bovine
Skim Milk (BSM) as described previously (Graham et al., 2019a). Briefly, overnight
cultures in BHI broth were standardised to an optical density of 1.0 at 600 nm and
inoculated at 1% (v/v) into 10% (w/v) BSM. Cells were grown at 37 °C for 20 h, then
centrifuged and supernatants were filter sterilised before being stored at -20 °C for further
analysis.

Protein hydrolysis
The o-phthaldialdehyde (OPA) method was used to quantify the degree of protein
hydrolysis by the enterococcal isolates following milk fermentation as previously
described with slight modifications (Church et al., 1983). Briefly, 1 ml of sample was
mixed with 4 ml 1.25% (w/v) sodium dodecyl sulphate (SDS, Sigma-Aldrich, Vale Road,
Arklow, Wicklow, Ireland) and incubated at room temperature for 1 h. A calibration
standard curve was prepared with concentrations of L-leucine (Sigma) ranging from 0-2
mg/ml in 1% (w/v) SDS. 20 µl of milk fermentate in SDS was added to 2.5 ml OPA
reagent and incubated in darkness at room temperature for 15 min. Absorbance was
measured at 340 nm. Non-fermented 10% (w/v) skim milk was used as a control and was
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subtracted from each sample value. Results were expressed as percentage degree of
hydrolysis (%DH) of milk proteins.

PCR amplification of virulence genes
The DNA of all enterococcal isolates was analysed for the presence of putative virulence
genes (Table 3.2). Template DNA was prepared using the High Pure PCR Template
Preparation Kit (Roche Diagnostics Ltd., West Sussex, United Kingdom). Primers used
for the amplification of virulence genes are listed in Table 3.3. Control strains used in the
PCR experiments for the detection of virulence genes were E. faecalis ATCC29212 (cad+,
cpd+, cob+, ccf+, efaAfs+, cylA+, cylB+ cylM+, agg+ and gelE+), E. faecalis F19190 (esp+)
and E. faecium C68 (hyl+).

Table 3.2. Enterococcus virulence determinants examined in this study.
Enterococcal virulence
factor
Sex pheromones

Gene(s)
cob, cad, ccf, cpd

Putative role
Facilitate conjugation, chemotactic
for human neutrophils

Reference
(Bhardwaj et al., 2008)

Aggregation substance

agg

Adherence to host cells, cell
aggregation and conjugation

(Chajęcka-Wierzchowska et
al., 2017)

Enterococcal surface protein

esp

Adhesion and colonisation

(Koort et al., 2004)

Cytolysin

cylA

Activation of cytolysin

(Eaton & Gasson, 2001)

Cytolysin

cylB

Transport of cytolysin

(Eaton & Gasson, 2001)

Cytolysin

cylM

Post-translational modification of
cytolysin

(Eaton & Gasson, 2001)

Endocarditis specific antigen

efaAfs

Cell wall adhesin expressed in
serum

(Chajęcka-Wierzchowska et
al., 2017)

Hyaluronidase

hyl

Plays a role in destroying
mucopolysaccharides of the
connective tissue and cartilage

(Chajęcka-Wierzchowska et
al., 2017)

Gelatinase

gelE

Hydrolyses gelatin, collagen,
haemoglobin and casein

(Chajęcka-Wierzchowska et
al., 2017; Gútiez et al., 2014)
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Table 3.3. Target genes and primers used in the PCR reactions carried out in this study.
Sequence (5’ to 3’)*

Partial 16S
rRNA

Primer
name
E1
E2

Random#

M13R2

Random

OPD-05

gelE

Gene

Annealing
Temperature
60 °C

Product
Size (bp)
733

Reference

GGAAACAGCTATGACCATGA

38 °C

n/a

(Martin et al., 2005)

TGAGCGGACA

35 °C

n/a

(Eissa et al., 2016)

GelE1
GelE2

ACCCCGTATCATTGGTTT
ACGCATTGCTTTTCCATC

60 °C

419

(Eaton & Gasson, 2001)

16S rRNA

27F
1492R

AGAGTTTGATCMTGGCTCAG
ACCTTGTTACGACTT

50 °C

1,518

(Lane, 1991)

cad

cad-F
cad-R

TGCTTTGTCATTGACAATCCG
ACTTTTTCCCAACCCCTCAA

52 °C

1,299

(Reviriego et al., 2005)

cpd

cpd-F
cpd-R

TGGTGGGTTATTTTTCAATTC
TACGGCTCTGGCTTACTA

52 °C

782

(Eaton & Gasson, 2001)

cob

cob-F
cob-R

AACATTCAGCAAACAAAGC
TTGTCATAAAGAGTGGTCAT

52 °C

1,405

(Eaton & Gasson, 2001)

ccf

ccf-F
ccf-R

GGGAATTGAGTAGTGAAGAAG
AGCCGCTAAAATCGGTAAAAT

47 °C

543

(Eaton & Gasson, 2001)

agg

agg1-F
agg1-R

GCTGTTCAGCTGACAAACGA
TTTAAGGCGGCCAATAGTGC

52 °C

410

This work

esp

esp1-F
esp1-R

TTGCTAATGCTAGTCCACGACC
GCGTCAACACTTGCATTGCCGAA

58 °C

933

(Akhondnezhad et al., 2017)

cylA

cylA-F
cylA-R

TGGATGATAGTGATAGGAAGT
TCTACAGTAAATCTTTCGTCA

50 °C

517

(Eaton & Gasson, 2001)

cylB

cylB-F
cylB-R

ATTCCTACCTATGTTCTGTTA
AATAAACTCTTCTTTTCCAAC

50 °C

843

(Eaton & Gasson, 2001)

cylM

cylM-F
cylM-R

CTGATGGAAAGAAGATAGTAT
TGAGTTGGTCTGATTACATTT

50 °C

742

(Eaton & Gasson, 2001)

efaAfs

efaAfs-F
efaAfs-R

GACAGACCCTCACGAATA
AGTTCATCATGCTGTAGTA

52 °C

705

(Eaton & Gasson, 2001)

hyl

hyl-F
hyl-R

ACAGAAGAGCTGCAGGAAATG
GACTGACGTCCAAGTTTCCAA

54 °C

276

(Vankerckhoven et al., 2004)

vanA

vanA2-F
vanA2-R

TGGAGCGACAGACATAACAGAT
ACACCTACGGGCGAGTTTC

53 °C

287

(Mirzaei et al., 2015)

vanB

vanB-F
vanB-R

GCTCCGCAGCCTGCATGGACA
ACGATGCCGCCATCCTCCTGC

56 °C

529

(Lemcke & Bülte, 2000)

TCAACCGGGGAGGGT
ATTACTAGCGATTCCGG

*

(Deasy et al., 2000)

Primers were synthesized by Eurofins Genomics, Germany.
Random Amplified Polymorphic DNA.
Virulence determinants: gelE (gelatinase); cad, cpd, cob, ccf (sex pheromones); agg (aggregation
substance); esp (enterococcal surface protein); cylA, cylB, cylM (cytolysin biosynthesis); efaAfs (call wall
adhesion); hyl (hyaluronidase);
Antibiotic resistance genes: vanA, vanB (vancomycin resistance).
#
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Antibiotic susceptibility testing
The antibiotic susceptibility of the Enterococcus isolates was determined by the disc
diffusion method using Oxoid antibiotic discs (Thermo Fisher Scientific) according to the
Clinical and Laboratory Standards Institute (CLSI) guidelines. The antibiotics tested were
ampicillin (AMP; 10 µg), chloramphenicol (C; 30 µg), ciprofloxacin (CIP; 5 µg),
erythromycin (E; 15 µg), gentamicin (CN; 120 µg), penicillin (P; 10 ug), rifampicin (RD;
5 µg), streptomycin (S; 300 µg), teicoplanin (TEC, 30 µg), tetracycline (TE; 30 µg) and
vancomycin (VA; 30 µg). After recommended incubation periods on Mueller-Hinton
(MH) agar (Sigma), inhibition zone diameters were measured using a Vernier calliper and
scored as sensitive, intermediate (reduced susceptibility) or resistant according to
breakpoint values recommended by the CLSI document M100, 28th edition (CLSI, 2018).
Staphylococcus aureus ATCC25923 was used for quality control in the antibiotic
susceptibility testing as per CLSI guidelines. The possession of genes associated with
vancomycin resistance (vanA and vanB) were determined by PCR (Table 3.3) with E.
faecium G7 (vanB+) and E. faecium G8 (vanA+ and vanB+) used as positive control strains.

Statistics
All milk fermentations were carried out in triplicate using three independently prepared
cultures in three independent preparations of 10% BSM. Subsequent assays performed
on the milk hydrolysates were also performed in triplicate and the mean and standard
deviation was calculated using Microsoft Excel.
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RESULTS
Isolation and identification of enterococcal isolates
A total of 100 isolates were recovered from the various food samples which were
considered presumptive proteolytic enterococci indicated by expected colony
morphology on KSMEA. All isolates were confirmed as Enterococcus and, following
RAPD-PCR and analysis of differences in observed band patterns (data not shown), a
total of 14 isolates were selected for further study in this work. These were determined to
species level by 16S rRNA sequencing and all 14 isolates were confirmed as
Enterococcus faecalis. Additionally, a total of 11 isolates were obtained from the Dairy
Products Research Centre (DPC) culture collection (Teagasc, Fermoy, Co. Cork), giving
a total of 25 E. faecalis isolates in this study (Table 3.1). The DPC isolates were
previously determined as Enterococcus faecalis and were further confirmed as E. faecalis
in this work.

Proteolytic and gelatinolytic activities
All 25 isolates demonstrated the ability to break down casein, noted by the presence of a
zone of hydrolysis around the colonies following growth on SMA, thereby indicating
proteolytic activity. Furthermore, all isolates used in this study tested positive for the gelE
genotype (gelE+) and phenotype noted by the production of a zone of turbidity around
colonies after growth on BHI-GEL (data not shown).

Protein hydrolysis
Data regarding percentage degree of hydrolysis (%DH) values determined by the OPA
assay for the milk fermentates is reported in Figure 3.1. E. faecalis DPC5154 displayed
the greatest degree of hydrolysis (8.86%). In general, isolates from cheese (DPC 5154,
ST02, DPC5083, and BR01) displayed greater %DH values than those obtained from
alternative sources. Despite observed casein hydrolysis on KSMEA and SMA, E. faecalis
PK02, RC11, TK01, DPC5237 and TK02 did not display any degree of hydrolysis of milk
proteins based on the OPA assay following growth in BSM for 20 h, but did display
proteolytic activity after 48 h fermentation (Figure A2.3, Appendix II). The proteolytic
activity of the enterococcal isolates was further assessed as outlined in Appendix II.
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9.00

Degree of Hydrolysis (%)

8.00
7.00
6.00
5.00
4.00
3.00
2.00
1.00

DPC5237
DPC5209
DPC4787
DPC4784
DPC5802

DPC4995
M10
M14

PK02
TK01
TK02
BF02
PK07
CK01

RC11
DPC4996
RC17
DPC810
RC01
ST01
DPC5173
BR01
DPC5083
ST02
DPC5154

0.00

Other

Milk

Meat

Cheese

Figure 3.1. Assessment of the level of proteolytic activity of Enterococcus faecalis strains,
isolated from food and other sources, grown in Bovine Skim Milk (BSM) for 20 h at 37 °C.
Proteolysis was determined by the OPA assay and values are reported as percentage degree of
hydrolysis (%DH) of milk proteins. Error bars represent the standard deviation of three
independent experiments.

Detection of virulence genes
Enterococcal isolates were examined for the presence of 12 genes associated with
virulence using PCR (Table 3.3) and results are presented in Table 3.4. Agarose gel
electrophoresis figures depicting the amplicons generated from the PCR screening of the
12 virulence genes are shown in Figure A3.2.1-13 in Appendix III. All isolates contained
at least two of the virulence determinants, but none of the isolates contained all of the
virulence genes investigated. Apart from E. faecalis DPC4784 and DPC5173, all isolates
encoded the genes for the sex pheromones (cob, cpd, cad and ccf). DPC4784 only
encoded the ccf determinant, while DPC5173 harboured all sex pheromone determinants
except for cob. Similarly, DPC4784 was the only strain that did not contain the efaAfs
gene (encoding a cell wall adhesin). Thirty-six percent of isolates possessed the genes
involved in cytolysin biosynthesis (cylA, cylB, cylM), while the esp (enterococcal surface
protein) and agg (aggregation substance) determinants were found in 44% and 76% of
strains, respectively. All E. faecalis strains carried the gelE gene (encoding gelatinase)
which, ultimately, is required for casein hydrolysis during milk fermentation (Gútiez et
al., 2014). None of the E. faecalis isolates harboured the hyl (hyaluronidase) gene. Among
the various virulence profiles, the combination of cob, cpd, cad, ccf + efaAfs + cylA, cylB,
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cylM + agg was the most common (found in 36% of isolates). E. faecalis DPC4784
harboured the least amount of virulence genes, where only ccf and gelE were detected. E.
faecalis DPC5154 (the most proteolytic strain) carried the sex pheromone determinants
and genes associated with adhesion (agg and efaAfs). However, this strain did not contain
genes associated with cytolysin or hyaluronidase production.

Antibiotic susceptibility testing
All enterococcal isolates were subjected to antibiotic susceptibility testing towards 11
antibiotics using the disc diffusion method outlined by the CLSI (Table 3.4, Fig. 3.2).
Supplementary data regarding the size of zones of inhibition towards the 11 antibiotics
are outlined in Table A3.1 and Figure A3.1 of Appendix III. All isolates were susceptible
to at least six of the tested antibiotics. Multi-drug resistance (MDR; resistant to at least
three classes of antibiotics) was found in seven (28%) of the strains. Isolates from nonfood sources (DPC5237, DPC5209 and DPC5802) displayed the greatest level of MDR,
showing resistance to chloramphenicol, erythromycin, streptomycin and tetracycline.
Isolates were generally susceptible to the tested antibiotics with the exception of
tetracycline, where 64% of isolates were considered resistant. Susceptibility levels to
chloramphenicol, ciprofloxacin, rifampicin and streptomycin were high with at least 16
of 25 isolates (64%) proving susceptible. Six of the 25 isolates (BR01, BF02, DPC5173,
DPC810, DPC5154, DPC4784) were completely susceptible to all eleven antibiotics.
100% of isolates were susceptible to the clinically relevant antibiotics ampicillin,
penicillin, the high-level aminoglycoside gentamicin and the glycopeptides (teicoplanin
and vancomycin). Susceptibility to vancomycin was further confirmed by the absence of
the vanA and vanB genes in all enterococcal isolates, which was determined by PCR. In
conjunction with proteolytic activity and the incidence of virulence genes, results of the
antibiotic susceptibility testing provided further promising evidence for the use of E.
faecalis DPC5154 and DPC4784 in foods as both strains were completely susceptible to
all of the tested antibiotics (Table 3.4, Fig. 3.3).
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Table 3.4. Distribution of virulence genes and antibiotic resistance among the 25 Enterococcus
faecalis isolates utilised in this study.
Strain

cob

cpd

cad

ccf

efaAfs

cylA

cylB

cylM

esp

agg

hyl

gelE

vanA

vanB

Antibiotic
resistance

Other
DPC4784

-

-

-

+

-

-

-

-

-

-

-

+

-

-

-

DPC4787

+

+

+

+

+

-

-

-

+

-

-

+

-

-

C, E, S, TE

DPC5209

+

+

+

+

+

+

+

+

+

+

-

+

-

-

C, E, S, TE

DPC5237

+

+

+

+

+

+

+

+

-

+

-

+

-

-

C, E, S, TE

DPC5802

+

+

+

+

+

+

+

+

+

+

-

+

-

-

C, E, S, TE

Milk
M10

+

+

+

+

+

-

-

-

+

+

-

+

-

-

S, TE

M14

+

+

+

+

+

-

-

-

+

+

-

+

-

-

S, TE

DPC4995

+

+

+

+

+

+

+

+

+

+

-

+

-

-

S, TE

BF02

+

+

+

+

+

-

-

-

-

-

+

-

-

-

CK01

+

+

+

+

+

-

-

-

-

+

-

+

-

-

C, E, TE

PK02

+

+

+

+

+

-

-

-

-

+

-

+

-

-

C, E, TE

PK07

+

+

+

+

+

+

+

+

-

+

-

+

-

-

TE

TK01

+

+

+

+

+

+

+

+

-

+

-

+

-

-

TE

TK02

+

+

+

+

+

-

-

-

-

+

-

+

-

-

CIP, E, TE

Meat
-

Cheese
BR01

+

+

+

+

+

-

-

-

-

+

-

+

-

-

-

RC01

+

+

+

+

+

-

-

-

+

+

-

+

-

-

TE

RC11

+

+

+

+

+

-

-

-

-

-

-

+

-

-

-

RC17

+

+

+

+

+

-

-

-

-

+

-

+

-

-

-

ST01

+

+

+

+

+

-

-

-

+

-

-

+

-

-

TE

ST02

+

+

+

+

+

-

-

-

+

-

-

+

-

-

-

DPC810

+

+

+

+

+

+

+

+

-

+

-

+

-

-

-

DPC4996

+

+

+

+

+

+

+

+

+

+

-

+

-

-

TE

DPC5083

+

+

+

+

+

+

+

+

+

+

-

+

-

-

TE

DPC5154

+

+

+

+

+

-

-

-

-

+

-

+

-

-

-

DPC5173

-

+

+

+

+

-

-

-

-

+

-

+

-

-

-

92%

96%

96%

100%

96%

36%

36%

36%

44%

76%

0%

100%

0%

0%

Positive
isolates (%)

Virulence determinants: cob, cpd, cad, ccf (sex pheromones); efaAfs (call wall adhesion); cylA, cylB, cylM
(cytolysin biosynthesis); esp (enterococcal surface protein); agg (aggregation substance); hyl
(hyaluronidase); gelE (gelatinase).
Antibiotics: E: Erythromycin; C: Chloramphenicol; CIP: Ciprofloxacin S: Streptomycin; TE: Tetracycline;
-: No resistant phenotype observed to any of the tested antibiotics; vanA, vanB (vancomycin resistance
genes).
E. faecalis ATCC 19433T: Included as a type strain in the study and contained the cob, cpd, cad, ccf and
efaAfs determinants.
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Figure 3.2. Antibiotic sensitivity patterns of the 25 Enterococcus faecalis isolates used in this
study. AMP: Ampicillin (10 µg); C: Chloramphenicol (30 µg); CIP: Ciprofloxacin (5 µg); E:
Erythromycin (15 µg); CN: Gentamicin (120 µg); P: Penicillin (10 µg); RD: Rifampicin (5 µg);
S: Streptomycin (300 µg); TEC: Teicoplanin (30 µg); TE: Tetracycline (30 µg); VA: Vancomycin
(30 µg).

RD
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CN
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Figure 3.3. Antibiotic susceptibility testing of Enterococcus faecalis DPC5154 towards
Ampicillin (AMP), Vancomycin (VA), Streptomycin (S), Ciprofloxacin (CIP), Gentamicin (CN),
Rifampicin (RD), Penicillin (P), Teicoplanin (TEC), Tetracycline (TE), Erythromycin (E) and
Chloramphenicol (C). Sensitivity testing to the 11 antibiotics was performed in triplicate. Figure
is representative of one independent experiment.
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DISCUSSION
The recent paradigm shift in the consideration of enterococci as harmless commensals
with low pathogenic potential to ubiquitous opportunistic pathogens capable of causing
infection is exemplified in the findings of several authors portraying an increasing
incidence of antibiotic resistance and virulence determinants in Enterococcus species
(Chajęcka-Wierzchowska et al., 2016, 2017; Eaton & Gasson, 2001; Franz et al., 2001;
Reviriego et al., 2005). However, the incidence of virulence determinants and antibiotic
resistance appears to be strain specific and that these traits are less frequent in isolates
from food than in those of clinical origin (Chajęcka-Wierzchowska et al., 2017; Eaton &
Gasson, 2001; Franz et al., 2001; Lepage et al., 2006). The majority of research regarding
the presence of virulence factors and antibiotic resistance in enterococci relates to isolates
of clinical origin, while data on isolates from food origin is somewhat limited. The aim
of this study was to assess the levels of proteolytic activity, incidence of virulence
determinants and antibiotic sensitivity in E. faecalis strains, isolated from food and other
sources, in order to determine their potential to be used as starter or adjunct cultures in
food fermentations. To the author’s best knowledge, the present study is the first to
examine the levels of proteolytic activity, and the incidence of antibiotic resistance and
virulence genes in E. faecalis isolates recovered from dairy, meat and other sources in
Southern Ireland.

Data in the literature regarding the proteolytic nature of enterococci is sporadic in
comparison to other LAB species. When data pertaining to the proteolytic activity of
enterococci is reported, the overall findings appear conflicting, with some authors
reporting that enterococci are highly proteolytic (Durlu-Ozkaya et al., 2001; Fabricio L
Tulini et al., 2016), while others conclude that they exhibit low levels of proteolysis
(Morandi et al., 2006; Sarantinopoulos et al., 2001). GelE confers the ability of
enterococci to hydrolyse casein (Gútiez et al., 2014). Therefore, because milk-based
media were used (KSMEA, SMA and BSM) when screening for proteolytic isolates for
use in this work, all strains were expected to contain the GelE phenotype and genotype.
Twenty-five Enterococcus faecalis strains were isolated and confirmed to possess a
functional gelE gene thereby conferring proteolytic activity when grown in BSM.
However, gelE is also understood to play a role in virulence and was suggested to increase
pathogenicity in a murine model (Chajęcka-Wierzchowska et al., 2017; Singh et al.,
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1998). Nevertheless, Singh et al. could not determine that gelE alone was directly
responsible for infection. Similarly, although the presence of functional gelatinase has
been associated with virulence, the presence of GelE is not required for enterococci to
cause disease (Galloway-Peña et al., 2011). Furthermore, the gelE gene is present in
enterococcal isolates from different ecological environments, suggesting that the
gelatinase protein may play a role in the biology of E. faecalis that is not exclusively
associated with virulence. This was further evidenced by Gútiez et al. (2014) who
demonstrated that gelatinase was responsible for casein degradation and subsequent
generation of bioactive peptides with human health connotations. Therefore, proteolytic
enterococci expressing gelatinase may have a useful role in food biotechnology
applications.

Levels of proteolytic activity varied among the isolates. As anticipated, isolates of cheese
origin were generally more proteolytic than those obtained from alternative sources and
may allude to niche-adaptation by E. faecalis (He et al., 2018). E. faecalis DPC5154
displayed the greatest level of hydrolysis of milk proteins (8.86% DH) and is therefore
considered the most proteolytic isolate utilised in the study (Fig. 3.1). The high proteolytic
activity observed in E. faecalis DPC5154 suggests this strain may be a useful candidate
in milk fermentations to improve the texture and flavour of cheese and for the potential
generation of bioactive compounds. However, prior to use in foods, the safety aspects of
individual strains, such as presence of virulence determinants and antibiotic resistance,
must also be considered.

In this work, the E. faecalis isolates were screened for the presence of virulence
determinants that have a considered role in the aetiology of enterococcal infections (Table
3.2) and results are presented in Table 3.4. The efaAfs, agg and esp genes are understood
to play a putative role in the adherence and colonisation of enterococci to host tissue,
which is the first step in infection and subsequent disease development (ChajęckaWierzchowska et al., 2017).The adhesion-like efaAfs and agg determinants were common
amongst isolates in this work, found in 96% and 76% of isolates, respectively. This is
similar to the findings of several other authors who also reported a high incidence of the
efaAfs and agg genes amongst E. faecalis isolates (Čanžek Majhenič et al., 2005; Cariolato
et al., 2008; Eaton & Gasson, 2001; Landete et al., 2018; Martín-Platero et al., 2009;
Martin et al., 2005). The incidence of esp, encoding an enterococcal surface protein, was
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lower both in our findings and also in the work of Cariolato et al. (2008) where the gene
was detected in 44% and 42% of E. faecalis isolates, respectively, and also correlated
well with the findings of Eaton and Gasson (2001) and Franz et al. (2001). However,
colonisation alone is not proof of pathogenicity while, in a safety assessment of probiotics
for human use, adhesion to cell lines was insufficiently associated with virulence (Sanders
et al., 2010). The cytolysin determinants (cylA, cylB and cylM) were present in 36% of
isolates and existed concomitantly in all cases. The presence of these genes in E. faecalis
isolates was determined to a similar level by Landete et al. (2018) but, despite harbouring
the cyl determinants, none of the isolates showed haemolysin activity, which was also
observed by Eaton and Gasson in 2001. Therefore, because of the potential presence of
silent genes, genotypic study of the cyl determinants is of utmost importance as
phenotypic screening alone may result in these determinants remaining undetected under
laboratory conditions.

A high incidence of genes encoding the sex pheromones (cob, cpd, cad and ccf) was
observed among the E. faecalis isolates which was also observed by several other authors
(Čanžek Majhenič et al., 2005; Chajęcka-Wierzchowska et al., 2016; Eaton & Gasson,
2001; Landete et al., 2018). Strains harbouring the sex pheromone determinants have the
potential to acquire the respective sex pheromone plasmids which may contain potential
virulence determinants. This becomes particularly problematic when enterococci, which
do not normally harbour genes for known virulence factors, accumulate plasmids
containing virulence and/or antibiotic resistant genes. In agreement with previous data,
the gene encoding hyaluronidase (hyl), understood to play a role in destroying
mucopolysaccharides of connective tissue, was not detected in any of the E. faecalis
isolates. However, the hyl gene appears to be specific for E. faecium, a species used as a
positive control in PCR amplification of virulence genes in this study, but not isolated in
our work (Vankerckhoven et al., 2004). Similarly, none of the isolates were positive for
the vanA or vanB determinants for vancomycin resistance which has also been reported
elsewhere (Franz et al., 2001; Martín-Platero et al., 2009), and Franz et al. (2001)
concluded that the vanA and vanB genes are not frequently found in food isolates.
Although strains harbouring putative virulence genes were observed, there is no data
showing a direct relationship between the consumption of foods containing virulent
enterococci and illness. The distribution of virulence determinants varied among isolates
in this study and echoes the findings of several other authors that the incidence of
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virulence determinants among enterococci is very much strain-specific (Eaton & Gasson,
2001; Franz et al., 2001; Lepage et al., 2006; Martín-Platero et al., 2009).

The incidence of antibiotic resistance among the 25 E. faecalis isolates was also
investigated (Table 3.4, Fig, 3.2). Isolates were largely susceptible to the tested
antibiotics, except in the case of tetracycline, where 64% of isolates showed resistance
and was higher than that reported by Franz et al. in 2001 (44.7%), but did coincide with
the findings of several other authors who also reported high levels of tetracycline
resistance among E. faecalis isolates (Cariolato et al., 2008; Chajęcka-Wierzchowska et
al., 2016; Hosseini et al., 2016; Peters et al., 2003). The worldwide incidence of
tetracycline resistance in enterococci from food of animal origin may be attributed to the
use of these antibiotics in veterinary practices. Nevertheless, resistance to tetracycline has
little clinical importance as it is not typically a drug of choice for the treatment of
enterococcal infection (Ogier & Serror, 2008). Resistance to at least one antibiotic was
observed in 64% of the strains which is similar to the frequency found in E. faecalis
isolates by Chajęcka-Wierzchowska et al. in 2016 (65.7%). Lower levels of resistance to
chloramphenicol and streptomycin were observed among the isolates in this work (24%
and 28%, respectively) compared to that reported in E. faecalis isolates by Franz et al. in
2001 (63.8% and 46.8%, respectively), while levels of resistance to erythromycin were
similar (28% vs 31.9% of isolates in the respective studies). Similarly, resistant profiles
observed in the E. faecalis isolates used in this study to erythromycin, ciprofloxacin,
ampicillin and vancomycin (28%, 4%, 0% and 0%, respectively) were much lower than
those reported by Hosseini et al. (71%, 30%, 40% and 46%, respectively), which is likely
due to differences in the geographical origin of the isolates (Čanžek Majhenič et al.,
2005). None of the strains were resistant to all of the tested antibiotics, but multi-drug
resistance (MDR) was observed in some isolates, particularly in those of non-food origin
(DPC5237, DPC5209 and DPC5802). Of the six isolates that were completely susceptible
to all of the antibiotics, five were isolated from cheese. In fact, of the 11 cheese isolates
used in this study, only four exhibited antibiotic resistance and this was to tetracycline
only. E. faecalis DPC5154, the strain that generated the milk fermentate with the highest
antioxidant, ACEI and α-glucosidase inhibitory activity in our previous work, was among
the cheese isolates that were completely susceptible to all antibiotics (Fig. 3.3) Cariolato
et al. (2008) also reported very high percentages of susceptibility to antibiotics in dairy
strains, except in the case of tetracycline.
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Successful treatment of enterococcal infection has usually required combinations of cell
wall active agents (such as penicillins and glycopeptides) with aminoglycosides which
results in a bactericidal effect on the organisms (Chow, 2000). Therefore, the fact that all
isolates were susceptible to clinically relevant ampicillin, penicillin, the glycopeptides
(vancomycin and teicoplanin) and to the high-level aminoglycoside gentamicin is
certainly a positive observation if these strains are to be considered for use in food
applications. Moreover, susceptibility to vancomycin coincided with the absence of the
vanA and vanB determinants in the genomes of the strains, which is favourable as these
determinants are considered to be acquired traits (Ogier & Serror, 2008). It is difficult to
determine the impact of antibiotic resistance on potential human pathogenicity, but it is
clear that antibiotics may influence selection of pathogenic enterococci in a hospital
environment. Although resistance traits were observed by some strains to a number of
antibiotics, our results showed that none of the strains tested were resistant to any of the
clinically relevant antibiotics. Susceptibility of the enterococcal isolates to clinically
relevant antibiotics is also corroborated in the findings of several other authors (Čanžek
Majhenič et al., 2005; Franz et al., 2001; Peters et al., 2003).
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CONCLUSION
In conclusion, there appears to be positive evidence that enterococci can find application
in food. Bacteria of the genera Lactobacillus and Bifidobacterium are commonly used in
fermented food production but there is merit in exploring the benefits of other genera of
LAB. Among these candidates, enterococci are prominent. However, for safety reasons,
their application in food has not been sufficiently exploited despite their well-documented
beneficial use in fermentation processes of traditional foods owing to their biochemical
properties of technological interest, probiotic properties and ability to generate bioactive
peptides during fermentation. Despite a long history of safe use in foods, the question of
whether enterococci can be used as starter, adjunct or probiotic cultures for development
of new food products remains controversial and difficult to answer. The principle concern
for enterococci in food is their pathogenic potential which is based on the presence of
putative virulence determinants and antibiotic resistant traits. Thus, before using
enterococci in food, the safety aspects of all strains must be evaluated and the advantages
of using new strains should be considered in a well contemplated risk/benefit analysis.
Data in the literature regarding the proteolytic capabilities and safety aspects of E. faecalis
strains is somewhat conflicting and it seems that these traits are strain, region or origin
dependant. Therefore, studies are urgently needed to reconcile the disparate reports in the
literature. The results obtained in this work yield new information regarding the
proteolytic activity and safety aspects of E. faecalis strains isolated mainly from foods of
animal origin in Southern Ireland. Isolates used in this study showed high proteolytic
activity and harboured few virulence genes. Furthermore, a very advantageous result of
our study is the observation that all 25 E. faecalis strains were susceptible to clinically
relevant antibiotics. However, the authors are aware that antibiotic resistance and
possession of virulence determinants alone does not fully explain the pathogenesis of
enterococci. To get a true indication of the safety of these strains, further studies are
required to assess their ability to acquire and transfer genetic elements related to these
traits, as well as examining the expression of virulence determinants and their phenotypic
implications in vivo. Nevertheless, recently established phenotypic methods and modern
genetic tools have enabled the differentiation of pathogenic from non-pathogenic
enterococci. Therefore, we suggest that the use of enterococcal strains in foods should be
possible on the basis of a case-by-case evaluation of each technological strain to establish
their innocuity or at least the lack of acquired antibiotic resistance genes and proven
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virulence factors. In that regard, some of the strains used in this study, particularly
DPC5154 and DPC4784 which were susceptible to all of the tested antibiotics and
generated milk fermentates with antihypertensive, antihyperglycaemic and antioxidant
activity as shown elsewhere in our work, have potential to be used in food biotechnology
for future development of multi-functional food products.
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Enterococcus faecalis milk fermentates display
antioxidant properties and inhibitory activity
towards key enzymes linked to hypertension and
hyperglycaemia
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ABSTRACT
In this study, Enterococcus faecalis milk fermentates were assayed for total phenolic
content, related antioxidant activity and the inhibition of key enzymes linked to
hypertension and hyperglycaemia. Of the 25 isolates, milk fermented with E. faecalis
DPC5154 had the highest level of total phenolic compounds (739.06 µg GAE/ml) and
demonstrated the highest level of Trolox Equivalent Antioxidant Activity (TEAA) based
on DPPH radical scavenging activity and ferric reducing antioxidant power (271.27
TEAA (µM) and 272.75 TEAA (µM), respectively). Inhibition of Angiotensin
Converting Enzyme (ACE) and α-glucosidase is considered a useful therapeutic approach
in the management of hypertension and hyperglycaemia, respectively. Milk fermented
with DPC5154 completely inhibited ACE and displayed the highest level of αglucosidase inhibitory activity (33.41%). These studies provide in vitro evidence for the
beneficial use of DPC5154 and other E. faecalis isolates for the generation of bioactive
milk products with antioxidant, antihypertensive and anti-hyperglycaemic activity.
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INTRODUCTION
Enterococci are ubiquitous lactic acid bacteria (LAB) that constitute an important part of
food, environmental and clinical microbiology. They occur in large numbers in dairy
products and other foods. Although some strains are considered opportunistic pathogens
due to the possession of virulence traits and an increasing incidence of antibiotic
resistance, enterococci have a long history of safe use in foods. Furthermore, virulence
factors are mainly detected among clinical isolates, while isolates of food origin tend to
lack pathogenic traits (Abriouel et al., 2008; Chajęcka-Wierzchowska et al., 2017; Gaglio
et al., 2016). Enterococci have successfully been utilised as starter or adjunct cultures,
particularly in the dairy industry, whereby they have improved the organoleptic properties
of food. They also possess notable biotechnological traits such as bacteriocin production
and probiotic characteristics (Achemchem et al., 2006; Franz et al., 2011). Moreover,
enterococci which display proteolytic activity have received considerable attention in
scientific literature in recent years due to their ability to generate bioactive peptides during
the fermentation of proteinaceous foodstuffs (Gútiez et al., 2013; Quirós et al., 2007).

Foods or food derived products which provide medical or health benefits, most notably
in the treatment/prevention of disease, can be considered nutraceuticals. These bridge the
gap between ‘nutrition’ and ‘pharmaceuticals’ and can add significant value to foods
beyond the sensory, rheological and nutritional properties (Santini & Novellino, 2018).
One area where they may show particular promise is the inclusion in Ready-To-Use
Therapeutic Foods (RUTF) which are designed for therapeutic use in severe acute
malnutrition (Santini & Armini, 2013). Furthermore, food naturally contains components
which may warrant use as nutraceuticals and where minimal effort is required to harvest
their potential. For example, many dietary proteins contain bioactive peptides encrypted
within their primary structure which display a wide range of physiological functions
including antioxidative, antihypertensive, immunomodulatory, antimicrobial and
hypocholesterolaemic effects (Bouglé & Bouhallab, 2017; Park & Nam, 2015). The
release of bioactive peptides from the precursor inactive protein can be achieved using
digestive enzymes or by hydrolysis with specific proteolytic enzymes. Furthermore, food
fermentation with proteolytic microorganisms provides an alternative approach for the
derivatization of peptides with biological activity (Ryan et al., 2011; Walther & Sieber,
2011). For this purpose, bacteria of the genera Lactobacillus and Bifidobacterium are
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commonly used in fermented food production. In a recent study, Lactobacillus plantarum
was shown to generate bovine and camel milk fermentates with ACEI, α-glucosidase,
antioxidant and anti-cancer activity (Ayyash et al., 2018). However, there is a need to
explore the benefits of other genera of LAB. Enterococci are leading microbes in
fermentation processes of traditional foods because of their ability to generate bioactive
peptides during fermentation, while the possession of notable biochemical properties of
technological interest, such as acid production, lipolytic activity and carbohydrate
metabolism, ensure enterococci remain an important consideration as starter or adjunct
cultures, particularly in the dairy industry.

Foods rich in antioxidants and phenolic compounds are increasingly used in food
manufacturing because they provide valuable nutritional and therapeutic properties and
prevent oxidative damage. Oxidative stress is caused by an imbalance between the
occurrence of reactive oxygen species (ROS) and the organism’s ability to counteract
their action using antioxidants. ROS modulate the function of all classes of biomolecules
and target almost all substrates in the cell, with lipids being the most susceptible to
oxidation. Antioxidants encompass any compound capable of delaying or preventing the
oxidation of a substrate by ROS (Pisoschi & Pop, 2015). Biological systems provide
favourable conditions for oxidative reactions to occur and the availability of antioxidants
and the ability for the inactivation or elimination of formed oxidised products can dictate
the susceptibility of a cell or tissue to oxidative stress. Oxidative damage has been shown
to contribute to the aetiology of many chronic health conditions such as atherosclerosis,
cancer, cirrhosis, arthritis and hypertension (Lobo et al., 2010; Pizzino et al., 2017).
Although endogenous antioxidants, such as glutathione, uric acid and bilirubin, aim to
maintain the redox homeostasis of the cell, the endogenous antioxidant repair system may
not always effectively counteract oxidative stress. Therefore, exogenous antioxidants can
be consumed to complement the activity of endogenous antioxidants and improve the
organism’s capacity to contain the oxidative stress. Concerns regarding the impact of
synthetic antioxidants on human health has resulted in the search for effective, nontoxic,
natural compounds with antioxidant activity. The consumption of foods containing
natural antioxidants and phenolic compounds and/or those derived from the microbial
fermentation of food appears to be a suitable alternative.
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Antioxidants function by several different mechanisms and thus, no single method can
reliably measure the antioxidant capacity of foods and biological samples. Nevertheless,
several in vitro assays are established and are widely used in research to estimate
antioxidant activity. Some of the most frequently employed methods include Hydrogen
Atom Transfer (HAT) methods such as Oxygen Radical Absorbance Capacity (ORAC)
and the ABTS radical scavenging method, and Electron Transfer (ET) methods such as
the measurement of Ferric Reducing Antioxidant Power (FRAP), DPPH free radical
scavenging activity and Total Phenolic Content (TPC) by the Folin-Ciocalteu method.
The benefits, limitations and considerations for use of these, and several other less
frequently used in vitro antioxidant assays, are reviewed elsewhere (Badarinath et al.,
2010; Prior et al., 2005). Many authors have utilised some of the aforementioned methods
to estimate antioxidant activity in fermented milk (Apostolidis, Kwon, Ghaedian, et al.,
2007; Hrnjez et al., 2014; A.B. Shori & Baba, 2013; Amal Bakr Shori & Baba, 2014),
while others have focused on individual components of milk that confer antioxidant
activity, such as bioactive peptides (Pihlanto, 2006; Power et al., 2013). Kudoh et al.
(2001) showed that a peptide derived from milk fermented with Lactobacillus delbrueckii
ssp. bulgaricus demonstrated strong DPPH radical scavenging activity, while Gútiez et
al. reported the liberation of antioxidant peptides from bovine skim milk fermented with
Enterococcus species (Gútiez et al., 2014, 2013; Kudoh et al., 2001). Antioxidant
peptides from meat and fish have also been reported (Ryan et al., 2011). Furthermore,
other food components which have been assessed include phenolic compounds. Recent
studies have shown that phenolic compounds not only have high antioxidant activity, but
they also provide therapeutic effects including anti-diabetic and anti-hypertensive activity
(Kwon et al., 2006; Lim & Loh, 2016).

Hypertension is a chronic degenerative disease characterised by high blood pressure and
is recognised as a serious, yet controllable risk factor for cardiovascular disease. The
release of peptides with Angiotensin Converting Enzyme Inhibitory (ACEI) activity, and
subsequent hypotensive effects, have been extensively studied due to the high prevalence
of hypertension worldwide (Gútiez et al., 2013; Hayes et al., 2007; Li et al., 2005;
Martínez-Maqueda et al., 2012; Phelan et al., 2014). Blood pressure is partially regulated
by the Rennin-Angiotensin System (RAS). Cleavage of the biologically inactive
decapeptide, angiotensin I, to its potent vasoconstrictor, angiotensin II, is carried out by
ACE and is considered one of the main components of the system (Ryan et al., 2011).
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Moreover, ACE degrades bradykinin, which exerts important vasodilation activity.
Therefore, compounds which display antihypertensive activity by inhibiting ACE, and
subsequently preventing the conversion of angiotensin to its potent form, can play a
crucial role in minimising the risk factors and alleviating symptoms of hypertension.
Although antihypertensive drugs play a fundamental role in the regulation of blood
pressure, they often present several side effects. Therefore, the search for food substances
which display antihypertensive activity has intensified. Liberation of antihypertensive
agents from food has been demonstrated in vivo and in vitro. This has mainly been
achieved through fermentation of milk with LAB (Beltrán-Barrientos et al., 2016).
Several studies have shown that E. faecalis strains produce protein hydrolysates with high
ACEI activity during food fermentation and that most, but not all, E. faecalis strains
produce milk-derived hydrolysates with high ACEI activity (Gútiez et al., 2013;
Muguerza et al., 2006; Quirós et al., 2007). Therefore, liberation of ACEI peptides from
enterococci fermented foods, particularly dairy based foods, may provide a
complementary therapeutic approach in the treatment of hypertension.

Diabetes mellitus is a metabolic disease characterized by hyperglycaemia, a condition
resulting from high blood glucose levels. Intestinal α-glucosidases are key players in the
uptake of glucose following the hydrolysis of dietary carbohydrates, such as starches
(Apostolidis, Kwon, & Shetty, 2007). Rapid uptake of glucose is likely to result in
elevated blood glucose levels followed by the subsequent onset of hyperglycaemia.
Several anti-diabetic drugs exist to counteract hyperglycaemia and reduce blood glucose
to safe levels. α-Glucosidase inhibitors, such as acarbose, are commonly used in the
treatment of diabetes mellitus. The activity of α-glucosidase inhibitors is centred in
helping to maintain blood sugar levels within a safe range by slowing down the rate at
which glucose is absorbed from foods by the intestines. Therefore, one potential strategy
for the management of type 2 diabetes is by the inhibition of intestinal α-glucosidases.
However, not only are concerns raised over the expense of anti-diabetic drugs, those such
as α-glucosidase inhibitory agents may also cause adverse gastrointestinal side effects
such as stomach aches, flatulence and diarrhoea (Wang et al., 2016). Subsequently, there
is a demand for effective, non-toxic, natural α-glucosidase inhibitory products.
Furthermore, one of the complications of diabetes is hypertension. These are interrelated
metabolic disorders that strongly predispose an individual to atherosclerotic
cardiovascular disease (CVD) (Petrie et al., 2018). Therefore, multifunctional food
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products, such as those derived from enterococci fermented milk, that display antioxidant
properties as well as ACEI and α-glucosidase inhibitory activity, provide a promising
means of neutralizing the potentially detrimental effect of oxidative compounds and
managing hypertension and type 2 diabetes.

The aim of this work was to evaluate the in vitro inhibitory effects of E. faecalis milk
fermentates towards α-glucosidase and ACE to assess anti-diabetic and anti-hypertensive
activity, respectively. Furthermore, quantitative analysis and subsequent correlation
studies were performed on the TPC, DPPH and FRAP assays to determine the antioxidant
capacity of the E. faecalis milk fermentates.
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MATERIALS AND METHODS
Bacterial strains and growth conditions
Various food samples were screened for the presence of proteolytic enterococci and
isolates used in this study are listed in Table 4.1.

Bovine Raw Milk
Bovine raw milk was obtained from a dairy farm in Southern Ireland. The raw milk was
obtained from a holding tank immediately after the milking process using a sterile 100 ml
disposable cup. The raw milk sample was serially diluted 10-fold in sterile ringers, spread
plated on Kanamycin Skim Milk Aesculin Azide (KSMEA) agar (Graham et al., 2017)
and incubated aerobically at 37 °C for 48 h.

Cheese
Roquefort (raw ewe’s milk, France), Brie (raw cow’s milk, France) and goat’s cheese
(raw goat’s milk, Western Ireland) were obtained from a local market in Co. Cork, Ireland
and screened for the presence of proteolytic enterococci. 1 g of cheese was added to 9 ml
of Kanamycin Aesculin Azide (KAA, Merck KGaA, Darmstadt, Germany) broth. The
sample was vortexed and incubated in a shaking incubator aerobically at 37 °C for 24 h.
Following incubation, homogenised cheese samples in KAA broth were serially diluted
10-fold in sterile ringers, spread plated on KSMEA agar and incubated aerobically at 37
°C for 48 h.

Meat
Raw beef, chicken, pork and turkey were obtained from a local butcher in Co. Cork,
Ireland. 1 g of minced meat sample was added to 9 ml of sterile KAA broth, vortexed and
incubated in a shaking incubator at 37 °C for 24 h. Following incubation, meat samples
were serially diluted 10-fold in sterile ringers, spread plated on KSMEA agar and
incubated aerobically at 37 °C for 48 h.
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DNA amplification and 16S rRNA sequencing for confirmation of
enterococci
DNA was extracted from all presumptive proteolytic enterococcal colonies on KSMEA
using the High Pure PCR Template Preparation Kit (Roche Diagnostics Ltd., West
Sussex, United Kingdom) according to the manufacturer’s instructions. Isolates were
confirmed as enterococci by PCR amplification of bacterial DNA with Enterococcus
specific

primers

(E1;

5′

TCAACCGGGGAGGGT

3′

and

E2;

5′

ATTACTAGCGATTCCGG 3′) using the procedure described previously (Deasy et al.,
2000). Species determination of Enterococcus isolates was achieved by 16S rRNA
sequencing with the 27F (5′ AGAGTTTGATCMTGGCTCAG 3′) and 1492R (5′
ACCTTGTTACGACTT 3′) universal primer set (Lane, 1991). Amplified PCR products
were determined by Sanger sequencing (Eurofins GATC Biotech, 78467 Constance,
Germany). To determine strain identity, obtained sequences were compared against the
GenBank database using the Basic Local Alignment Search Tool (BLAST, NCBI).
Following isolation and confirmation of enterococci, all isolates were routinely
maintained on Brain Heart Infusion (BHI) agar or in BHI broth at 37 °C for 24 h for
further use.

Confirmation of proteolysis
Overnight cultures of enterococci in BHI broth were cultured on skim milk agar (SMA)
plates and incubated at 37 °C for 48 h. A clear zone of hydrolysis around colonies on
SMA was deemed positive for proteolytic activity.

Preparation of fermented milk
Milk fermentations were carried out to generate cell free supernatants of milk
hydrolysates. Overnight cultures of isolates in BHI broth were standardised to an optical
density of 1.0 at 600 nm. 100 µl the standardised overnight culture in BHI broth was
added to 9.9 ml of 10% (w/v) bovine skim milk (BSM) (Glanbia, Ballyragget, Co.
Kilkenny, Ireland) and incubated at 37 °C for 20 h. The cultures in skim milk were
vigorously stirred and then centrifuged at 7085g for 10 min. The resulting supernatants
were filtered through 0.2 µm filters (Sarstedt, Nümbrecht, Germany) and stored at -20 °C
for future use. All overnight cultures in BHI broth were prepared in triplicate using three
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independent colonies from BHI agar. Subsequently, milk fermentations were also
performed in triplicate from respective overnight cultures in BHI broth.

Table 4.1. Bacterial strains used in this study.
Genus

Species

Strain

Source

Reference

Enterococcus
Enterococcus
Enterococcus
Enterococcus
Enterococcus
Enterococcus
Enterococcus
Enterococcus
Enterococcus
Enterococcus
Enterococcus
Enterococcus
Enterococcus
Enterococcus
Enterococcus
Enterococcus
Enterococcus
Enterococcus
Enterococcus
Enterococcus
Enterococcus
Enterococcus
Enterococcus
Enterococcus
Enterococcus

Faecalis
Faecalis
Faecalis
Faecalis
Faecalis
Faecalis
Faecalis
Faecalis
Faecalis
Faecalis
Faecalis
Faecalis
Faecalis
Faecalis
Faecalis
Faecalis
Faecalis
Faecalis
Faecalis
Faecalis
Faecalis
Faecalis
Faecalis
Faecalis
Faecalis

M10
M14
BR01
RC01
RC11
RC17
ST01
ST02
BF02
CK01
PK02
PK07
TK01
TK02
DPC810
DPC4996
DPC5173
DPC5154
DPC5083
DPC4995
DPC5237
DPC5209
DPC5802
DPC4784
DPC4787

Raw milk
Raw milk
Brie cheese
Roquefort cheese
Roquefort cheese
Roquefort cheese
Goat’s cheese
Goat’s cheese
Beef
Chicken
Pork
Pork
Turkey
Turkey
Cheddar cheese
Washed rind cheese
Italian cheese
Fontina cheese
Goat’s cheese
Raw milk
Horse
Human faeces
Farm water
Unknown
Unknown

This work
This work
This work
This work
This work
This work
This work
This work
This work
This work
This work
This work
This work
This work
DPC Collection
DPC Collection
DPC Collection
DPC Collection
DPC Collection
DPC Collection
DPC Collection
DPC Collection
DPC Collection
DPC Collection
DPC Collection

DPC: Dairy Products Research Centre culture collection, Teagasc, Moorepark, Fermoy, Co. Cork,
Ireland.

Determination of anti-oxidant activity
With the knowledge that phenolic compounds are effective antioxidants and that radical
scavenging activity (by oxidation/reduction reactions) is the main mechanism by which
antioxidants exert their effect in foods, the Folin-Ciocalteu (measures total phenolic
content), DPPH and FRAP (both based on hydrogen donation or electron transfer
mechanisms) assays were used to assess the antioxidant capacity of the milk fermentates
in this work (Pihlanto, 2006). Furthermore, although the Folin-Ciocalteu assay is used to
measure total phenolics, the basic mechanism of the assay is an oxidation/reduction
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reaction and is therefore considered an antioxidant method (Prior et al., 2005). The
aforementioned assays were also utilised by other authors when assessing the antioxidant
capacity of fermented milk samples (Apostolidis, Kwon, Ghaedian, et al., 2007; Ozcan
et al., 2017).

Total Phenolic Content (TPC)
The total phenolic content of milk fermentates was determined using the Folin-Ciocalteu
reagent as described by Singleton and Rossi (Singleton & Rossi, 1965) with some
modifications. 50 µl of Enterococcus milk fermentate was mixed with 250 µl of FolinCiocalteu reagent (Sigma-Aldrich, Vale Road, Arklow, Wicklow, Ireland). Samples were
vortexed and incubated in darkness at room temperature for 4 min. 500 µl of 20% (w/v)
Na2CO3 (Merck KGaA, Darmstadt, Germany) was added following incubation and the
reaction mixture was made up to a final volume of 5 ml with distilled water. Samples
were incubated at room temperature for 2 h and the absorbance was measured at 765 nm.
Distilled water was used as a blank. Standard curves were established using various
concentrations of gallic acid in water. Absorbance values of samples were converted to
total phenolics and were expressed in microgram equivalents of gallic acid per ml of
fermentate (µg GAE/ml). The phenolic content of each fermentate was determined in
triplicate, results were averaged, and the data reported as the mean ± standard deviation.

1,1-diphenyl-2-picrylhydrazyl (DPPH) free radical-scavenging assay
The radical scavenging activity of the milk fermentates was evaluated using the DPPH
assay as previously described (Brand-Williams et al., 1995) with slight adjustments. The
DPPH solution was prepared fresh on the day of analysis and was used at a concentration
of 60 μM, dissolved in methanol. Aliquots of 250 µl of sample (milk fermentate) were
transferred to test tubes with 3 ml of the 60 µM DPPH solution and homogenized by
vortexing. 250 µl methanol with 3 ml of the DPPH solution was used as a control.
Samples were incubated at room temperature for 1 h and absorbance was measured at 517
nm. Standard curves were established using various concentrations of trolox in methanol.
The radical scavenging activity of the milk fermentates was expressed as Trolox
Equivalent Antioxidant Activity [TEAA (µM)].
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Ferric Reducing Antioxidant Power (FRAP)
The ferric reducing antioxidant power of the milk fermentates was assessed using the
FRAP assay as described previously (Benzie & Strain, 1996) with some modifications.
The FRAP assay is based on the rapid reduction in ferric-tripyridyltriazine (Fe3+-TPTZ)
by the presence of antioxidants. This reduction results in the formation of ferroustripyridyltriazine (Fe2+-TPTZ) which is a blue-coloured product. The FRAP reagent was
prepared by mixing 300 mM acetate buffer, pH 3.6 (3.1 g sodium acetate trihydrate
(C2H3NaO2.3H2O), plus 16 ml glacial acetic acid (C2H4O2)), 10 mM TPTZ (2,4,6-tris (2pyridyl)-s-triazine) in 40 mM HCl, and 20 mM ferric chloride hexahydrate (FeCl3.6H2O)
in a 10:1:1 (v/v/v) ratio. The FRAP reagent was warmed at 37 °C prior to use. 150 µl of
milk fermentate was added to 2850 µl of FRAP reagent and incubated at 37 °C in the dark
for 30 min. A blank was prepared by adding 150 µl of deionised water to 2850 µl of
FRAP reagent and readings were measured at 593 nm. Standard curves were established
using trolox solutions ranging from 0 – 600 µM. The ferric reducing antioxidant power
(FRAP) of the milk fermentates was expressed as Trolox Equivalent Antioxidant Activity
[TEAA (µM)].

Determination of ACEI Activity
Angiotensin Converting Enzyme Inhibitory (ACEI) activity was measured as described
previously (Li et al., 2005) with slight adjustments. 20 µl ACE inhibitor (milk fermentate
or 0.1M captopril as a positive control) and 50 µl of 5 mM Hippuryl-L-histidyl-L-leucine
(HHL) in 100 mM sodium borate buffer (pH 8.3) containing 300 mM NaCl was
preincubated at 37 °C for 10 min. 20 µl of borate buffer was used as a negative control to
allow the enzymatic reaction to occur. The reaction was initiated by the addition of 20 µl
of ACE solution (100 mU/ml) and the mixture was incubated at 37 °C for 1.5 h. The
reaction was stopped by the addition of 100 µl of 1 M HCl. 300 mM sodium borate buffer
was added to the reaction mixture to a volume of 500 µl. To measure the hippuric acid
(HA) released from HHL by ACE, 600 µl of quinoline was added to the reaction mixture
in darkness followed by immediate vortexing for 10 s. Subsequently, 200 µl of benzene
sulfonyl chloride (BSC) was added and the reaction mixture was vortexed for 20 s. The
reaction mixtures were incubated at 30 °C for 1 h in a shaking water bath. 3700 µl of
ethanol was then added to the mixture followed by further incubation at 30 °C for 30 min.
Following incubation, the reaction blank (HCl added before ACE) was used to zero the
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spectrophotometer and absorbance of samples was measured at 492 nm. All
measurements were performed in triplicate and the extent of ACE inhibition was
calculated as follows:

ACE inhibitory activity (%) =

B−A
× 100
B

Where B is the absorbance of the control (buffer added instead of inhibitor), and A is the
absorbance in the presence of the inhibitor (milk fermentate or captopril).

α-Glucosidase inhibition assay
Inhibition of α-glucosidase by the milk fermentates was assessed as previously described
(Apostolidis, Kwon, & Shetty, 2007). Briefly, 50 µl of milk fermentate was mixed with
100 µl glucosidase solution (1.0 U/ml) in 0.1 M phosphate buffer (pH 6.9) and incubated
at 25 °C for 10 min. After pre-incubation, 50 µl of 5 mM p-nitrophenyl-α-ᴅglucopyranoside solution dissolved in phosphate buffer was simultaneously added to each
sample and incubated at 25 °C for 5 min. Absorbance readings were measured before and
after the 5 min incubation period at 405 nm using a microplate reader (Spectramax340,
Molecular Device Co., Virginia, USA). The absorbance values of the milk fermentates
were compared to a control solution which had 50 µl of buffer solution in place of the
fermentate. The α-glucosidase inhibitory activity was expressed as percentage inhibition
and was calculated as follows:
∆𝐴𝐶𝑜𝑛𝑡𝑟𝑜𝑙
− ∆𝐴𝐹𝑒𝑟𝑚𝑒𝑛𝑡𝑎𝑡𝑒
405
405
% Inhibition = (
) × 100
𝐶𝑜𝑛𝑡𝑟𝑜𝑙
∆𝐴405

Statistical Analysis
All experiments were performed in triplicate using three independent milk fermentates
derived from three independently prepared cultures in 10% BSM. The mean and standard
deviation of the replicates were calculated using Microsoft Excel. Correlation studies
were performed using the Statistical Package for Social Sciences (SPSS v.24) utilising
either the Pearson’s correlation coefficient or Spearman’s rho coefficient based on the
nature of the data with a significance level of P ≤ 0.05.
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RESULTS
Identification of enterococci and evaluation of proteolytic activity
All isolates recovered from the initial screen were confirmed as Enterococcus faecalis
and gave a zone of clearing on skim milk agar following growth, thereby indicating the
presence of proteolytic activity (data not shown). Isolates obtained from the Dairy
Products Research Centre (DPC) culture collection in Teagasc, Fermoy, Co. Cork were
previously confirmed as Enterococcus faecalis and were subject to further confirmation
as E. faecalis in this work. Similarly, all the E. faecalis isolates obtained from the DPC
demonstrated the ability to break down casein in skim milk agar, noted by the presence
of a clear zone of hydrolysis around the colonies following growth.

Total Phenolic Content
The total phenolic content in the enterococci fermented milk samples was analysed by
the Folin-Ciocalteu method and was expressed as microgram equivalents of gallic acid
per ml of fermentate (µg GAE/ml). The phenolic content of the milk fermentates ranged
from 160.83 µg GAE/ml to 739.06 µg GAE/ml (Fig. 4.1). Milk fermented with DPC5154
(isolated from cheese) contained the greatest amount of phenolic compounds (739.06 µg
GAE/ml), while milk fermented with other cheese isolates such as ST02, BR01,
DPC5173 and DPC5083 also displayed high levels of phenolics. Milk fermentates
generated with isolates from non-dairy sources appeared to have lower levels of total
phenolic compounds. E. faecalis PK02, a strain isolated from pork, generated the milk
fermentate with the lowest measured total phenolic content (160.83 µg GAE/ml).
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Figure 4.1. Antioxidant activity of the 25 E. faecalis milk fermentates determined by the DPPH
radical scavenging activity, measured as Trolox Equivalent Antioxidant Activity [TEAA (µM)],
and the Total Phenolic Content (TPC), measured as microgram equivalents of gallic acid per ml
of fermentate (µg GAE/ml). Error bars represent the standard deviation of three independent
experiments.

DPPH Radical Scavenging Assay
The radical scavenging activity of the E. faecalis milk fermentates was determined using
the DPPH assay (Fig. 4.1). The milk fermentate generated with E. faecalis DPC5154
demonstrated the highest level of radical scavenging activity (271.27 µM TEAA), while
milk fermented with E. faecalis TK02 demonstrated the lowest antioxidant activity based
on DPPH free radical scavenging activity (41.97 µM TEAA). A high level of activity was
also observed for the ST02 and DPC4784 fermentates which gave TEAA values of 203.02
µM and 198.01 µM, respectively. The DPC5209, DPC4996, DPC4995 and DPC4787
fermentates demonstrated 163.38, 157.22, 137.74, 134.27 µM TEAA, respectively, while
the remainder of isolates generated milk fermentates with moderate to weak TEAA (<82
µM).
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Ferric reducing antioxidant power
Antioxidant activity of the milk fermentates was also assessed using the Ferric reducing
antioxidant power (FRAP) assay and results are presented in Figure 4.2. Milk fermented
with E. faecalis DPC5154 (272.75 µM TEAA) and DPC4784 (271.76 µM TEAA)
displayed the greatest level of antioxidant activity based on the reduction of the Fe3+TPTZ complex to Fe2+. Of the 25 isolates, milk fermented with DPC5802 had the lowest
antioxidant activity (70.95 µM TEAA). E. faecalis DPC4996, DPC4787, ST02, DPC5209
and DPC4995 fermentates demonstrated high antioxidant activity compared to other
isolates which coincides with the findings of the DPPH assay. In contrast to the DPPH
radical scavenging activity, the milk fermentates generated with E. faecalis CK01, RC11,
DPC5237, TK01, and TK02 demonstrated high TEAA based on the FRAP assay.
Nevertheless, a statistically significant positive correlation was observed between the data
obtained for the DPPH and FRAP assays (P < 0.05; r = 0.425; Fig. 4.3). In fact, one of
the aims of this study was to assess the relationship between the data obtained for each of
the antioxidant assays. A statistically significant strong positive correlation was also
observed between the DPPH and TPC data sets (P < 0.05, r = 0.530, Fig. 4.1) but no
correlation was observed when comparing the FRAP values of the E. faecalis milk
fermentates with the total phenolic concentration (Table 4.2).
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Figure 4.2. Ferric reducing antioxidant power (FRAP) of milk fermentates generated by growing
E. faecalis isolates in 10% (w/v) bovine skim milk (BSM). FRAP is presented as Trolox
Equivalent Antioxidant Activity [TEAA (µM)]. Error bars represent the standard deviation of
three independent experiments.
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Figure 4.3. Correlation of the DPPH scavenging activity with Ferric Reducing Antioxidant Power
(FRAP), measured as Trolox Equivalent Antioxidant Activity [TEAA (µM)], of milk fermentates
generated by growing E. faecalis isolates in 10% (w/v) bovine skim milk (BSM).

Angiotensin Converting Enzyme Inhibitory (ACEI) activity
The milk fermentates of all isolates were evaluated for their ACEI activity after growth
in BSM (Fig. 4.4). All 25 isolates demonstrated a very high level of ACEI activity which
ranged from 89.18% inhibition for milk fermented with E. faecalis TK01 to 107.78%
inhibition for the DPC5154 fermentate. 11 isolates completely inhibited ACEI (≥100%
inhibition) when grown in BSM, while 13 of the remaining 14 isolates showed greater
than 90% inhibition. Therefore, out of 25 isolates utilised in this work, only the fermentate
of TK01 displayed less than 90% ACEI activity (89.18%).
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Figure 4.4. Angiotensin Converting Enzyme Inhibitory (ACEI) activity (%) of milk fermentates
generated by growing E. faecalis isolates in 10% (w/v) bovine skim milk (BSM). Error bars
represent the standard deviation of three independent experiments.
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α-Glucosidase inhibitory activity
The ability of the enterococci fermented milk samples to inhibit the α-glucosidase enzyme
was also evaluated (Fig. 4.5). Milk fermented with E. faecalis DPC5154 was noted as the
most active, demonstrating the highest level of α-glucosidase inhibitory activity
(33.41%). The E. faecalis ST02 fermentate was also among the most potent α-glucosidase
inhibitors (30.52% inhibition), while milk fermentates generated with E. faecalis RC11,
DPC5237, PK02, TK02 and TK01 did not demonstrate any inhibitory activity towards
the α-glucosidase enzyme. No correlation was observed between cell growth and αglucosidase inhibitory activity after 20 h fermentation (P > 0.05) thereby suggesting that
cell growth did not influence the levels of α-glucosidase inhibitory activity observed for
the E. faecalis milk fermentates (data not shown).
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Figure 4.5. Summary of the results obtained for % α-glucosidase inhibitory activity of milk
fermentates generated by growing E. faecalis isolates in 10% (w/v) bovine skim milk (BSM).
Error bars represent the standard deviation of three independent experiments.
Table 4.2. Correlation analysis of assays performed on the milk fermentates of Enterococcus
faecalis isolates grown in 10% (w/v) bovine skim milk (BSM).
Assay under study

Correlation coefficient

FRAP & DPPH

0.425**

FRAP & TPC

NS

DPPH & TPC

0.530*

GI & TPC

0.734*

FRAP: Ferric Reducing Antioxidant Power; DPPH: 1,1-diphenyl-2-picrylhydrazyl scavenging activity;
TPC: Total Phenolic Content; GI: α-Glucosidase Inhibition.
*Pearson’s correlation coefficient.
** Spearman rho’s coefficient.
Significance level: P ≤ 0.05; NS: Not significant.
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DISCUSSION
Type 2 diabetes and hypertension are interrelated metabolic disorders that can predispose
an individual to atherosclerotic cardiovascular disease (CVD). α-Glucosidase and
Angiotensin Converting Enzyme (ACE) are enzymes which play a role in the onset of
diabetes and hypertension, respectively (Apostolidis, Kwon, & Shetty, 2007; Petrie et al.,
2018; Ryan et al., 2011). Inhibition of these enzymes is considered a useful therapeutic
approach in the management of such conditions and concerns over the side effects of
synthetic inhibitors has resulted in an increasing interest in the use of natural food derived
inhibitory compounds (Kumar et al., 2010). Similarly, because biological systems
provide favourable conditions for oxidative reactions, coupled with the safety concerns
associated with synthetic antioxidants, the search for effective nontoxic natural
compounds with antioxidant activity has also intensified (Embuscado, 2015; Grażyna et
al., 2017). The aim of this study was to quantitatively determine the total phenolic content
and antioxidant capacity of E. faecalis milk fermentates and to assess their inhibitory
potential towards ACE and α-glucosidase.

There is an increasing interest in phenolic compounds due to their antioxidant properties.
Although their presence in milk is rarely investigated, it has been reported as a good
source of phenolics containing levels of milligrams per litre (Kuhnen et al., 2014;
O’Connell & Fox, 2001). In this work, the total phenolic content of the milk fermentates
was measured by the Folin-Ciocalteu method. Phenolic content levels differed among the
E. faecalis milk fermentates which may be explained by the formation and/or further
degradation of polymeric phenolics during fermentation (McCue & Shetty, 2005). The
milk fermentates generated with cheese isolates such as E. faecalis ST02, BR01,
DPC5173 and DPC5083 had higher levels of phenolics compared to milk fermented with
non-cheese isolates. The milk fermentate generated with E. faecalis DPC5154, isolated
from fontina cheese, demonstrated the highest level of total phenolics (739.06 µg
GAE/ml, Fig. 4.1). The higher level of phenolics observed in the fermentates of cheese
isolates may be attributed to growth of the strains in a dairy environment, similar to that
from which they were originally isolated, and may allude to niche-adaptation by E.
faecalis (He et al., 2018).
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The antioxidant activities of the E. faecalis milk fermentates were evaluated by DPPH
radical scavenging activities (Fig. 4.1) and by the Ferric Reducing Antioxidant Power
(FRAP) assay (Fig. 4.2). Antioxidant compounds delay or prevent damage caused by
oxidative stress and with concerns raised over the side effects of synthetic antioxidants,
there is a need for effective, non-toxic, natural antioxidants. Foods, such as fruit and
vegetables, are a rich source of antioxidants, while the liberation of antioxidant peptides
from milk during fermentation with E. faecalis has also been demonstrated (Gútiez et al.,
2013; Pisoschi & Pop, 2015). When comparing total phenolic content of the milk
fermentates with the DPPH radical scavenging activities, a statistically significant
positive correlation was observed (P < 0.05, Table 4.2) which may indicate the
contribution of phenolic compounds to antioxidant activity (Martins et al., 2016).
Similarly, DPPH radical scavenging activity was also positively correlated with the FRAP
values of the fermentates (P < 0.05, Fig. 4.3), thereby indicating that, although different
assays were used to evaluate antioxidant capacity, activity was consistent among the
isolates. However, no correlation was observed between the total phenolic content of the
fermentates and FRAP values (Table 4.2). Therefore, while phenolic compounds may
have contributed to observed antioxidant activity, noted by a positive correlation between
the total phenolic content and DPPH radical scavenging activity, the absence of a
correlation between the FRAP values and phenolic content alludes to an alternative source
of antioxidant activity. According to previous studies, E. faecalis have released peptides
with reported antioxidant activity upon the hydrolysis of milk proteins during
fermentation (Gútiez et al., 2014, 2013). Thus, non-phenolic linked antioxidant activity
observed for the isolates may be attributed to the liberation of antioxidant peptides from
the milk proteins during growth. This argument is strengthened by the findings of Sai-Ut
et al. who observed that gelatinolytic enzyme producing bacteria generated hydrolysates
with antioxidant activity, while Gútiez et al. established that the gelE gene encoding
gelatinase is responsible for caseinolytic activity observed in E. faecalis fermented milk
(Gútiez et al., 2014; Sai-Ut et al., 2013). Based on these findings, it is likely that
gelatinase producing E. faecalis isolates possess great potential to generate antioxidant
peptides upon casein hydrolysis. Thus, it is possible that both phenolic compounds and
antioxidant peptides contributed to the antioxidant activity observed among the E.
faecalis milk fermentates in this study. Upon analysis of the three assays utilised to
determine antioxidant potential, the E. faecalis DPC5154 milk fermentate demonstrated
the highest level of antioxidant activity (739.06 µg GAE/ml, 271.27 TEAA (µM) and
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272.75 TEAA (µM) determined by the TPC, DPPH and FRAP assays, respectively). This
alludes to the potential use of DPC5154 and other E. faecalis species in milk
fermentations to generate compounds displaying antioxidant activity. Further studies are
required to establish the physiological effects of liberated compounds in vivo

Hypertension is recognised as a serious yet controllable risk factor for cardiovascular
disease. One of the most important intermediary factors for controlling hypertension is
the action of ACE. Inhibition of ACE is considered a useful therapeutic approach in the
treatment of high blood pressure as it prevents the conversion of the inactive angiotensinI into a potent vasoconstrictor, angiotensin-II (Ryan et al., 2011). ACEI peptides derived
from milk fermented with E. faecalis have been reported by several authors (Gútiez et al.,
2014, 2013; Muguerza et al., 2006; Quirós et al., 2007; Regazzo et al., 2010). ACEI
activity was also observed across all milk samples fermented with proteolytic E. faecalis
isolates used in this study, where only E. faecalis TK01 demonstrated inhibitory activity
(89.18%) below 90% (Fig. 4.4). Therefore, because the level of ACEI activity was
considerably high, the products of fermentation could prove beneficial for complimentary
diet-related treatment of hypertension. Given the vastly reported evidence documenting
the liberation of ACEI peptides by hydrolysis of milk proteins during fermentation with
enterococci, it is likely that inhibitory activity observed in this study is due to the presence
of bioactive peptides in the milk fermentates. Further studies are in progress to elucidate
the compounds conferring ACEI activity.

Although liberation of ACEI peptides from milk proteins by enterococci are extensively
studied, α-glucosidase inhibitors derived from food fermentation by LAB are less
reported, particularly in the case of enterococci. α-Glucosidase inhibitory compounds
play a beneficial role in anti-diabetic activity as they retard the rapid uptake of glucose
postprandial, thereby preventing the onset of hyperglycaemia. With concerns over the
expense of anti-diabetic drugs and associated gastrointestinal side effects, non-toxic food
derived α-glucosidase inhibitors are becoming of increasing interest (Wang et al., 2016).
Apostolidis et al. demonstrated an increase in α-glucosidase inhibitory activity of milk
and soymilk fermented with Lactobacillus bulgaricus and Lactobacillus acidophilus,
while in 2013, Mukherjee and Ganguli developed a food snack that showed increased αglucosidase activity after fermentation with Lactococcus lactis. Similarly, in a more
recent study, Ayyash et al. showed that milk fermented with Lactobacillus spp. exhibited
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α-glucosidase activity (Apostolidis, Kwon, Ghaedian, et al., 2007; Ayyash et al., 2018;
Mukherjee & Ganguli, 2013). Coinciding with the results obtained for antioxidant and
ACEI activity, milk fermented with E. faecalis DPC5154 also demonstrated the highest
level of α-glucosidase inhibitory activity (Fig. 4.5). Interestingly, the total phenolic
content of the E. faecalis milk fermentates was positively correlated with α-glucosidase
inhibitory activity (P < 0.05, Table 4.2). Thus, with the previously reported knowledge
that phenolic compounds contribute to inhibition of α-glucosidase (Kwon et al., 2006),
inhibitory activity observed in the E. faecalis milk fermentates may also be attributed to
the formation/degradation of phenolic compounds during fermentation. Considering that
α-glucosidase catalyses the final step of glucose absorption during carbohydrate
digestion, E. faecalis fermented milk products displaying α-glucosidase inhibitory
activity may have positive benefits in the management of type 2 diabetes by slowing down
the rapid uptake of glucose and subsequently suppressing postprandial hyperglycaemia.
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CONCLUSION
The aim of this study was to provide in vitro evidence of antioxidant, antihypertensive
and anti-diabetic activity of E. faecalis fermented milks. Several studies have
demonstrated the in vitro and in vivo bioactivity of fermented milks, which has mostly
been attributed to milk peptides. Although a great deal of research related to bioactive
compounds in milk has been carried out, there is a need to find and evaluate new LAB
that possess the ability to generate these compounds, as well as possessing good
technological properties for the production of fermented dairy products. Although some
enterococci are viewed as opportunistic pathogens, they are commonly isolated from
foods and have been featured in the dairy industry for decades as starter, adjunct or
probiotic cultures. Moreover, isolates of food origin tend to lack pathogenic traits and
therefore a balanced evaluation of both the beneficial and undesirable traits may enable
the selection and subsequent utilization of certain enterococcal strains in foods. The milk
fermentate generated with E. faecalis DPC5154 demonstrated the highest level of
antioxidant activity based on total phenolic content, DPPH radical scavenging activity
and ferric reducing antioxidant power, and the greatest level of α-glucosidase and ACEI
activity. Although the bioactivity of the milk fermentates was assessed in vitro, this work
provides a good foundation for analysing the bioactivity of the E. faecalis fermented
milks in vivo and raises the possibility of using E. faecalis DPC5154 as a starter or adjunct
culture to obtain multifunctional food products with antioxidant, antihypertensive and
anti-diabetic activity. These bioactive compounds may be further developed and
incorporated as food supplements and/or functional foods. This would require in vivo
studies and subsequent clinical trials to test the efficacy of the fermented milk product(s),
as well as careful consideration for the regulatory legislation surrounding the
development of functional dairy foods. Nevertheless, this strategy could prove useful as
an effective complimentary approach to improve health, alleviate concerns over the use
of synthetic inhibitors and antioxidants, reduce the increasing health-care costs for the
expanding global population and offers new market opportunities.
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ABSTRACT
Milk proteins are an abundant source of latent bioactive peptides which display a wide
range of physiological health benefits such as antihypertensive, antioxidant,
hypoglycaemic, immunomodulatory and hypocholesterolaemic effects. Fermentation
with lactic acid bacteria (LAB) has proved a useful strategy in the liberation of potential
bioactive peptides from milk. Enterococcus faecalis DPC5154, a proteolytic strain
isolated from cheese, was previously shown to generate a bovine skim milk (BSM)
fermentate with high Angiotensin Converting Enzyme Inhibitory (ACEI) activity, in
addition to having antioxidant and α-Glucosidase Inhibitory (α-GI) activity. The aim of
this study was to identify multifunctional bioactive peptides in the DPC5154 fermentate
responsible for the previously observed bioactivities. Fractionation of the crude DPC5154
fermentate by membrane filtration and a series of Reversed-Phase High Performance
Liquid Chromatography (RP-HPLC) steps resulted in the generation of two fractions
displaying high ACEI activity. The active fractions were subjected to Electrospray
Ionisation-Tandem Mass Spectrometry (ESI-MS/MS) and potential bioactive peptide(s).
were identified via the Proteome Discoverer 2.2 software using the Bos taurus database.
A total of three peptides were identified, IPPLTQTPVVVPP, corresponding to β-casein
f(74-86), VLPVPQK, corresponding to β-casein f(170-176), and AVPYPQR,
corresponding to BSM β-casein f(177-183). These peptides were chemically synthesized
for assessment of bioactivity in vitro. All three peptides displayed ACEI, antioxidant and
α-GI activity. This is the first report on the multifunctional bioactivities of these three
peptide sequences and also for the generation of BSM derived bioactive peptides by
fermentation with DPC5154. Thus, we have identified three multifunctional peptides
conferring ACEI, antioxidant and α-GI activity which may prove useful as ingredients in
functional foods or as nutraceuticals for the alleviation and treatment of hypertension,
oxidative stress and hyperglycaemia.
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INTRODUCTION
Enterococci are ubiquitous lactic acid bacteria (LAB) that form an integral part of
environmental, food and clinical microbiology. E. faecalis is the most prominent species
of the Enterococcus genus and is frequently studied in scientific literature due to its
diverse nature. On one hand, E. faecalis is viewed as an opportunistic pathogen capable
of causing nosocomial infections, particularly in immunocompromised patients, due to
the possession of virulence factors and an increasing incidence of antibiotic resistance
(Abriouel et al., 2008; Bhardwaj et al., 2008). However, these traits are strain dependant
and appear to be more common among isolates of clinical origin than those isolated from
food, thereby suggesting that food isolates have a lower potential for pathogenicity (Eaton
& Gasson, 2001; Franz et al., 2001; Lepage et al., 2006). Moreover, although some strains
may be considered as opportunistic pathogens, it is doubtful they would cause disease in
healthy individuals and the morbidity of healthy humans resulting from enterococcal
infections appears to be very low (EFSA, 2012; Franz et al., 2003). On the contrary, some
E. faecalis strains possess notable beneficial traits of biotechnological importance and
have a long history of safe use in foods. They produce bacteriocins effective against
foodborne pathogens such as Listeria and Clostridium spp., while probiotic
characteristics have also been reported (Achemchem et al., 2006; Franz et al., 2011).
Furthermore, they have successfully been utilised as starter and/or adjunct cultures,
particularly in the dairy industry, whereby they have improved the organoleptic properties
of food. This is due to the possession of biochemical traits such as lipolysis and
proteolysis (Foulquié Moreno et al., 2006; Giraffa, 2003). Enterococci displaying
proteolytic activities have received considerable attention in scientific literature in recent
years. Not only does proteolysis contribute to the texture and flavour of food, proteolytic
E. faecalis isolates have also demonstrated the ability to generate bioactive peptides
during the fermentation of proteinaceous foodstuffs (Gútiez et al., 2013; Miguel et al.,
2006; Quirós et al., 2007).

Dietary proteins are a rich source of bioactive peptides which display a wide range of
physiological functions including antioxidative, antihypertensive, immunomodulatory,
antimicrobial and hypocholesterolaemic effects (Bouglé & Bouhallab, 2017; Park &
Nam, 2015). Several studies have been conducted concerning the liberation, identification
and characterisation of bioactive peptides in a wide variety of foods (Bouglé & Bouhallab,
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2017; Ryan et al., 2011; Walther & Sieber, 2011). However, milk proteins are currently
considered a vital source of a range of bioactive peptides and subsequently, much of the
effort to date regarding the identification of bioactive peptides has concentrated on
hydrolysates of milk and/or milk products (Graham et al., 2019a; Gútiez et al., 2014; Park
& Nam, 2015; Pihlanto, 2006; Tonolo et al., 2018).

Bioactive peptides are often encrypted within the parent protein molecule and require
release to unlock their true potential. This can be achieved using digestive enzymes or by
hydrolysis with specific proteolytic enzymes. Furthermore, food fermentation with
proteolytic microorganisms provides an alternative approach for the derivatisation of
peptides with biological activity (Ryan et al., 2011; Walther & Sieber, 2011). This is
particularly evident in milk fermentations with LAB where the proteins in milk are the
key source of essential and growth stimulating amino acids. Bioactive peptides can, thus,
be generated by the proteolytic activities of starter and non-starter LAB in fermented dairy
products. Although bacteria of the genera Lactobacillus and Bifidobacterium are
commonly used for this purpose, there is merit in exploring the benefits of other genera
of LAB. Enterococci are leading microbes in fermentation processes of traditional foods,
are commonly isolated from dairy products and show higher proteolytic activities
compared to other LAB (Bhardwaj et al., 2008; Monika et al., 2017). Therefore, they are
useful candidates for the liberation of bioactive peptides from food, particularly from milk
and other dairy products.

Bioactive peptides derived from milk proteins are currently of great scientific interest due
to their beneficial health properties. The group of bioactive peptides most frequently
studied are those which display Angiotensin Converting Enzyme Inhibitory (ACEI)
activity and coincides with the high prevalence of hypertension worldwide (Gútiez et al.,
2013; Hayes et al., 2007; Martínez-Maqueda et al., 2012; Phelan et al., 2014).
Hypertension is a chronic degenerative disease characterised by high blood pressure. The
Renin-Angiotensin System (RAS) is a signalling pathway that is partially responsible for
regulating blood pressure. Angiotensin Converting Enzyme (ACE) catalyses the cleavage
of the biologically inactive decapeptide, angiotensin I, to its potent vasoconstrictor,
angiotensin II (octapeptide), a process which is considered one of the main components
of the RAS (Ryan et al., 2011). Furthermore, ACE degrades bradykinin, a hormone which
exerts important vasodilation activity. Therefore, peptides which exert antihypertensive
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effects by inhibiting the activity of ACE may play a crucial role in minimising the risk
factors and alleviating the symptoms of hypertension. Although food derived ACE
inhibitors tend to have lower ACEI activity in vitro compared to ACEI drugs like
captopril, they do not display harmful side effects such as dry cough and angioedema
which are often associated with chemically synthesised drugs (Riordan, 2003).
Subsequently, the search for natural food derived compounds displaying ACEI and
antihypertensive activity has intensified. ACEI peptides are utilised in several
commercialised nutraceutical products such as Calpis®, Ameal S® (Calpis Co., Tokyo,
Japan) and Evolus® (Valio Ltd., Helsinki, Finland), all of which contain the wellestablished antihypertensive peptide sequences Val-Pro-Pro and Ile-Pro-Pro (Korhonen,
2009). Therefore, ACEI peptides derived from milk fermented by proteolytic E. faecalis
strains may prove useful as an effective therapeutic approach in the treatment of
hypertension.

Although extensively studied, bioactive peptides are not limited to those which just
provide ACEI effects. Antioxidant peptides are increasingly becoming the focus of
scientific interest due to their positive impact on human oxidative stress regulation against
lipid and protein oxidation. Oxidative stress is caused by an imbalance between the
occurrence of Reactive Oxygen Species (ROS) and the organism’s ability to counteract
their action using endogenous antioxidants (Pisoschi & Pop, 2015). This can lead to cell
damage which initiates body disfunctions like ageing, atherosclerosis, arthritis, diabetes
and cancer (Iwaniak et al., 2018). When the endogenous antioxidant repair system fails
to effectively counteract oxidative stress, exogenous antioxidants can be consumed to
complement the activity of endogenous antioxidants and improve the organism’s capacity
to contain the oxidative stress. However, there are concerns regarding the impact of
synthetic antioxidants on human health which has subsequently resulted in the search for
effective, non-toxic, natural antioxidants. Food derived antioxidant peptides appear to be
a suitable alternative and have been identified in milk, meat, fish and plant hydrolysates
(Power et al., 2013).
α-Glucosidase Inhibitory (α-GI) peptides appear to be less studied, particularly those
derived from the hydrolysis of milk proteins, but are also an important area of
investigation. Intestinal α-glucosidases are enzymes which play a role in the metabolism
of dietary carbohydrates and the subsequent liberation of monosaccharides, such as
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glucose, which get absorbed into the blood, thereby increasing blood glucose levels
(Iwaniak et al., 2018). Rapid uptake of glucose is likely to result in elevated blood glucose
levels followed by the onset of hyperglycaemia. α-GI agents are considered useful in the
management of type 2 diabetes as they can delay carbohydrate hydrolysis, thereby
extending its digestion time, resulting in a reduced level of glucose absorption and
subsequent postprandial levels of glucose and insulin (Patil et al., 2015). Similar to ACE
inhibitors and antioxidant compounds, synthetic α-glucosidase inhibitors exist but their
associated expense and adverse gastrointestinal side effects such as stomach aches,
flatulence and diarrhoea have greatly limited their use (Wang et al., 2016). This has
compelled researchers to search for novel, naturally derived α-GI agents. Therefore, food
derived peptides displaying α-GI activity may be considered promising agents in the
treatment of type 2 diabetes. Moreover, one of the complications of diabetes is
hypertension. These are interrelated metabolic disorders that strongly predispose an
individual to atherosclerotic Cardiovascular Disease (CVD) (Petrie et al., 2018).
Similarly, oxidative stress is also considered a contributing factor in the development of
hypertension and associated implications in CVD (Berry et al., 2001). Therefore,
bioactive peptides, such as those derived from enterococci fermented milk, that display
multiple biological functions pertaining to ACEI, antioxidant and α-GI activity, provide
a promising means of neutralizing the potentially detrimental effect of oxidative
compounds and managing hypertension, type 2 diabetes and related CVD.

Much of the research on food-derived bioactive peptides to date has reported on peptides
with one specific biological function, while peptides with multiple functions are reported
less often (Daliri et al., 2017). Single peptides with more than one biological function are
more desirable than their mono-functional counterparts as they would simultaneously
elicit multiple health benefits. The aim of this study was to identify the bioactive peptides
responsible for the high ACEI, antioxidant and α-GI activity previously observed in the
hydrolysate of BSM fermented with E. faecalis DPC5154 (Graham et al., 2019a), a
proteolytic strain isolated from cheese.
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MATERIALS AND METHODS
Substrates and chemicals
Hippuryl-L-histidyl-L-leucine (HHL), angiotensin converting enzyme (ACE; from rabbit
lung), captopril, quinoline, Benzene Sulfonyl Chloride (BSC), 2,2-diphenyl-1picrylhydrazyl (DPPH), trolox, sodium acetate trihydrate, glacial acetic acid, 2,4,6-tris
(2-pyridyl)-s-triazine (TPTZ), ferric chloride hexahydrate, α-glucosidase (from
Saccharomyces cerevisiae), p-nitrophenyl-α-ᴅ-glucopyranoside and acarbose were
obtained from Sigma-Aldrich, (Vale Road, Arklow, Wicklow, Ireland). Bovine Skim
Milk (BSM) powder was obtained from Glanbia (Ballyragget, Co. Kilkenny, Ireland).

Microorganisms and culture conditions
Enterococcus faecalis DPC5154, previously shown to generate milk fermentates with
high ACEI, antioxidant and α-GI activity (Graham et al., 2019a), was obtained from the
Dairy Products Research Centre (DPC) culture collection (Teagasc, Fermoy, Co. Cork,
Ireland) and confirmed as E. faecalis by 16S rRNA sequencing as previously described
(Graham et al., 2017). This strain was routinely grown in Brain Heart Infusion (BHI)
broth or on BHI agar (LabM, Heywood, Lancashire, United Kingdom) at 37 °C for 24 h
for further use.

Preparation of the E. faecalis DPC5154 fermented milk
Overnight cultures of E. faecalis DPC5154 in BHI broth were prepared in triplicate from
isolated colonies on BHI agar and standardised to an optical density of 1.0 at 600 nm. 100
µl of the respective standardised overnight cultures in BHI broth were added to 9.9 ml of
BSM (10% (w/v)) and incubated at 37 °C for 20 h. The skim milk cultures were
vigorously stirred and centrifuged at 7085g for 10 min. The resulting supernatants were
filtered through 0.2 µm filters (Sarstedt, Nümbrecht, Germany) and combined before
being passed through a 3-kDa Amicon Ultra-15 centrifugal filter unit (Sigma) in a swing
bucket centrifuge at 4000g for 30 min.

RP-HPLC analysis of the 3-kDa E. faecalis DPC5154 bovine skim milk
fermentate
The <3-kDa permeate was fractionated by a series of Reversed-Phase High Performance
Liquid Chromatography (RP-HPLC) steps. Initially, 3800 µl of the E. faecalis <3-kDa
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permeate was applied to a semi-preparative Proteo Jupiter C12 RP-HPLC column (250 x
10 mm, 4µ, 90Å) running a 1-50% acetonitrile 0.1% Trifluoroacetic Acid (TFA) gradient
where buffer A was 0.1% TFA and buffer B was 90% acetonitrile 0.1% TFA. Eluent was
monitored at 214 nm and fractions were collected at 1-minute intervals at a flow rate of
2.5 ml/min. Acetonitrile was removed from HPLC fractions by rotary evaporation and
the fractions were resuspended in distilled water prior to analysis for ACEI activity.
Fractions displaying ≥ 60% ACEI activity (Table 5.1) were subjected to a second semipreparative RP-HPLC separation step to further separate the peptides running gradients
specific to each fraction as outlined in Table 5.1 on the RP-HPLC column described
above, except buffer B was 100% acetonitrile 0.1% TFA. Fractions were tested for ACEI
activity and active fractions (Table 5.2) were subjected to a final separation on an
analytical Proteo Jupiter C12 column (4.6 x 10 mm, 4µ, 90Å), running a gradient specific
to each fraction, as outlined in Table 5.2, where buffer B was 90% acetonitrile 0.1% TFA.
Eluent was monitored at 214 nm and fractions were collected at 1 min intervals at a flow
rate of 1 ml/min. The resulting fractions from the final RP-HPLC step were assessed for
ACEI activity and are outlined in Table 5.3.

Determination of angiotensin converting enzyme inhibitory (ACEI)
activity
ACEI activity was the bioassay utilised to identify active RP-HPLC fractions. This was
based on the fact that, in previous work, the DPC5154 fermentate showed higher ACEI
activity compared to antioxidant and α-GI effects, while E. faecalis has also been reported
to generate ACEI peptides during milk fermentation (Quirós et al., 2007). ACEI activity
was measured as described previously (Li et al., 2005) with minor modifications. 20 µl
ACE inhibitor (RP-HPLC fraction or 0.1M captopril (positive control)) and 50 µl of 5
mM HHL in 100 mM sodium borate buffer (pH 8.3) containing 300 mM NaCl were
preincubated at 37 °C for 10 min. 20 µl of borate buffer was used as a negative control to
allow the enzymatic reaction to occur. The reaction was initiated by the addition of 20 µl
of ACE solution (100 mU/ml) and the mixture was incubated at 37 °C for 1.5 h. The
reaction was stopped by the addition of 100 µl of 1 M HCl. 300 mM sodium borate buffer
was added to the reaction mixture to a volume of 500 µl. To measure the hippuric acid
released from HHL by ACE, 600 µl of quinoline was added to the reaction mixture in
darkness followed by immediate vortexing for 10 s. Subsequently, 200 µl of BSC was
added and the reaction mixture was vortexed for 20 s. The reaction mixtures were
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incubated at 30 °C for 1 h in a shaking water bath. 3700 µl of ethanol was then added to
the mixture followed by further incubation at 30 °C for 30 min. Following incubation, the
reaction blank (HCl added before ACE) was used to zero the spectrophotometer and
absorbance of samples was measured at 492 nm. All measurements were performed in
triplicate and the extent of ACE inhibition was calculated as follows:

ACE inhibitory activity (%) =

B−A
× 100
B

Where B is the absorbance of the control (buffer added instead of inhibitor) and A is the
absorbance in the presence of the inhibitor (fraction, peptide or captopril).

Identification of putative bioactive peptide(s)
Fractions displaying high ACEI activity were analysed for their peptide mass profile by
Matrix Assisted Laser Desorption/Ionisation-Time-of-Flight Mass Spectrometry
(MALDI-TOF-MS) in positive ion reflectron mode using an Axima TOF2 MALDI TOF
mass spectrometer (Shimadzu Biotech, Manchester, UK). Fractions with putative ACEI
activity were sent to Alta Biosciences (University of Birmingham, Redditch, UK) for
MS/MS analysis by Electrospray Ionisation (ESI) mass spectrometry to determine the
amino acid sequence of the peptides present in the samples. Peptide sequences in the
fractions were identified with the Proteome Discoverer 2.2 software (ThermoFisher
Scientific, MA, US) using the Bos taurus database (UniProt taxon ID 9913).

Synthesis of identified peptides
Peptides were synthesised using microwave-assisted solid phase peptide synthesis (MWSPPS) performed on a Liberty Blue microwave peptide synthesizer (CEM Corporation,
Mathews, North Carolina, USA). Peptides VLPVPQK and AVPYPQR were synthesized
on Fmoc-Lys-Wang resin, and Fmoc-Arg-Wang resins (Matrix Innovation, Quebec,
Canada), respectively and IPPLTQTPVVVPP was synthesised on H-Pro-2-ClTrt resin
(Novobiochem®, Darmstadt, Germany). Crude VLPVPQK and AVPYPQR were purified
using RP-HPLC on a semi preparative Jupiter Proteo (10 x 250 mm, 4µ, 90Å) column
(Phenomenex, Cheshire, UK) running a 5-30% acetonitrile 0.1% TFA gradient over 40
minutes and IPPLTQTPVVVPP was purified using a 15-45% gradient where buffer A is
Milli Q water containing 0.1% TFA and buffer B is 90% acetonitrile 0.1% TFA. Fractions
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containing the desired molecular mass were identified using matrix assisted laser
deionisation-time of flight-mass spectrometry (MALDI-TOF-MS) on an Axima TOF2
MALDI TOF mass spectrometer (Shimadzu Biotech, Manchester, UK) and were pooled
and lyophilized on a Genevac HT 4X lyophilizer (Genevac Ltd., Ipswich, UK). Peptides
were resuspended to desired concentration in molecular grade water prior to analysis for
bioactivity.

Determination of angiotensin converting enzyme inhibitory (ACEI)
activity
ACEI activity of the chemically synthesised peptides was determined as described above
for the RP-HPLC fractions, using 20 µl of peptide at various concentrations as the ACE
inhibitor.

Antioxidant Activity
1,1-diphenyl-2-picrylhydrazyl (DPPH) inhibition assay
The radical scavenging activity of the peptides was evaluated using the DPPH assay as
previously described (Brand-Williams et al., 1995) with slight adjustments. The DPPH
solution was prepared fresh on the day of analysis and was used at a concentration of 60
μM, dissolved in methanol. Aliquots of 250 µl of sample (peptide) were transferred to
test tubes with 3 ml of the 60 µM DPPH solution and homogenized by vortexing. 250 µl
methanol with 3 ml of the DPPH solution was used as a control. Samples were incubated
at room temperature for 1 h and absorbance was measured at 517 nm. Standard curves
were established using various concentrations of trolox in methanol. All measurements
were performed in triplicate and the radical scavenging activity of the peptides was
expressed as Trolox Equivalent Antioxidant Activity [TEAA (µM)].

Ferric Reducing Antioxidant Power (FRAP)
The ferric reducing antioxidant power of the synthesised peptides was assessed using the
FRAP assay as described previously (Benzie & Strain, 1996) with some modifications.
The FRAP reagent was prepared by mixing 300 mM acetate buffer, pH 3.6 (3.1 g sodium
acetate trihydrate (C2H3NaO2.3H2O), plus 16 ml glacial acetic acid (C2H4O2)), 10 mM
TPTZ (2,4,6-tris (2-pyridyl)-s-triazine) in 40 mM HCl, and 20 mM ferric chloride
hexahydrate (FeCl3.6H2O) in a 10:1:1 (v/v/v) ratio. The FRAP reagent was warmed at 37
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°C prior to use. 150 µl peptide at various concentrations was added to 2850 µl of FRAP
reagent and incubated at 37 °C in darkness for 30 min. A blank was prepared by adding
150 µl of deionised water to 2850 µl of FRAP reagent and readings were measured at 593
nm. Standard curves were established using trolox solutions ranging from 0–600 µM. The
ferric reducing antioxidant power (FRAP) of the synthesised peptides was expressed as
Trolox Equivalent Antioxidant Activity [TEAA (µM)].

α-Glucosidase inhibitory (α-GI) activity
Inhibition of α-glucosidase was assessed as previously described (Apostolidis, Kwon, &
Shetty, 2007). Briefly, 50 µl of peptide was mixed with 100 µl glucosidase solution (1.0
U/ml) in 0.1 M phosphate buffer (pH 6.9) and incubated at 25 °C for 10 min. After preincubation, 50 µl of 5 mM p-nitrophenyl-α-ᴅ-glucopyranoside solution dissolved in
phosphate buffer was simultaneously added to each sample and incubated at 25 °C for 5
min. Absorbance readings were measured before and after the 5 min incubation period at
405 nm using a microplate reader (Spectramax340, Molecular Device Co., Virginia,
USA). The absorbance values of the samples were compared to a control solution which
had 50 µl of buffer solution in place of the peptide. The α-GI activity was expressed as
% inhibition and was calculated as follows:
∆𝐴𝐶𝑜𝑛𝑡𝑟𝑜𝑙
− ∆𝐴𝑃𝑒𝑝𝑡𝑖𝑑𝑒
405
405
% α-Glucosidase inhibition = (
) × 100
∆𝐴𝐶𝑜𝑛𝑡𝑟𝑜𝑙
405

Statistical Analysis
All experiments were performed at least in triplicate and the mean and standard deviation
of the replicates were calculated using Microsoft Excel. IC50 values, where applicable,
were calculated using GraphPad Prism V. 8.1.1 (GraphPad Software, San Diego,
California USA).
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RESULTS
Production of a bovine skim milk hydrolysate with ACEI, antioxidant
and α-GI activity
E. faecalis DPC5154 was chosen for the potential release of bioactive peptides from BSM
due to its inherent proteolytic characteristics and previously observed ability to generate
a milk fermentate with high ACEI activity, antioxidant and α-GI activity. It was
subsequently used in this study for the production of BSM derived bioactive peptides
which were assessed for the aforementioned activities.

Isolation and detection of bioactive peptides
The BSM fermentate produced by DPC5154 was filtered through a size exclusion 3-kDa
Amicon ultra 15 centrifugal filter unit to obtain permeate containing peptides of ≤3-kDa.
The workflow for the isolation and detection of peptides in the DPC5154 fermentate is
described in figure 5.1. The peptide masses present in the ≤3-kDa permeate were detected
by MALDI-TOF-MS (Fig. 5.2). The permeate was fractionated by RP-HPLC and the
resulting chromatogram showed that most peptides eluted between 10 and 35 minutes
(Fig. 5.3). A total of 52 fractions were obtained and were initially assayed for ACEI
activity. Fractions displaying ≥60% ACE inhibition were subjected to further analysis
(Table 5.1). From the 8 fractions exhibiting ≥60% inhibition, Fraction 37 and Fraction 39
displayed the highest level of ACE inhibition (89.47 and 79.61%, respectively). The
peptide masses within these fractions were detected by MALDI-TOF-MS and peptides in
the fractions were further separated by RP-HPLC (Fig. 5.4). Sub-fractions in the area of
interest on the HPLC chromatogram were assayed for ACEI activity (Table 5.2) and,
again, those displaying the highest level of ACE inhibition were analysed by MALDITOF-MS and subject to a final RP-HPLC separation step to achieve maximal separation
of peptides (Fig. 5.5). Fractions of interest were tested for ACEI activity and those which
demonstrated the ability to inhibit ACE (Table 5.3) were selected for peptide sequencing
and identification.
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Figure 5.1. Workflow for the separation, purification, identification and synthesis of bioactive peptides in bovine skim milk fermented with Enterococcus
faecalis DPC5154.
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Figure 5.2. MALDI-TOF mass spectrum of the supernatant of E. faecalis DPC5154 grown in
bovine skim milk for 20 h and passed through a 3-kDa cut off membrane. The mass-to-charge
ratio of the peptides and relative intensity are represented by the X and Y axes, respectively.
Individual peaks and associated values represent the mass of each peptide detected.
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Table 5.1. Angiotensin converting enzyme inhibitory (ACEI) activity of fractions* obtained by
the RP-HPLC separation of the <3-kDa permeate from E. faecalis DPC5154 fermented bovine
skim milk.
Peptide Fraction

% ACE Inhibition

% Acetonitrile

25
32

64.42
75.66

5-15
12-27

33
34
35
37

73.68
64.47
70.39
89.47

15-35
15-35
15-35
20-40

38
39

60.00
79.61

20-40
20-40

Fractions which displayed ≥ 60% ACEI activity.
Note: Fractions 37 & 39 gave highest ACEI activity and were selected for further analysis.
*
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Figure 5.4. MALDI-TOF mass spectrum (A) and peptide profile by RP-HPLC (B) of Fraction 37
(i) and Fraction 39 (ii) which displayed the highest level of angiotensin converting enzyme
inhibitory (ACEI) activity following initial RP-HPLC separation.
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Table 5.2. Analysis of angiotensin converting enzyme inhibitory (ACEI) activity and further
separation of fraction 37 & 39 obtained by RP-HPLC of the E. faecalis DPC5154 fermentate as
outlined in Table 5.1.
Initial fraction
37

Sub-fraction
33

% ACE Inhibition
0

% Acetonitrile

37

34

0

37

35

5

37

36

51.67

37

37

100.00

25-27

37

38

90.00

25-27

37

39

42.50

37

40

0

37

42

0

37

43

5.00

39

41

0

39

42

9.66

39

43

53.41

39

44

22.73

39

45

5.11

39

46

7.39

39

47

10.80

39

48

7.39

39

49

12.50

39

50

8.52

39

51

22.73

25-30

Note: Fraction 37 sub-fractions 33-43 and Fraction 39 sub-fractions 41-51 were tested for ACEI activity
(see Fig. 5.4 (B)). The subsequent 3 highlighted fractions in this table gave the highest ACEI activity and
were subject to further separation and analysis. All other fractions were not analysed further.
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Figure 5.5. MALDI-TOF mass spectrum (A) and peptide profile by RP-HPLC (B) of Fraction 37
sub-fraction 37 (i), Fraction 37 sub-fraction 38 (ii) and Fraction 39 sub-fraction 43 (iii).
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Table 5.3. Analysis of angiotensin converting enzyme (ACEI) activity of the sub-sub fractions of
Fraction 37 sub-fractions 37 & 38 and Fraction 39 sub-fraction 43 obtained by RP-HPLC
separation as outlined in Table 5.2.
Initial fraction

Sub-fraction

Sub-sub-fraction

% ACE Inhibition

Protein Conc. (µg/ml)

37

37

15

0.00

n/a

37

37

16

0.00

n/a

37

37

17

0.00

n/a

37

37

18

0.00

n/a

37

37

19

0.00

n/a

37

20a

16.10

50

37

37

21a

41.53

70

37

37

22

4.88

n/a

37

37

23

0.00

n/a

37

37

24

0.00

n/a

37

37

25

0.81

n/a

37

38

15

0.00

n/a

37

38

16

0.00

n/a

37

38

17

0.00

n/a

37

38

18

0.00

n/a

38

19b

30.51

60

37

38

20b

78.81

50

37

38

21

0.00

n/a

37

38

22

0.00

n/a

37

38

23

0.00

n/a

39

43

19

0.00

n/a

39

43

20

0.81

n/a

39

43

21

6.50

n/a

39

43

22

1.63

n/a

39

43

23

0.00

n/a

39

43

24

0.00

n/a

39

43

25

0.00

n/a

39

43

26

1.52

n/a

39

43

27

0.00

n/a

39

43

28

0.00

n/a

37

37

a

Fractions combined for sequencing.
Fractions combined for sequencing.
n/a: Protein content of fraction not measured.
b

Protein identification and sequencing
The fractions displaying the most potent ACEI activity were combined, as outlined in
Table 5.3, and were analysed by HPLC ESI MS/MS by Alta Biosciences. A total of three
peptides were identified through the Proteome Discoverer 2.2 software using the Bos
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taurus database (UniProt taxon ID 9913). The amino acid sequences, observed masses
and previously reported activities are shown in Table 5.4.

Synthesis of peptides and assessment of bioactivity
To determine that the identified peptides in the fractions were responsible for the
previously observed ACEI, antioxidant and α-GI activity observed in the DPC5154
fermentate, each of the three peptides, IPPLTQTPVVVPP, VLPVPQK and AVPYPQR,
were chemically synthesised. Following synthesis, purified peptides were assayed for
ACEI, antioxidant and α-GI activity.
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Table 5.4. IC50 values for angiotensin converting enzyme (ACEI) activity of the chemically synthesised peptides identified in the RP-HPLC fractions from the
Enterococcus faecalis DPC5154 bovine skim milk fermentate and sequence homology with previously described bioactive peptides.
Chemically synthesised
peptide

Casein fragment

Observed
mass

IC50 (µM)*
value assayed

Peptide/propeptide
previously reported

IC50 (µM)
reported

Bioactivity previously
reported

Reference

IPPLTQTPVVVPP

β-CN f(74-86)

1358.2

523.80

NIPPLTQTPVVVPPFIQ
NIPPLTQTPV
TPVVVPPF
SLPQNIPPLTQTPVVVPP
LTQTPVVVPPF

450
173.3
NR
NR
> 1500

ACEI
ACEI
ACEI & antihypertensive
ACEI & antihypertensive
ACEI

(Hayes et al., 2007)
(Gobbetti et al., 2000)
(Ahtesh, 2016)
(Ahtesh, 2016)
(Quirós et al., 2007)

VLPVPQK

β-CN f(170-176)

780.05

776.90

VLPVPQK
KVLPVP
KVLPVPQ
KVLPVPQ
KVLPVPQK
SKVLPVPQ
SQSKVLPVPQ

N/A
5
>1000
1000
N/A
39
92

Antioxidant
ACEI
ACEI
Antihypertensive
Antioxidant
ACEI
ACEI

(Mada et al., 2017; Rival et al., 2001)
(Gobbetti et al., 2000)
(Gobbetti et al., 2000)
(Maeno et al., 1996)
(Rival et al., 2001)
(Yamamoto et al., 1994)
(Hayes et al., 2007)

AVPYPQR

β-CN f(177-183)

829.96

387.60

AVPYPQR
AVPYPQR
AVPYPQR
AVPYPQR
AVPYPQ
LAVPYPQ

15.6
274
N/A
N/A
> 1000
> 1000

ACEI
ACEI
Antioxidant
Antioxidant
ACEI
ACEI

(Karaki et al., 1990)
(Pihlanto-Leppälä et al., 1998)
(Tonolo et al., 2018)
(Rival et al., 2001)
(Yamamoto et al., 1994)
(Yamamoto et al., 1994)

*

IC50 (µM): Peptide concentration necessary to inhibit 50% ACE activity as reported in this study.
CN: Casein; NR: Not reported in study; N/A: Not applicable.
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Angiotensin converting enzyme inhibitory (ACEI) activity
All three peptides displayed ACEI activity (Table 5.4, Fig. 5.6). Of the three peptides,
AVPYPQR was considered the most potent ACE inhibitor (IC50 = 387.6 µM). The ACEI
peptide IPPLTQTPVVVPP demonstrated an IC50 value of 523.8 µM, while VLPVPQK
was considered the least potent of the three synthesised peptides (IC50 = 776.9 µM).

ACE inhibition (%)

100
80
60
40
20
0
-20

1.0

2.0

3.0

4.0

5.0

Logconcentration
concentration(µM)
(M )
Log

AVPYPQR

IPPLTQTPVVVPP

VLPVPQK

Figure 5.6. Angiotensin converting enzyme inhibitory (ACEI) activity of the chemically
synthesised β-casein peptides derived from the fermentation of bovine skim milk with
Enterococcus faecalis DPC5154. Error bars represent the standard deviation of three independent
experiments.

Antioxidant activity
DPPH radical scavenging activity
Antioxidant activity of the peptides was assessed by the 2,2- diphenyl-1-picrylhydrazyl
(DPPH) assay, which measures the ability of a test compound to scavenge the DPPH
radical. Concentrations ranging from 0.001–100 mM of peptide were used to assess their
antioxidant potential. DPPH radical scavenging activities were generally low for all three
peptides (Fig. 5.7). At a concentration of 100 mM peptide, AVPYPQR demonstrated the
greatest level of Trolox Equivalent Antioxidant Activity (TEAA) based on the DPPH
method (47.26 µM TEAA). As concentration decreased, so too did the DPPH radical
scavenging activity, which appeared to plateau at ≈20 µM TEAA for peptide
concentrations of 1 mM and lower. A similar phenomenon was observed for VLPVPQK
where the highest antioxidant activity based on DPPH radical scavenging activity was
observed at a peptide concentration of 100 mM (42.01 µM TEAA), while activity
appeared to plateau at ≈20 µM TEAA at peptide concentrations of 1 mM and lower. Due
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to limitations in the quantity of peptide available for analysis, the maximum concentration
tested for IPPLTQTPVVVPP was 10 mM. At this concentration, IPPLTQTPVVVPP
demonstrated the highest TEAA based on DPPH radical scavenging activity (29.97 µM
TEAA) compared to AVPYPQR and VLPVPQK at the same concentration (26.19 and
26.67 µM TEAA, respectively). IC50 values for DPPH radical scavenging activity of the
peptides could not be calculated as inhibition of DPPH did not exceed 50% at the highest
tested peptide concentration (data not shown).
60.00

TEAA (µM)

50.00
40.00
30.00
20.00
10.00

AVPYPQR

IPPLTQTPVVVPP

0.001 mM

0.01 mM

0.1 mM

1 mM

10 mM

100 mM

0.001 mM

0.01 mM

0.1 mM

1 mM

10 mM

0.001 mM

0.01 mM

0.1 mM

1 mM

10 mM

100 mM

0.00

VLPVPQK

Figure 5.7. Antioxidant activity of the chemically synthesised β-casein peptides derived from the
fermentation of bovine skim milk with Enterococcus faecalis DPC5154. Antioxidant activity was
determined by DPPH radical scavenging activity, measured as Trolox Equivalent Antioxidant
Activity [TEAA (µM)]. Error bars represent the standard deviation of three independent
experiments.

Ferric Reducing Antioxidant Power (FRAP)
The antioxidant activity of each peptide was also assessed based on ferric reducing
antioxidant power (FRAP, Fig. 5.8). The FRAP assay is based on the ability of a
compound to reduce Fe3+ (ferric ion) to Fe2+ (ferrous ion), thus indicating the antioxidant
potential of that compound. Peptides were assessed for FRAP activity in the concentration
range 0.01-10 mM. Due to limitations in peptide quantity, the antioxidant activity of
peptides based on FRAP was not tested at concentrations above 10 mM. Only AVPYPQR
demonstrated the ability to reduce Fe3+ to Fe2+, where activity was highest at a
concentration of 10 mM (96.31 µM TEAA) and decreased at concentrations of 5 mM and
1 mM (54.17 and 13.45 µM TEAA, respectively). Minimal antioxidant activity based on
FRAP was observed at lower concentrations of peptide. IPPLTQTPVVVPP and
VLPVPQK did not display any antioxidant activity based on the FRAP assay where
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activity was ≈1 µM TEAA or less at peptide concentrations in the range 0.01-10 mM
(data not shown).

FRAP TEAA (µM)

100.00
80.00
60.00
40.00
20.00
0.00
10 mM

5 mM

1 mM

0.1 mM

0.01 mM

AVPYPQR concentration (mM)

Figure 5.8. Antioxidant activity of the chemically synthesised β-casein peptide AVPYPQR
derived from the fermentation of bovine skim milk with Enterococcus faecalis DPC5154.
Antioxidant activity was determined by Ferric Reducing Antioxidant Power (FRAP), measured
as Trolox Equivalent Antioxidant Activity [TEAA (µM)]. Error bars represent the standard
deviation of three independent experiments.

α-Glucosidase inhibitory activity
All three peptides displayed α-GI activity at the tested concentrations (1-100 mM) (Fig.
5.9). AVPYPQR was noted as the most potent α-GI peptide with an IC50 value of 60.77
mM. However, inhibitory activity was similar among all peptides with IC 50 values of
61.78 and 62.32 mM obtained for VLPVPQK and IPPLTQTPVVVPP, respectively.

(%)
inhibition (%)
α-Glucosidase
-Glucosidase Inhibition

100
80

AVPYPQR. IC50 = 60.77 mM
IPPLTQTPVVVPP. IC50 = 62.32 mM
VLPVPQK. IC50 = 61.78 mM

60
40
20
0
0.5
-20

1.0

1.5

2.0

Log concentration (mM)

Figure 5.9. α-Glucosidase inhibitory (α-GI) activity of the chemically synthesised β-casein
peptides derived from the fermentation of bovine skim milk with Enterococcus faecalis
DPC5154. Error bars represent the standard deviation of three independent experiments.
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DISCUSSION
The liberation of bioactive peptides from milk proteins by the proteolytic activities of
LAB such as Lactobacillus, Lactococcus and Bifidobacterium have been reported, but
few consider the use of Enterococcus faecalis strains in milk fermentations for the
generation of these peptides. Many E. faecalis isolates are in possession of beneficial
biochemical properties of technological interest, such as lipolysis and proteolysis, which
contribute secondary benefits during fermentation such as an improvement in the
rheological and organoleptic properties of the fermented product, while many produce
enterocins and have demonstrated probiotic characteristics (Bhardwaj et al., 2008; Franz
et al., 2011; Hanchi et al., 2018).

The aim of this study was to isolate, identify and characterise potential bioactive peptides
responsible for the high level of ACEI, antioxidant and α-GI activity in the hydrolysate
of BSM fermented with Enterococcus faecalis DPC5154 (Graham et al., 2019a), a
proteolytic strain isolated from cheese. Following a series of RP-HPLC purification steps
of the DPC5154 fermentate and assessment of subsequent fractions for ACEI activity
(Fig. 5.1-5.5, Table 5.1-5.3), a total of three BSM derived β-casein peptides were
identified (Table 5.4). These peptides were subsequently chemically synthesised and
tested for ACEI activity, antioxidant effects and α-GI activity. This is the first report on
the use of DPC5154 for the generation of bioactive peptides from BSM.

ACEI and antihypertensive peptides, particularly those derived from milk proteins, are
the most frequently studied bioactive peptides to date and their effectiveness has been
demonstrated in vitro (Gútiez et al., 2013; Phelan et al., 2014; Pihlanto, 2006), in vivo
(Miguel et al., 2006; Quirós et al., 2007) and in clinical studies (Hata et al., 1996; Mizuno
et al., 2005; Townsend et al., 2004). Fermentation of milk with LAB appears to be a
suitable approach for the liberation of ACEI peptides (Hayes et al., 2007; Regazzo et al.,
2010), particularly using E. faecalis strains, which were previously shown to generate
milk hydrolysates with high ACEI activity (Graham et al., 2019a; Gútiez et al., 2013;
Quirós et al., 2007). In this work, all three chemically synthesised peptides displayed
ACEI activity (Table 5.4, Fig. 5.6). One of these peptides, AVPYPQR, corresponding to
BSM β-casein f(177-183), shares full or partial sequence homologies with previously
reported peptides for which ACEI activity has been reported (Table 5.4). However,
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following an extensive search of both the literature and several databases which contain
information pertaining to bioactive peptides, including the Database of Antihypertensive
Peptides

(AHTPDB;

http://crdd.osdd.net/raghava/ahtpdb/),

(http://www.uwm.edu.pl/biochemia/index.php/en/biopep)

and

BIOPEPUMW
EROP-Moscow

(http://erop.inbi.ras.ru/index.html), two of the three identified peptides in our work,
IPPLTQTPVVVPP, corresponding to β-casein f(74-86), and VLPVPQK, corresponding
to β-casein f(170-176), have not been previously shown to display ACEI or
antihypertensive activity. Therefore, although the peptides IPPLTQTPVVVPP and
VLPVPQK share amino acid sequence homologies with previously identified ACEI and
antihypertensive peptides, to the author’s best knowledge, this is the first report of ACEI
activities for the complete sequence of these two peptides.

Of the three chemically synthesised peptides, AVPYPQR was considered the most potent
ACE inhibitor, displaying an IC50 value (concentration of peptide required to inhibit 50%
of ACE activity) of 387.60 µM. This is somewhat comparable with the findings of
Pihlanto-Leppälä et al. (1998) who reported an IC50 of 274 µM but is much higher than
that reported by Karaki et al. in 1990 (IC50: 15.6 µM) for the same peptide sequence.
Discrepancies observed are likely due to differences in methodologies used to determine
ACEI activity and perhaps even advancements in techniques over time. In our work,
liberation of hippuric acid and subsequent ACEI activity was measured by the method of
Li et al. (2005). However, in the study by Karaki et al. (1990), hippuric acid was measured
by ethyl acetate extraction and absorbance at 228nm, while Pihlanto-Leppälä et al. (1998)
used a modified method of Cushman and Cheung (1971). Peptides AVPYPQ and
LAVPYPQ, which share six amino acids with AVPYPQR, have also shown ACEI
activity elsewhere, although IC50 values were > 1000 µM for both peptides (Yamamoto
et al., 1994).

As previously stated, peptide IPPLTQTPVVVPP (IC50: 523.8 µM) has not been
previously reported as possessing ACEI activity. However, similar to AVPYPQR, partial
sequence homologies to this peptide have been reported to have ACEI activity, such as
NIPPLTQTPVVVPPFIQ (Hayes et al., 2007), corresponding to β-casein f(73-89), and
NIPPLTQTPV (Gobbetti et al., 2000), corresponding to β-casein f(73-82) which
displayed IC50 values of 450 and 173.3 µM, respectively. The higher potency observed
for these peptides, compared to IPPLTQTPVVVPP, is likely due to shorter amino acid
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chain lengths as the potency of ACE inhibitors tends to decrease as the amino chain length
increases (Manoharan et al., 2017; Vermeirssen et al., 2004). The peptides TPVVVPPF,
corresponding to β-casein f(79-86), and SLPQNIPPLTQTPVVVPP, corresponding to
f(69-86), which also share sequence homologies to IPPLTQTPVVVPP, have previously
shown ACEI and antihypertensive activity but IC50 values were not reported for either
peptide (Ahtesh, 2016).

The peptide VLPVPQK (IC50: 776.9 µM), until this work, has not been reported to
possess ACEI activity. In fact, Phelan et al. (2014) assessed this peptide for ACE
inhibition and found that the peptide did not exert an ACEI effect, which is in contrast to
the findings in our work. Reasons why VLPVPQK displayed ACEI activity in our work
but not in the work of Phelan et al. are unknown but it is possibly due to the fact that
FAPGG was utilised as the substrate for ACE by Phelan et al., whereas HHL was used in
our work. Differences in substrates used for ACE may have caused discrepancies in
measurement of ACE inhibition. Indeed, it is true that differences in ACE inhibition
assays, where other substrates and calculations for the inhibitory concentrations (IC50) are
used, hamper the comparison of ACEI activities between studies. VLPVPQK also shares
homology with the previously identified ACEI peptides KVLPVP, SKVLPVPQ and
SQSKVLPVPQ which displayed IC50 values of 5, 39 and 92 µM, respectively (Gobbetti
et al., 2000; Hayes et al., 2007; Yamamoto et al., 1994).

The structural properties of ACEI peptides have been assessed, and it has been shown
that the composition and specific position of amino acids within the peptide sequences
influences ACEI activity. Peptides which contain proline (P) residues appear favourable
for ACEI activity, particularly at the ultimate and antepenultimate positions of the Cterminal which was reported to enhance binding of the peptide to ACE (Quirós et al.,
2007). These observations may explain the ACEI activity observed for AVPYPQR and
VLPVPQK, both of which contain proline residues, one of which crucially is at the
antepenultimate position of the C-terminal. Furthermore, the presence of proline also
confers resistance to degradation of peptides by digestive enzymes, an important
consideration if these bioactive peptides are to be incorporated as functional food
ingredients and/or nutraceuticals. Moreover, these peptides also contain an arginine (R)
and lysine (K) residue at the ultimate position of the C-terminal, respectively, a
phenomenon which was previously reported to enhance ACEI activity (Iwaniak et al.,
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2018; Phelan et al., 2014). Activity of IPPLTQTPVVVPP is also likely due to a high
content of proline residues, particularly at the C-terminal, while the presence of IPP and
VPP, which are recognised as some of the most potent ACEI peptides, may also explain
the ACEI activity observed for this peptide sequence (Iwaniak et al., 2018; Quirós et al.,
2007). Interestingly, although the liberation of ACEI peptides from milk proteins has been
extensively studied, there is still potential for the liberation of novel ACEI peptides with
greater potency than those previously identified. This was the case in our work as
IPPLTQTPVVVPP (IC50: 523.8 µM) and VLPVPQK (IC50: 776.9 µM) were found to be
more potent than other previously reported ACEI peptides, particularly those sharing
partial sequence homologies such as LTQTPVVVPPF (IC50 > 1500 µM) and KVLPVPQ
(IC50 > 1000 µM), thereby indicating that there is merit in further exploring the bioactive
potential of peptides in milk, particularly those derived through the process of
fermentation with Enterococcus.

The chemically synthesised peptides were also examined for antioxidant activity given
that the DPC5154 BSM fermentate previously displayed high levels of antioxidant
activity (Graham et al., 2019a). Milk contains several antioxidant factors such as vitamins
and enzymes, while antioxidant peptides derived from milk proteins have also been
reported (Pihlanto, 2006). The antioxidant activity of the chemically synthesised peptides
was achieved by assessment of DPPH radical scavenging activity, which is considered
the main mechanism by which antioxidants act in foods and also by FRAP activity, an
electron transfer based method (Pihlanto, 2006). Antioxidant activity of the peptides was
measured at various concentrations and DPPH radical scavenging activity was generally
low for all peptides, even at the highest concentration tested (100 mM), with similar
activity levels observed among all three peptides (Fig. 5.7). Based on the FRAP assay,
AVPYPQR was the only peptide that demonstrated ability to reduce Fe3+ to Fe2+, where
a decrease in concentration of peptide coincided with reduced activity levels (Fig. 5.8).
At the highest tested concentration (10 mM peptide), IPPLTQTPVVVPP and VLPVPQK
both demonstrated ≈1 µM TEAA or less, which was considered negligible for FRAP
activity. Although IPPLTQTPVVVPP has not previously been reported as an antioxidant
peptide, both AVPYPQR and VLPVPQK are frequently reported to have antioxidant
activity. It may therefore come as a surprise that the latter displayed no activity based on
the FRAP assay. However, several assays exist to measure antioxidant activity in vitro
and no single assay can give a true reflection of the antioxidant capacity of a compound.
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Therefore, a combination of assays are usually employed which incorporate different
mechanisms of antioxidant activity and both the DPPH and FRAP assays were selected
for the purpose of this study.

AVPYPQR and VLPVPQK have been reported to share either partial or full sequence
homology with previously reported antioxidant peptides. Both peptide sequences, in their
entirety, were shown to exhibit DPPH radical scavenging activities (Rival et al., 2001).
Furthermore, in a different study, AVPYPQR caused a decrease in the production of ROS
and protected against oxidative stress in a Caco-2 cell model (Tonolo et al., 2018), while
VLPVPQK exhibited protective effects against cellular oxidative damage in rat osteoblast
cells (Mada et al., 2017). Antioxidant effects of IPPLTQTPVVVPP, and sequence
homologies thereof, have not previously been reported. Therefore, we are the first to
describe the antioxidant effects of this peptide based on DPPH radical scavenging
activities.

Neither the structure-activity relationship nor the antioxidant mechanism of peptides are
fully understood. However, antioxidant peptides from milk proteins which have been
identified to date contain one or more histidine, proline, tyrosine and tryptophan residues
(Pihlanto, 2006). All peptides identified in this work contain at least two proline residues
which may therefore be a contributing factor to the observed antioxidant activity. A
greater understanding of the relationship between peptide sequence and antioxidant
activity could lead to the formation of extremely effective antioxidant peptides with
various food applications. In spite of the relatively low antioxidant activity observed,
these results indicate that the synthesised peptides exhibit a degree of antioxidant activity.
α-GI peptides and those which confer antidiabetic effects are reported less often but have
been found in several food sources such as milk, cheese, eggs, fish, fruits and vegetables
(Patil et al., 2015). Peptides which inhibit α-glucosidase were first identified in an alkaline
protease hydrolysate of sardine muscle tissue and have since been reported in other foods
such as egg white and milk protein hydrolysates where IC50 values of the hydrolysates
were comparable with that of Acarbose, an anti-diabetic α-GI drug (Iwaniak et al., 2018).
In this work, AVPYPQR, VLPVPQK and IPPLTQTPVVVPP all displayed α-GI activity
where IC50 values observed were similar for all three peptides (60.77, 61.78 and 62.32
mM, respectively; Fig. 5.9). Although IC50 values were higher than previously reported
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α-GI food derived peptides such as VW and YYPL (IC50 22.6 and 3.7 mM, respectively)
(Matsui et al., 1999), to the authors best knowledge, our work is the first report on the αGI activity for the peptides AVPYPQR, VLPVPQK and IPPLTQTPVVVPP.
Although a number of peptides with α-GI activity have been identified, the structural and
physiochemical requirements for optimal activity were, until recently, poorly understood.
In a recent article, Ibrahim et al. (2018) suggested that there is no direct relationship
between amino acid chain length and activity, which was corroborated in our findings as
IPPLTQTPVVVPP displayed similar levels of α-GI activity to AVPYPQR and
VLPVPQK, despite containing almost twice the number of amino acids. Furthermore,
analysis of amino acid composition suggested that the most active α-GI peptides contain
proline residues and either a lysine or arginine (Ibrahim et al., 2018). The presence of
proline residues in all three peptides in this study may explain the observed α-GI activity,
while AVPYPQR and VLPVPQK contain arginine and lysine residues at the C-terminal,
respectively. According to Ibrahim et al. (2018), a total of 43 fully sequenced α-GI
peptides have been reported, none of which share sequence homology to the three
identified peptides in our work nor were any identified in milk. The hydrolysates of milk
fermented with LAB were previously shown to exhibit α-GI activity but the compounds
responsible for the observed activity were not identified (Apostolidis, Kwon, Ghaedian,
et al., 2007; Graham et al., 2019a). The peptides conferring α-GI activity in this study are
likely to be fully or partially responsible for the α-GI activity observed in the DPC5154
milk fermentate in our previous work.
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CONCLUSION
The potential health benefits of milk derived bioactive peptides have been a subject of
growing commercial interest in the context of health-promoting functional foods. Several
commercial developments have been launched on the market and this trend is likely to
continue with the ever-increasing knowledge regarding the functionalities of peptides.
Therefore, the liberation of bioactive peptides from milk, particularly those displaying
multifunctional bioactivities which simultaneously elicit multiple health benefits, is an
important area of investigation. In a previous study, we identified E. faecalis DPC5154
as a strain capable of producing a milk fermentate with high ACEI, antioxidant and α-GI
activity. This study identified three peptides, AVPYPQR, VLPVPQK and
IPPLTQTPVVVPP, all of which conferred ACEI, antioxidant and α-GI activity in vitro.
To the best of our knowledge, we are the first to describe the multifunctional bioactivities
of these peptides, while this is also the first report on the generation of BSM derived
bioactive peptides by E. faecalis DPC5154. Although further work in the form of stability
studies, in vivo experiments and clinical trials is warranted in order to demonstrate the
physiological effects of the identified bioactive peptides, evidence of activity in vitro is a
good starting point as it gives an indication of the potential bioactivities associated with
the peptides. Thus, this study reinforces the concept of using E. faecalis DPC5154 as a
starter or adjunct culture for the generation of multifunctional bioactive peptides from
BSM. These peptides could prove useful as multifunctional ingredients in functional
foods or as nutraceuticals for the treatment of hypertension, oxidative stress and type 2
diabetes, thereby alleviating concerns over the expense and side effects of
commercialised synthetic drugs while it also offers new market opportunities.
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Enterococci have the paradoxical position of providing several benefits of technological
interest in food fermentations, but are also considered as opportunistic pathogens capable
of causing infection in immunocompromised patients. Several species of the genus have
been implicated in the development of disease in humans such as bacteraemia, urinary
tract infections and endocarditis. The pathogenesis of enterococci has been attributed to
the increasing incidence of antibiotic resistance and the possession of virulence
determinants. On the contrary, enterococci have potential to be employed in food
applications, particularly dairy products, where they have positively influenced product
properties such as the rheological, textural and sensory attributes. Their beneficial use in
foods is also exemplified in their application as probiotics to improve human and animal
health and also as protective cultures for food bio-preservation. Furthermore, they have
emerged as important candidates for the generation of bioactive peptides, particularly
from milk, which provide new opportunities for the development of functional foods and
nutraceuticals for human nutrition and health and aligns well with consumer demand for
natural health promoting food products.

The work presented in this thesis explored the potential application of enterococci in milk
fermentations focusing on the production of bioactive peptides by Enterococcus faecalis
isolates. Importantly, the work also examined the safety aspects of the enterococcal
isolates including antibiotic resistance and the presence of virulence determinants.

Chapter I: Safety, beneficial and technological properties of enterococci for use in
functional food applications – a review
Chapter I reviewed the current literature regarding the Enterococcus genus, common
sources of enterococci and media used for their isolation, before giving a well-balanced,
in-depth insight into the dualistic nature of the genus. The controversial nature of
enterococci, their paradoxical position as opportunistic pathogens but also as promising
starter, adjunct, probiotic and protective cultures for application in the food industry, and
their ability to generate bioactive peptides during fermentation are extensively reviewed
in this work.
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Chapter II: Development of a rapid, one-step screening method for the isolation of
presumptive proteolytic enterococci
Chapter II described the development of a method using a selective and differential
medium known as Kanamycin Skim Milk Aesculin Azide (KSMEA) agar to isolate
proteolytic enterococci. The work in this chapter highlighted the limitations in current
screening practices for proteolytic enterococci and was necessary given the anticipated
level of screening required for the isolation of enterococcal strains displaying proteolytic
activity for use in this work. Current screening practices can be time consuming, requiring
a two-step approach which may take up to 96 hours. KSMEA was developed for isolating
proteolytic enterococci in one step and reduced the time required by the current two-step
screening method by 50%. KSMEA proved effective at isolating, detecting and
distinguishing between proteolytic and non-proteolytic enterococci from different sources
(milk, faeces and soil) and retained the selectivity of Kanamycin Aesculin Azide (KAA)
agar with no significant differences in colony counts observed between KSMEA, KAA,
and Brain Heart Infusion (BHI) agar following growth.

Supplementary work for Chapter II outlined an alternative preparation method for
KSMEA to that utilised in the finalised work and compared the results observed for the
growth of proteolytic and non-proteolytic isolates on both preparations. It also assessed
the effect of altering the sodium chloride concentration on the selectivity and differential
properties of the medium in order to optimise performance for the isolation of
presumptive proteolytic enterococci.

Chapter III: Proteolytic activity and safety assessment of Enterococcus faecalis
isolates from food and other sources
In Chapter III, KSMEA (developed in Chapter II) was utilised in the screening process to
isolate proteolytic enterococci from various foods (including meats, cheeses and milk).
A total of 25 proteolytic enterococci were identified and utilised for the work in Chapter
III and for proceeding work thereafter. All 25 isolates were confirmed as E. faecalis by
16S rRNA sequencing and were grown in 10% bovine skim milk to assess their
proteolytic activity and subsequent suitability for the production bioactive milk
fermentates as described in Chapter IV and V. E. faecalis DPC5154 demonstrated the
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greatest level of proteolytic activity (8.86% DH), measured by the o-phthalaldehyde
(OPA) assay, and was thus considered the most proteolytic of the 25 isolates.

Chapter III also studied antibiotic susceptibility and virulence factors of the enterococcal
isolates with a view to identifying isolates which may be considered non-pathogenic and
therefore potentially safe for use in generating milk derived bioactive compounds.
Antibiotic susceptibility testing was performed by the disc diffusion method according to
the Clinical and Laboratory Standards Institute (CLSI) guidelines using a total of 11
antibiotics.

All 25 isolates were susceptible to the clinically relevant antibiotics

ampicillin, penicillin, the high-level aminoglycoside gentamicin and the glycopeptides
(teicoplanin and vancomycin). E. faecalis DPC5154 was one of six isolates which were
susceptible to all of the tested antibiotics. The presence of virulence determinants was
analysed using PCR targeting the presence of 12 genes associated with virulence and also
for genes associated with vancomycin resistance (vanA and vanB). The presence of
virulence determinants varied among the isolates. The prevalence of the sex pheromones
(cob, cpd, cad, ccf) was most common (found in 23 of 25 isolates), which may have
implications in transfer of genetic material, but further work is required. The vanA and
vanB genes associated with vancomycin resistance were not present in any of the 25
isolates and coincides with the susceptibility observed towards vancomycin in the
antibiotic sensitivity testing. E. faecalis DPC5154 (most proteolytic strain) did not
contain any of the cytolysin determinants (cylA, cylB, cylM), vancomycin determinants
(vanA, vanB) or the gene for the cell-wall associated protein involved in immune evasion
(esp).

Supplementary work for Chapter III includes the analysis of proteolysis, cell growth and
acid production over a 48 h fermentation period with a view to determining reasons for
differences in levels of proteolytic activity among the isolates. In addition, primers were
designed to amplify the gelE gene sequence (responsible for casein hydrolysis) from three
strains that were considered highly proteolytic and three strains considered weakly
proteolytic after 20 hours of growth in BSM. Amplicons from the 6 isolates were then
sequenced to determine the potential effect of any differences in the nucleotide, and
subsequent amino acid, sequences on proteolytic activity. Further work may encompass
genomic studies to fully elucidate the proteolytic nature of enterococci as well as the
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potential of these isolates to transfer and/or acquire antibiotic resistance genes and
virulence determinants.

Chapter IV: Enterococcus faecalis milk fermentates display antioxidant properties
and inhibitory activity towards key enzymes linked to hypertension and
hyperglycaemia
In Chapter IV, the E. faecalis fermented milk supernatants generated in Chapter III were
assayed in-vitro for total phenolic content, antioxidant activity (measured by the DPPH
and FRAP assays) and the inhibition of key enzymes linked to hypertension (ACE
inhibition assay) and hyperglycaemia (α-glucosidase inhibition assay). Of the 25 isolates,
the E. faecalis DPC5154 fermentate had the highest level of total phenolic compounds
(739.06 µg GAE/ml) and demonstrated the highest level of Trolox Equivalent
Antioxidant Activity (TEAA) based on DPPH radical scavenging activity and ferric
reducing antioxidant power (271.27 TEAA (µM) and 272.75 TEAA (µM), respectively).
Similarly, the DPC5154 fermentate completely inhibited ACE and displayed the highest
level of α-glucosidase inhibitory (α-GI) activity (33.41%). The work in Chapter IV
provides in vitro evidence for the beneficial use of DPC5154 and other E. faecalis isolates
for the generation of bioactive milk fermentates with antioxidant, antihypertensive and
anti-hyperglycaemic activity.

The supplementary work for Chapter IV examined the antimicrobial activity of the E.
faecalis milk fermentates.

Chapter V: Identification of multifunctional bioactive peptides in milk fermented
with Enterococcus faecalis DPC5154
Chapter V aimed to isolate, identify and characterise the peptide(s) potentially responsible
for the bioactivities observed in the E. faecalis DPC5154 fermentate in Chapter IV. The
milk fermentate of DPC5154 was purified by several RP-HPLC steps and resulting
fractions were tested for ACEI activity. RP-HPLC chromatograms and mass spectrometry
data alluded to the presence of a small number of peptides in two fractions, both of which
gave high ACEI activity. Fractions with putative ACEI activity were sent to Alta
Biosciences (University of Birmingham, Redditch, UK) for MS/MS analysis by
electrospray ionisation mass spectrometry to determine the amino acid sequence of the
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peptides present in the samples. Three peptides were identified in the fractions:
IPPLTQTPVVVPP, VLPVPQK, AVPYPQR. These peptides were chemically
synthesised for assessment of bioactivity in vitro. All three peptides displayed ACEI (IC50
= 523.8, 776.9 and 387.60 µM, respectively), antioxidant and α-GI activity (IC50 = 62.32,
61.78, 60.77 mM, respectively). Thus, because more than one biological activity was
observed for each peptide, this work represents the first report on the multifunctional
activities for these three peptides. To summarise, the peptides responsible for the
observed activities in the DPC5154 fermentate in Chapter IV were isolated, identified and
confirmed to confer multiple biological functions considered novel for these peptides as
outlined in the table below.

Table 6.1. Observed biological activity for the chemically synthesised peptides used in this
study.

Peptide

ACEI activity

Antioxidant activity

α-GI activity

IPPLTQTPVVVPP

Novel

Novel

Novel

VLPVPQK

Novel

Previously reported

Novel

AVPYPQR

Previously reported

Previously reported

Novel
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CONCLUSION
Overall, the work encompassed in this thesis examined the potential use of E. faecalis
isolates in milk fermentations for the generation of health-promoting bioactive milk
fermentates with a due consideration for their safety aspects pertaining to antibiotic
resistance and the possession of virulence determinants. E. faecalis DPC5154 was the
most promising strain utilised in this work. DPC5154 was susceptible to all antibiotics
examined and harboured only a few putative virulence determinants. The strain was also
the most proteolytic of the 25 isolates and generated the milk fermentate with the highest
level of antioxidant activity, the highest α-GI activity (associated with hyperglycaemia)
and it also completely inhibited the ACE enzyme (associated with hypertension). In the
final chapter, three peptides within the DPC5154 fermentate responsible for conferring
the previously observed bioactivities were identified and characterised. Subsequently,
this work is the first to report on the presence of three peptides in the E. faecalis DPC5154
fermentate which displayed multifunctional biological effects in the form of ACEI,
antioxidant and α-GI activity.

Although some enterococcal species are considered as opportunistic pathogens,
enterococci have a long history of safe use in foods and the benefits of their application
in the food industry, particularly in dairy products, is well documented. Promisingly,
recently established phenotypic methods and modern genetic tools have enabled the
differentiation between pathogenic and non-pathogenic strains. Furthermore, pathogenic
traits of enterococci are strain- or species-specific and food isolates harbour fewer
virulence determinants than clinical isolates, while they are generally susceptible to
clinically relevant antibiotics. Moreover, the use of enterococci in food has previously
been permitted on a case-by-case basis in conjunction with a well contemplated
risk/benefit analysis, while there are also several commercialised probiotic products
containing enterococci. Therefore, although not the major focus of this PhD thesis, the
recent developments in identifying safe enterococcal strains for use in food raises the
possibility of using the E. faecalis isolates in this study as starter or adjunct cultures in
the dairy industry for cheese production or as functional cultures. This requires further
study of their biochemical properties to assess the ability of these isolates to positively
influence the organoleptic properties of fermented dairy products as well as their probiotic
properties and suitability as protective cultures.
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Indeed, the major focus of this thesis was to identify bioactive peptides derived from
bovine skim milk by fermentation with E. faecalis isolates. The work in this thesis
provides strong evidence for the use of DPC5154 and potentially other E. faecalis isolates
used in this study for the generation of health promoting bioactive milk peptides with
multifunctionalities most notably antioxidant, antihypertensive and antihyperglycaemic
activity. This avenue is particularly promising in the case that the enterococcal strains are
not permitted for inclusion in the final food product. Pending further research, including
peptide stability and bioavailability studies, in vivo experiments and clinical trials, the
peptides identified in this thesis could be further developed as multifunctional ingredients.
These peptides could then be directly incorporated in the development of functional foods
and nutraceuticals for the treatment of hypertension, oxidative stress and type 2 diabetes,
thereby removing the possible risk associated with the inclusion of potentially harmful
isolates in food. This strategy could prove useful as an effective complimentary approach
to improve health, to develop new food products, and to alleviate concerns over the use
of synthetic drugs.

However, because of the potential multiple benefits associated with including enterococci
as a starter or adjunct culture in milk fermentations, whereby they could simultaneously
improve the organoleptic properties of dairy products, act as probiotics and protective
cultures, and generate bioactive peptides, there is merit in further exploring the suitability
of DPC5154 for direct use in food. This would require genomic studies with a strong
focus on the ability of the strains to transfer or acquire genetic material associated with
pathogenesis. Implementation of an appropriate risk analysis as well as consideration for
relevant guidelines, legislation and regulatory aspects surrounding functional food
development, may help industry, health-staff and consumers accept enterococci, like
other LAB, as important candidates for useful and beneficial applications in food
biotechnology.
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INTRODUCTION
The following study is supplementary to that of the work presented in Chapter II and
describes experimental approaches carried out during the initial development of
Kanamycin Skim Milk Aesculin Azide Agar (KSMEA). As detailed in Chapter II,
KSMEA provides a quicker, cost efficient and more convenient means of isolating
presumptive proteolytic enterococci in comparison to current screening methods. The
growing interest in enterococci which display proteolytic capabilities coupled with the
limitations of current screening methods were the primary stimuli for the development
and progression of the work described in Chapter II and subsequent supplementary work
presented here. The aim of this study was to examine the effect of different preparatory
methods on the selective and differential properties of KSMEA in order to optimise
performance of the medium for isolating presumptive proteolytic enterococci.
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MATERIALS AND METHODS
Initial preparation of KSMEA
KSMEA was initially prepared by individually adding the selective and differential
components of Kanamycin Aesculin Azide Agar (KAA) to sterile reconstituted skim milk
(RSM) which was then subsequently added to sterile agar. In order to achieve this,
concentrated stock solutions of each selective and differential component were prepared
(Table A1.1) and filter sterilised into the medium using 0.2µm filters. Aesculin hydrate
was only partially soluble in water and therefore could not be filter sterilised into RSM
following sterilisation. According to manufacturer’s instructions, aesculin hydrate is
present at a concentration of 1 g/L in KAA. Therefore, double concentrated aesculin
hydrate was added to 20% (w/v) RSM prior to sterilisation at 110°C for 10 min. After
sterilisation, the remaining selective and differential components of KAA (Table A1.1)
were individually filter sterilised into the RSM/aesculin hydrate solution. The solution
was mixed to homogeneity and maintained at 50°C. 3% (w/v) agar was sterilised at 121°C
for 15 min and aseptically added to the skim milk solution in a 1:1 ratio, gently mixed to
homogeneity ensuring that the formation of air bubbles was avoided, and poured into
sterile petri dishes.

Table A1.1. Concentration and volumes of selective/differential components required in KSMEA
Component

Function

Manufacturer

Sigma Aldrich

Stock
concentration
(g/L)
250

Concentration
required in final
medium (g/L)
5

Sodium chloride

Selective

Sodium citrate

Selective

Sigma Aldrich

200

1

Ferric ammonium citrate

Differential

Sigma Aldrich

200

0.5

Sodium azide

Selective

Sigma Aldrich

50

0.15

Kanamycin sulphate

Selective

Sigma Aldrich

10

0.02

Aesculin hydrate

Differential

Sigma Aldrich

n/a*

1

*Not filter sterilised into KSMEA. Added to RSM before sterilisation due to solubility issues.

Comparison of the growth of enterococci on two different KSMEA
preparations
E. faecalis DPC5173, E. faecalis DPC4996, E. faecalis DPC5209 (all proteolytic) and E.
faecalis ATCC29212, E. faecalis DPC5171, E. faecalis DPC5199 (all non-proteolytic)
were recovered from frozen stocks and maintained in BHI broth. Each culture was serially
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diluted 10-fold in sterile ringers and spread plated on KSMEA which was prepared firstly
as described above (KSMEA 1 for the purpose of description here) and secondly as
described in Chapter II (KSMEA 2 for the purpose of description here). Briefly, KSMEA
2 was prepared by the addition of 10% (w/v) sterile RSM (sterilised at 110°C for 10 min)
to sterile double concentrated KAA (sterilised at 121°C for 15 min) in a 1:1 ratio. Growth,
proteolysis and aesculin hydrolysis on both media were assessed for all 6 cultures
following a 48 h incubation period at 37 °C.

Assessment of sodium chloride (NaCl) concentration on the selectivity
of KSMEA
The sodium chloride concentration of KSMEA was altered in an attempt to improve the
selectivity of the medium. One of the distinguishing features of members of the
Enterococcus genus from other Gram-positive, catalase-negative, homofermentative
cocci is their ability to survive and grow in 6.5% NaCl (Domig et al., 2003; Foulquié
Moreno et al., 2006). NaCl is present in a final concentration of 0.5% (w/v) in
commercialised KAA. Therefore, for all other purposes and for general use, KSMEA was
also prepared with a final concentration of 0.5% (w/v) NaCl. However, to assess the effect
of NaCl on the selectivity of the medium, KSMEA was prepared with 1, 2 and 3% (w/v)
NaCl. A total of six Enterococcus cultures, one S. bovis culture and two Streptococcus
agalactiae cultures (Table A1.2) were cultivated on KSMEA (prepared with each of the
aforementioned NaCl concentrations) at 37 °C for 48 h. Growth, proteolysis and aesculin
hydrolysis were examined following propagation.
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RESULTS AND DISCUSSION
Comparison of the growth of enterococci on two different KSMEA
preparations
Prior to the publication of the study presented in Chapter II, KSMEA was initially
prepared by the manual addition of selective and differential components (Table A1.1),
to sterile RSM, as outlined in the above materials and methods section. Growth, aesculin
hydrolysis and protein hydrolysis on this KSMEA preparation (KSMEA 1 for the purpose
of this discussion) were then examined and compared to that on KSMEA prepared by the
addition of sterile KAA to sterile RSM as outlined in Chapter II (KSMEA 2 for the
purpose of this discussion). The proteolytic E. faecalis strains DPC5173, DPC4996 and
DPC5209 all grew and hydrolysed both aesculin and protein on KSMEA 1 and KSMEA
2 producing colonies characterised by a zone of clearing encompassed by a black halo
(Fig. A1.1). The non-proteolytic E. faecalis strains ATCC29212, DPC5171, DPC5199 all
grew and hydrolysed aesculin on KSMEA 1 and KSMEA 2. Expectedly, none of the
strains demonstrated proteolytic activity on either medium noted by the absence of zones
of clearing (Fig. A1.2). Growth, aesculin hydrolysis and protein hydrolysis (where
present) were much more pronounced on KSMEA 2 compared to KSMEA 1.
Furthermore, colony size was typically smaller when strains were grown on KSMEA 1
compared to that observed on KSMEA 2. Similarly, aesculin hydrolysis was less apparent
on KSMEA 1 compared to KSMEA 2, while zones of protein hydrolysis were also smaller
and less notable on KSMEA 1. The most likely reason for the observation of this
phenomenon is due to lack of nutrients in KSMEA 1 that were provided in the KSMEA
2 preparation. The only nutrients provided by the KSMEA 1 preparation were those that
are naturally present in the skim milk. However, KSMEA 2, prepared by the direct
addition of sterile KAA to sterile RSM, provided additional nutrients which are included
in the formula of the commercialised KAA, namely tryptone and yeast extract. These
were not added to the KSMEA 1 preparation. Due to the expense and labour associated
with the preparation of KSMEA 1, coupled with the observation of better growth, aesculin
hydrolysis and protein hydrolysis (where applicable) on KSMEA 2 by both proteolytic
and non-proteolytic enterococci, the KSMEA 2 preparation was selected as the preferred
method for the study outlined in Chapter II of this thesis.
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Figure A1.1. Colonies of the proteolytic E. faecalis strains (A) DPC5173, (B) DPC4996 and (C)
DPC5209, on Kanamycin Skim Milk Aesculin Azide Agar (KSMEA) prepared two different
ways; by the addition of selective components of Kanamycin Aesculin Azide Agar (KAA) only
to Reconstituted Skim Milk (RSM) (KSMEA 1) and by the direct addition of KAA to RSM
(KSMEA 2) following growth at 37°C for 48 h.

Figure A1.2. Colonies of the non-proteolytic E. faecalis strains (A) DPC5199, (B) DPC5171 and
(C) ATCC29212 on Kanamycin Skim Milk Aesculin Azide Agar (KSMEA) prepared two
different ways; by the addition of selective components of Kanamycin Aesculin Azide Agar
(KAA) only to Reconstituted Skim Milk (RSM) (KSMEA 1) and by the direct addition of KAA
to RSM (KSMEA 2) following growth at 37°C for 48 h.
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Assessment of sodium chloride (NaCl) concentration on the selectivity
of KSMEA
Although growth of different bacterial species (including those of other bacterial genera)
on KSMEA was consistent with that on KAA (Chapter II, Fig. 2.1), in the study presented
here, the salt concentration in the final KSMEA preparation was altered in an attempt to
inhibit the growth of non-enterococcal cultures, particularly those of the Streptococcus
genus. Current literature suggests that enterococci can survive and grow in up to 6.5%
NaCl while the growth of other Gram-positive, catalase-negative cocci is generally
inhibited at higher salt concentrations (Domig et al., 2003; Foulquié Moreno et al., 2006).
NaCl is present at a final concentration of 0.5% (w/v) in commercialised KAA. Therefore,
for all other purposes and for general laboratory use, KSMEA was also prepared with a
final concentration of 0.5% NaCl. However, for this study, KSMEA was prepared with
1, 2 and 3% (w/v) NaCl to examine the effect of NaCl on growth and subsequent aesculin
and protein hydrolysis on KSMEA. This was achieved using six Enterococcus, one S.
bovis and two S. agalactiae strains (Table A1.2). KSMEA as it is typically prepared (with
0.5% (w/v) NaCl) permitted the growth of all six Enterococcus strains and S. bovis while
possible pinpoint colonies were evident for the two S. agalactiae cultures after 48 h
incubation at 37°C. This result was also observed when these strains were propagated on
KAA (data not shown). All six Enterococcus cultures and S. bovis grew on KSMEA with
1% sodium chloride. Out of these seven cultures, only E. faecium DPC5030 failed to
hydrolyse aesculin while E. faecalis DPC4996 was the only culture that demonstrated
proteolytic activity with a notable loss in proteolytic activity by E. faecalis DPC810 and
DPC5209. Growth of both S. agalactiae cultures was completely inhibited. KSMEA
prepared with 2% NaCl inhibited the growth of S. bovis CITCCK05 while growth and
aesculin hydrolysis for all six Enterococcus strains was consistent with that observed on
KSMEA prepared with 1% NaCl. Despite hydrolysing casein on KSMEA with 1% NaCl,
DPC4996 did not produce a zone of clearing on KSMEA prepared with 2% NaCl, thereby
indicating a lack of proteolytic activity. On KSMEA prepared with 3% NaCl, growth of
all three Streptococcus strains was inhibited while only two of the Enterococcus strains,
E. faecalis DPC810 and E. faecium DPC5030, showed clear growth and colony
morphology. Growth of E. faecalis DPC4996 was completely inhibited while pinpoint
colonies were observed for the remaining three Enterococcus strains, DPC5802,
ATCC29212 and CITCCK07. No strain hydrolysed aesculin or demonstrated proteolytic
activity on KSMEA prepared with 3% NaCl. Therefore, although increasing the salt
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concentration of KSMEA did appear to have an inhibitory effect on Streptococcus strains,
it also negatively impacted the growth and subsequent aesculin and protein hydrolysis of
enterococci. Interestingly, not only was growth inhibited at higher salt concentrations, but
proteolytic activity appeared to decrease with increasing salt concentration and was
absent for all strains at 2% and 3% NaCl. These findings are similar to those of Hegazi in
1990 who also noted that salt levels higher than 2% were inhibitory to bacterial growth
and proteolysis (Hegazi, 1990).
Table A1.2. Analysis of the effect of NaCl concentration on the selectivity of KSMEA.
0.5% (w/v) NaCl

1% (w/v) NaCl

2% (w/v) NaCl

3% (w/v) NaCl

Genus

Species

Strains

G

AH

PH

G

AH

PH

G

AH

PH

G

AH

PH

Enterococcus

faecalis

DPC810

+

+

+

+

+

-

+

+

-

+

-

-

Enterococcus

faecalis

DPC4996

+

+

+

+

+

+

+

+

-

-

-

-

Enterococcus

faecalis

DPC5802

+

+

+

+

+

-

+

+

-

±

-

-

Enterococcus

faecalis

ATCC29212

+

+

-

+

+

-

+

+

-

±

-

-

Enterococcus

faecium

DPC5030

+

+

-

+

-

-

+

-

-

+

-

-

Enterococcus

faecium

CITCCK07

+

+

-

+

+

-

+

+

-

±

-

-

Streptococcus

bovis

CITCCK05

+

+

-

+

+

-

-

-

-

-

-

-

Streptococcus

agalactiae

CITCCK12

±

-

-

-

-

-

-

-

-

-

-

-

Streptococcus

agalactiae

CITCCK13

±

-

-

-

-

-

-

-

-

-

-

-

G: Growth; AH: Aesculin Hydrolysis; PH: Protein Hydrolysis.
+: Positive; -: Negative; ±: Possible Pinpoint.
Note: Growth of additional Gram positive and Gram negative non-enterococcal strains (not presented in
this table) was inhibited on KSMEA prepared with 0.5% (w/v) NaCl (Fig. 2.1, Chapter II).
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CONCLUSION
The supplementary work presented here was performed during the early development
stages of KSMEA in an attempt to optimise the performance of the medium for the
isolation of presumptive proteolytic enterococci. Taking all results into consideration,
KSMEA is best prepared by combining sterile KAA and sterile RSM post sterilisation (as
described in Chapter II), rather than individually adding the selective and differential
components to the medium as described in this supplementary work. Growth, aesculin
hydrolysis and protein hydrolysis was more pronounced on the KSMEA preparation
described in Chapter II compared to that observed on the KSMEA preparation described
here. Moreover, increasing the final salt concentration in KSMEA had a negative impact
on the ability of enterococci to hydrolyse casein. Furthermore, considering at 1% NaCl,
the growth of S. bovis CITCCK05 was not inhibited, coupled with the observation that E.
faecalis DPC810 and DPC5802 lost their ability to hydrolyse casein, it is desirable to
maintain the original salt concentration of KAA (0.5%) when preparing KSMEA.
Combining the work presented here with that of Chapter II, KSMEA provides an
alternative, quicker and more efficient method for isolating presumptive proteolytic
enterococci and is therefore suitable for routine laboratory use
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INTRODUCTION
The emergence of enterococci as one of the most proteolytic bacteria to date, coupled
with the fact that they show higher proteolytic activity than other lactic acid bacteria
(Bhardwaj et al., 2008; Centeno et al., 1996; Monika et al., 2017; Fabrício Luiz Tulini et
al., 2015), has culminated in the increasing interest in isolates displaying proteolytic
capabilities. The release of proteolytic enzymes by enterococci is essential for optimal
growth in milk, which enables them to use milk casein as a source of amino acids and
nitrogen. Moreover, proteolysis is considered a desirable biochemical trait in food
fermentation, particularly in the dairy industry where casein breakdown and subsequent
peptides released contribute to the rheological, textural and sensory attributes of
fermented milk products. As outlined in this thesis, proteolytic enterococci have also
demonstrated the ability to generate bioactive milk fermentates during fermentation.
However, data in the literature regarding the proteolytic activities of enterococci is
somewhat conflicting, with some authors reporting that they show high levels of
proteolytic activity, while others conclude that they are weakly proteolytic. What authors
do agree on, however, is that E. faecalis species show higher proteolytic activities
compared to E. faecium isolates, while there also appears to be a marked strain-to-strain
variation of this phenotypic trait (Dagdemir & Ozdemir, 2008; Morandi et al., 2006;
Sarantinopoulos et al., 2001). The study presented here accompanies the work of Chapter
III and aimed to provide a better understanding of the proteolytic nature of enterococci
with a view to reconciling the disparate reports in the literature.
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MATERIALS AND METHODS
Protein quantitation
To accompany the works in Chapter III regarding the levels of proteolytic activity
observed among the 25 E. faecalis isolates determined by the OPA assay, this study also
determined the protein concentration of the E. faecalis milk fermentates. This was
achieved using the bicinchoninic acid (BCA) protein assay (Pierce, Thermo Fisher
Scientific Inc., Rockford, IL, USA). A calibration curve was prepared with 0-2 mg/ml of
albumin. The milk fermentates were diluted 1:50 and protein was quantified as per
manufacturer’s instructions. Correlation studies were performed on the OPA and BCA
data sets as outlined below.

Assessment of proteolysis, analysis of cell growth and monitoring of
acid production during fermentation
For the purposes of the main body of work in this thesis, milk fermentations were carried
out for 20 h as described in Chapters III & IV. For the supplementary work presented
here, milk fermentations were also performed for the duration of 48 h to assess levels of
proteolysis, cell growth and pH over time. Overnight cultures of the E. faecalis isolates
in BHI broth were standardised as described in Chapter III and a 1% inoculum was made
into 50 ml volumes of 10% Bovine Skim Milk (BSM). The enterococcal inoculated milks
were sampled at 0, 6, 20 and 48 h and the degree of hydrolysis (DH) of milk proteins by
the isolates, cell growth and pH was analysed as a means of examining the varying levels
of proteolytic activity observed among the isolates. The DH was determined by the OPA
assay as described in Chapter III. Cell growth was monitored by standard plate counting
by preparing 10-fold serial dilutions of milk samples at each time point and spread plating
on BHI agar, followed by incubation at 37 °C for 24 h. The pH of the milk samples was
measured using a pH meter to monitor acid production during fermentation.
Fermentations and associated measurements were performed in triplicate and data
reported as the mean with error in measurements represented as the standard deviation.
Correlation studies were performed between cell growth and percentage DH, and between
pH and percentage DH values after 20 and 48 h growth.
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GelE sequence analysis
The gelE gene encoding gelatinase is responsible for casein hydrolysis by enterococci
when grown in milk (Gútiez et al., 2014). In an attempt to explain the varying levels of
proteolytic activity observed among the E. faecalis isolates, the gelE gene sequences of
E. faecalis DPC5154, ST02, DPC4784 (considered highly proteolytic), RC11, DPC5237,
PK02 (weakly proteolytic) and ATCC 29212 (non-proteolytic) were amplified and
analysed for differences in the nucleotide composition and subsequent translated
gelatinase amino acid sequences. For this purpose, gelE specific primers were designed.
To achieve this, several known enterococcal gelE gene sequences were aligned using the
ClustalW multiple sequence alignment program and SnapGene software. The gelE
sequences used in the alignment were obtained from the GenBank Sequence Database
(https://www.ncbi.nlm.nih.gov/GenBank;
CP002491.1,

CP002621.1,

Accession

CP003726.1,

numbers:

CP008816.1,CP014949.1,

CP015883.1, CP018004.1, CP018102.1, CP022059.2,
EU862241.3,

FJ858146.1,

ASDV01000011.1,

GG692906.1,

CP015410.2,

D85393.1, EU862241.3,

HE574483.1,

JAHR01000004.1,

JAHZ01000004.1, JAIB01000001.1, JAIF01000003.1, JN246675.1, JQ815406.1,
M37185.1, M37185.1, NGMY01000001.1.). Conserved regions upstream of the 5’ region
and downstream of the 3’ region of the gelE gene were identified and used to develop
primers which were designed in accordance with standard characteristics for PCR primer
design (Chuang et al., 2013). The designed primers were denoted GelE-2DF (5'
GCCGGTTAGGTAGTTGTC 3') and GelE-2DR (5' CARGCTAAAACCGGCKATCA
3') and were synthesized by Eurofins Genomics (expected product size 1810 bp).

PCR amplification of gelE gene and sequence analysis
Template DNA was prepared using the High Pure PCR Template Preparation Kit
(Roche). Amplifications were performed in 50 µl reactions using KOD Hot Start DNA
Polymerase (Merck) as per manufacturer’s instructions. Following an initial denaturation
at 95 °C for 2 min, enterococcal DNA was amplified by 30 cycles of denaturation at 95
°C for 20 s, annealing at 64 °C for 20 s and elongation at 70 °C for 30 s. PCR products
were separated by electrophoresis on a 1% agarose gel and visualised by UV
transillumination. Amplified PCR products were purified using a High Pure PCR Product
Purification kit (Roche) and purified PCR product sequences were determined by Sanger
sequencing from the forward and reverse ends (GATC Biotech AG, Cologne, Germany)
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using the GelE-2DF and GelE-2DR primer set. A consensus sequence was produced from
the overlapping reads for the gelE gene of each isolate using Unipro UGENE software
and sequences were analysed for nucleotide and subsequent amino acid differences.

Statistics
All milk fermentations were carried out in triplicate using three independently prepared
Enterococcus cultures in three independent preparations of 10% BSM. Subsequent assays
performed on the milk fermentates were also performed in triplicate and the mean and
standard deviation was calculated using Microsoft Excel. Correlation studies were
performed using the Statistical Package for Social Sciences (SPSS v.24) utilising the
Pearson’s correlation coefficient or Spearman’s Rho coefficient depending on the nature
of the data.
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RESULTS AND DISCUSSION
Protein quantitation
In addition to the degree of protein hydrolysis measured for the 25 E. faecalis isolates in
Chapter III, the protein content of the milk fermentates generated by the isolates was also
examined. The E. faecalis DPC5154 hydrolysate had the highest protein content (15.41
mg/ml). This strain was previously determined as the most proteolytic isolate based on
the OPA assay (8.86% DH). Of the 25 isolates, the supernatant of milk fermented with E.
faecalis PK02 had the lowest protein content (8.85 mg/ml). A similar trend to that of the
OPA assay (presented in Chapter III) was observed where the supernatant of milk
fermented with strains isolated from cheese generally had a higher protein concentration
than those obtained from alternative sources (Fig. A2.1.). This observation was confirmed
by statistical analysis of the data where Pearson’s Correlation coefficient indicated the
presence of a statistically significant strong positive correlation between %DH values and
protein concentration (mg/ml) of the E. faecalis fermentates (P < 0.01, r = 0.962; Fig.
A2.2). The high proteolytic activity observed for E. faecalis DPC5154, coupled with a
consideration for its safety aspects as outlined in Chapter III, resulted in this strain being
utilised in Chapter IV and V for the generation of bioactive peptides from BSM.
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Figure A2.1. Protein concentration (mg/ml) of Enterococcus faecalis milk fermentates
generated by growing isolates in bovine skim milk for 20 h at 37 °C. Protein concentration
was determined by the Bicinchoninic Acid (BCA) assay. Error bars represent the standard
deviation of three independent experiments.

Figure A2.2. Scatterplot depicting the relationship between degree of protein hydrolysis
(%), determined by the OPA assay, and protein concentration (mg/ml) determined by the
BCA assay for the Enterococcus faecalis bovine skim milk fermentates.
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Assessment of proteolysis, analysis of cell growth and monitoring of
acid production during fermentation
Assessment of proteolysis
Similar to the conclusions made in Chapter III after 20 h growth, the levels of proteolytic
activity after 48 h growth in BSM also varied among the 25 E. faecalis isolates (Fig.
A2.3). This agrees with the work of Daliri et al. (2017) who also concluded that bacterial
strains within the same species may differ in their proteolytic capacities (Daliri et al.,
2017). The majority of isolates displayed increased levels of proteolytic activity after 48
h, particularly those which did not display any proteolysis after 20 h growth as determined
by the OPA assay (DPC5237, PK02, TK01, TK02, and RC11). This indicates that,
although cell growth reached lag phase after 20 h (data not shown), the proteolytic activity
of the isolates continued up until the 48 h time point. Interestingly, the E. faecalis isolates
from raw turkey (TK01 and TK02) did not display any degree of hydrolysis of milk
proteins after 20 h, but were among the most proteolytic isolates following 48 h growth.
This may allude to increased time required by the strains to adapt to an environment which
differed from the original source of isolation. In an attempt to explain the differing levels
of proteolytic activity observed among the isolates, correlation studies were performed to
assess the impact of cell growth and pH on proteolysis as outlined below.
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Figure A2.3. Assessment of the level of proteolytic activity of Enterococcus faecalis
strains, isolated from food and other sources, following growth in bovine skim milk for
20 h and 48 h at 37 °C. Proteolysis was determined by the OPA assay and values are
reported as percentage degree of hydrolysis (%DH) of milk proteins. Error bars represent
the standard deviation of three independent experiments.
pH analysis
Similar to observations made for levels of proteolytic activity, acid production also varied
among the isolates and agrees with reports in the literature that the acidifying ability of
enterococcal isolates may also be strain- or species-specific. Although the general
consensus in the literature suggests that E. faecalis strains exhibit weak acidification
activities during growth in milk (Aspri et al., 2017; Jaouani et al., 2015; Sarantinopoulos
et al., 2001), the results of this study suggest otherwise. 72% of the E. faecalis isolates
reduced the pH of the milk below 5.0 after 20 h growth which is considered advantageous
for the ripening process in cheese production. Conversely, none of the isolates decreased
the pH below 5.3 after 6 h growth (data not shown), which coincides with previous reports
that acid production among enterococci is slow (Aspri et al., 2017; Sarantinopoulos et al.,
2001). A rapid decrease in pH is important in cheese manufacture for coagulation, for
flavour and aroma development, and for bio-preservation. Therefore, because the isolates
used in this work were slow acidifiers, these strains would be of little use as starter
cultures but show great potential for use as adjunct cultures. For 88% of isolates, there
was no major change in the pH of the milk at 20 h compared to 48 h, thereby confirming
the suitability of a 20 h fermentation time.
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Figure A2.4. Assessment of the pH of bovine skim milk fermented with Enterococcus
faecalis strains, isolated from food and other sources, following 0, 20 and 48 h growth at
37 °C. Error bars represent the standard deviation of three independent measurements.

Assessment of the relationship between cell growth and levels of proteolytic
activity
The relationship between cell growth and levels of proteolytic activity was examined in
an attempt to explain the varying levels of proteolytic activity observed among the 25
isolates. As outlined in Chapter I, the expression of the gelE gene (responsible for casein
hydrolysis during growth of enterococci in milk) is controlled by the fsr quorum sensingdependent regulatory system which encodes fsrA, fsrB, fsrC and fsrD. The fsrD gene
encodes the gelatinase biosynthesis activating pheromone (GBAP), which is exported out
of the cell during growth and upregulates the fsr operon. This, in turn, induces the
expression of gelE, which subsequently confers the ability of isolates to hydrolyse casein.
Therefore, theoretically, if the number of cells with a functional fsr operon is higher, this
should also be reflected in higher levels of proteolytic activity as more GBAP would be
produced leading to greater expression levels of gelE and subsequent protein hydrolysis.
Based on 20 h fermentation, this theory was considered to be true. The levels of
proteolytic activity were positively correlated with cell counts after 20 h growth in BSM
(P < 0.05, r = 0.465; Fig. A2.5). Conversely, no correlation was observed between levels
of proteolytic activity and cell counts after 48 h fermentation (P > 0.05, data not shown).
Therefore, due to the conflicting nature of the findings, further work is needed to fully
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understand the impact of cell numbers on the proteolytic activities of enterococci. This
may entail using a larger sample size of enterococcal isolates from several different
ecological niches and monitoring cell growth and proteolysis at a greater number of time
points within the 48 h fermentation period.

Figure A2.5. Scatterplot depicting the relationship between degree of protein hydrolysis
(%), determined by the OPA assay, and cell counts (Log CFU/ml) for the Enterococcus
faecalis isolates grown in bovine skim milk for 20 h at 37 °C.

Assessment of the relationship between pH and levels of proteolytic activity
Acid production effects the conformity of milk proteins and their subsequent availability
for hydrolysis by the enterococcal isolates during growth. Therefore, acid production
could play a role in the varying levels of proteolytic activities observed among the
enterococcal isolates. Data in the literature regarding the relationship between proteolytic
and acidifying activities is conflicting. Some reports suggest that higher proteolytic
activities are observed in strains that have higher acidifying activities (Delgado et al.,
2002). Conversely, it has also been suggested that no relationship exists between the
proteolytic and acidifying activities of E. faecalis strains where strains can exhibit strong
acidifying and low proteolytic, weak acidifying and high proteolytic or weak acidifying
and low proteolytic activities (Durlu-Ozkaya et al., 2001). Although it initially appeared
that the strains exhibiting higher levels of proteolytic activity were also those which
showed high acidifying activities, a statistically insignificant correlation was found
between the data after fermentation for 20 h (P > 0.05, Fig. A2.6). Similarly, after 48 h
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fermentation, no correlation was observed between proteolytic and acidifying activities
(P > 0.05, data not shown). Therefore, based on these results and the findings of previous
studies, the precise role of acid production on levels of proteolysis among E. faecalis
isolates remains largely unknown and further work is required. As previously suggested,
this may involve a larger sample of E. faecalis isolates from different habitats and
monitoring levels of acid production and proteolytic activity at more time points during
fermentation.

Figure A2.6. Scatterplot depicting the relationship between degree of protein hydrolysis
(%), determined by the OPA assay, and pH for the Enterococcus faecalis bovine skim
milk fermentates after 20 h growth at 37 °C.

GelE sequence analysis
The gelE gene of a selection of E. faecalis isolates utilised in this study was sequenced
with the aim of comparing the translated amino sequences across isolates to determine
the potential implications of any differences in the sequences on levels of proteolytic
activity observed during growth of the isolates in BSM. The gelE gene of E. faecalis
ATCC29212 was obtained from GenBank and translated into the gelatinase protein
sequence as a point of reference and means of control. In this work, the gelE gene of
ATCC29212 from our collection of cultures was also sequenced for comparative
purposes. The gelE gene sequences obtained from the GenBank database were highly
conserved (data not shown). Therefore, we suspected that the gelE gene sequences and
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subsequent amino acid sequences among our isolates would also be highly conserved,
and that any changes at the amino acid level may have alluded to potential implications
on the varying levels of proteolytic activity. To achieve this, we sequenced the gelE gene
of three isolates which were considered highly proteolytic (DPC5154, ST02 and
DPC4784) and three isolates considered weakly proteolytic (PK02, RC11 and DPC5237).
Although the beginning of the gelatinase sequences appears highly conserved, several
differences in amino acid sequences were observed towards the latter half of the protein
sequence (Fig A2.6). It was also expected that both ATCC29212 amino acid sequences
would be identical, but differences were also observed between the reference sequence
and the sequence obtained from the isolate in our culture collection. Therefore, it appears
there may have been errors in the sequencing reaction at the genetic level. Consequently,
we could not draw any significant conclusions from the sequence data obtained from
GATC. Admittedly, inferring any real conclusions regarding variation in the proteolytic
activity among the isolates based on single or multiple differences in the amino acid
sequences would prove rather difficult, but may provide some insight as to why
proteolysis is a strain-to-strain dependent trait. Future work should entail sequencing of
the E. faecalis genomes to accurately determine the gelE sequences in order to gain a
better understanding of the gelE gene encoding gelatinase and its conservation across
isolates.
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Figure A2.7. Alignment of the gelatinase amino acid sequences translated from the gelE
gene sequences as determined by GATC. Alignments show the gelatinase amino acid
sequences from a selection of E. faecalis isolates utilised in this work. The gelatinase
protein sequence of E. faecalis ATCC29212 obtained from the GenBank database
(referenceATCC29212) was included as a point of reference and measure of control.
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CONCLUSION
Because both the degree of protein hydrolysis and subsequent protein concentration of
the milk fermentates varied among the isolates, the findings in this work agree with the
current literature that proteolytic activity among enterococci is very much strain-specific.
Although higher levels of proteolytic activity were observed among the isolates after 48
h fermentation compared to 20 h, it was previously determined that the peptide profile of
E. faecalis milk fermentates after 48 h was not significantly different from that observed
after 24 h and that most of the peptides are released within the first 24 hours of growth
(Gútiez et al., 2014). Considering that extended fermentation times involve higher energy
and economical expenses and increase the risk of microbial contamination, the growth of
E. faecalis in bovine skim milk (BSM) for 20 h may be considered satisfactory for the
release of potential bioactive peptides from BSM. Subsequently, in this thesis, milk
fermentations were performed for 20 h.

Interestingly, because a higher cell count was correlated with a higher degree of
proteolysis after 20 h fermentation, it may be considered that cell growth directly effects
levels of proteolytic activity in E. faecalis isolates, likely due to increased levels of GBAP
and subsequent upregulation of the fsrABCD operon and expression of gelE. However,
this was somewhat disproved after 48 h growth, where no significant correlation was
observed between cell growth and levels of proteolysis.

Similarly, the pH of the milk following fermentation at both 20 h and 48 h was statistically
shown to play no significant role in the varying levels of proteolytic activity among the
isolates. Nevertheless, cell growth, acidifying ability, and proteolytic activity should be
examined with a larger number of E. faecalis isolates from different environments in
order to achieve a greater understanding of the impact of cell count and pH on proteolytic
activity. Evidently, further work is required to fully elucidate the proteolytic nature of
enterococci.
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Table A3.1. Antibiotic susceptibility profile of the 25 Enterococcus faecalis isolatesa
Strain

Chloramphenicol

Ciprofloxacin

Erythromycin

Ampicillin

Vancomycin

Streptomycin

Gentamicin

Penicillin

Tetracycline

Teicoplanin

Rifampicin

M10

25.0

21.5

21.0

26.8

19.0

0.0

24.5

21.3

8.8

20.7

19.8

M14

24.3

22.8

19.8

26.3

22.3

0.0

25.8

22.7

8.7

20.7

19.7

ST01

24.0

19.8

19.7

26.3

19.2

19.5

24.3

20.5

0.0

20.2

16.7

ST02

24.8

19.0

21.0

26.0

19.0

19.2

21.2

22.3

25.7

19.3

16.3

RC01

25.5

20.5

21.8

25.8

19.2

20.8

24.0

22.7

9.5

20.5

17.8

RC11

28.0

20.7

22.5

28.5

20.5

19.2

21.2

24.3

30

21.7

17.0

RC17

25.2

22.3

21.2

27.0

19.0

19.2

22.0

22.0

26.7

20.5

20.0

BR01

26.2

24.2

22.8

29.7

21.5

20.8

22.0

24.2

27.3

21.3

19.7

BF02

24.7

21.5

24.5

26.7

20.8

19.5

22.5

22.3

27.2

19.2

31.3

TK01

26.8

22.5

20.8

28.0

19.8

18.0

20.8

22.0

8.8

20.2

17.3

TK02

24.0

0.0

10.3

26.5

18.7

19.3

20.2

22.0

0.0

20.8

19.7

CK01

10.3

22.0

0.0

26.0

18.3

19.8

23.0

22.7

0.0

19.2

20.8

PK02

10.3

22.0

8.5

27.2

19.5

18.8

21.7

22.5

0.0

18.0

22.2

PK07

25.3

21.8

20.7

29.0

20.0

21.0

23.5

22.7

14.3

19.7

21.0

DPC5173

25.5

29.7

28.8

28.7

21.3

20.3

24.3

24.0

27.5

21.3

17.8

DPC5237

10.7

21.5

0.0

27.3

19.5

0.0

20.3

22.3

8.2

19.2

19.5

DPC4996

27.8

22.0

17.7

28.7

19.8

9.2

19.7

23.5

9.2

22.7

20.0

DPC4995

26.5

23.3

20.0

27.8

20.2

0.0

20.0

21.8

8.7

21.5

22.0

DPC810

26.0

22.5

26.2

26.7

19.8

23.0

25.7

22.8

26.7

20.7

20.5

DPC5154

27.5

21.3

25.5

27.2

19.8

20.3

24.7

22.7

26.0

21.7

20.0

DPC5802

9.7

24.0

0.0

26.8

20.0

0.0

24.3

22.5

8.5

20.7

20.8

DPC5083

25.0

25.7

20.0

28.5

21.0

8.0

22.0

21.8

9.2

21.7

22.3

DPC4784

29.0

20.7

26.5

37.3

25.7

25.3

28.0

34.7

29.7

23.0

31.3

DPC4787

10.8

22.0

0.0

26.0

19.3

0.0

23.5

22.5

0.0

19.3

17.2

DPC5209

11.5

22.3

0.0

26.3

19.7

0.0

23.2

22.5

0.0

19.2

19.0

a

Zones of inhibition (mm) against the tested antibiotics. Data is representative of the mean of triplicate experiments.
Colour coding: Green denotes complete sensitivity, Red denotes complete resistance and Yellow denotes intermediate sensitivity to the tested antibiotics based on CLSI
guidelines.
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Figure A3.1. The following figures depict the antibiotic susceptibility testing of the 25
Enterococcus faecalis isolates utilised in this study. Antibiotics: Ampicillin (AMP), Vancomycin
(VA), Streptomycin (S), Ciprofloxacin (CIP), Gentamicin (CN), Rifampicin (RD), Penicillin (P),
Teicoplanin (TEC), Tetracycline (TE), Erythromycin (E) and Chloramphenicol (C). Sensitivity
testing to the 11 antibiotics was performed in triplicate. Figures are representative of one
independent experiment for each strain
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Figure A3.2.1-13. Agarose gel electrophoresis figures depicting the amplicons
generated from the DNA of the 25 Enterococcus faecalis isolates using the virulence
gene primers as outlined in Table 3.3, Chapter III.

Figure A3.2.1. Agarose gel electrophoresis of amplicons generated from E. faecalis DNA
utilising the cob primer set. M: Molecular weight marker (HyperLadder 1Kb); L1: ATCC29212
L2: CK01; L3: TK01; L4: TK02; L5:PK02; L6: PK07; L7: ST02; L8: BF02; L9: BR01; L10:
RC01; L11: M14; L12: M10; L13: RC11; L14: DPC4996; L15: DPC5173; L16: DPC5083; L17:
DPC4995; L18: DPC5237; L19: DPC5209; L20: DPC5802; L21: DPC4784; L22: RC17; L23:
DPC810; L24: DPC4787; L25: DPC5154; L26: ST01; L27: Blank.

Figure A3.2.2. Agarose gel electrophoresis of amplicons generated from E. faecalis DNA
utilising the cpd primer set. M: Molecular weight marker (HyperLadder 1Kb); L1: ATCC29212
L2: CK01; L3: TK01; L4: TK02; L5:PK02; L6: PK07; L7: ST02; L8: BF02; L9: BR01; L10:
RC01; L11: M14; L12: M10; L13: RC11; L14: DPC4996; L15: DPC5173; L16: DPC5083; L17:
DPC4995; L18: DPC5237; L19: DPC5209; L20: DPC5802; L21: DPC4784; L22: RC17; L23:
DPC810; L24: DPC4787; L25: DPC5154; L26: ST01; L27: Blank.
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Figure A3.2.3. Agarose gel electrophoresis of amplicons generated from E. faecalis DNA
utilising the cad primer set. M: Molecular weight marker (HyperLadder 1Kb); L1: ATCC29212
L2: CK01; L3: TK01; L4: TK02; L5:PK02; L6: PK07; L7: ST02; L8: BF02; L9: BR01; L10:
RC01; L11: M14; L12: M10; L13: RC11; L14: DPC4996; L15: DPC5173; L16: DPC5083; L17:
DPC4995; L18: DPC5237; L19: DPC5209; L20: DPC5802; L21: DPC4784; L22: RC17; L23:
DPC810; L24: DPC4787; L25: DPC5154; L26: ST01; L27: Blank.

Figure A3.2.4. Agarose gel electrophoresis of amplicons generated from E. faecalis DNA
utilising the ccf primer set. M: Molecular weight marker (HyperLadder 100bp); L1: PK07; L2:
ST01; L3: RC01; L4: RC11; L5: RC17; L6: TK01; L7: TK02; L8: ST02; L9: DPC5237; L10:
DPC4995; L11: BF02; L12: PK02; L13: BR01; L14: CK01; L15: M14; L16: M10; L17:
DPC1144; L18: DPC4996; L19: DPC5802; L20: DPC4784; L21: DPC4787; L22: DPC5154;
L23: DPC810; L24: DPC5209; L25: DPC5083; L26: DPC5173; L27: P4; L28: V583; L29:
Blank
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Figure A3.2.5. Agarose gel electrophoresis of amplicons generated from E. faecalis DNA
utilising the efaAfs primer set. M: Molecular weight marker (HyperLadder 1Kb); L1:
ATCC29212 L2: CK01; L3: TK01; L4: TK02; L5:PK02; L6: PK07; L7: ST02; L8: BF02; L9:
BR01; L10: RC01; L11: M14; L12: M10; L13: RC11; L14: DPC4996; L15: DPC5173; L16:
DPC5083; L17: DPC4995; L18: DPC5237; L19: DPC5209; L20: DPC5802; L21: DPC4784;
L22: RC17; L23: DPC810; L24: DPC4787; L25: DPC5154; L26: ST01; L27: Blank.

Figure A3.2.6. Agarose gel electrophoresis of amplicons generated from E. faecalis DNA
utilising the cylA primer set. M: Molecular weight marker (HyperLadder 100bp); L1: DPC5237
L2: DPC1144; L3: ATCC29212; L4: DPC4787; L5: DPC4784; L6: DPC5154; L7: DPC5173;
L8: DPC4995; L9: DPC4996; L10: DPC5802; L11: DPC810; L12: DPC5083; L13: DPC5209;
L14: RC17; L15: RC11; L16: BF02; L17: TK02; L18: TK01; L19: M14; L20: M10; L21: PK07;
L22: ST01; L23: RC01; L24: PK02; L25: CK01; L26: ST02; L27: BR01; L28: Blank
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Figure A3.2.7. Agarose gel electrophoresis of amplicons generated from E. faecalis DNA
utilising the cylB primer set. M: Molecular weight marker (HyperLadder 100bp); L1: DPC5237
L2: DPC1144; L3: ATCC29212; L4: DPC4787; L5: DPC4784; L6: DPC5154; L7: DPC5173;
L8: DPC4995; L9: DPC4996; L10: DPC5802; L11: DPC810; L12: DPC5083; L13: DPC5209;
L14: RC17; L15: RC11; L16: BF02; L17: TK02; L18: TK01; L19: M14; L20: M10; L21: PK07;
L22: ST01; L23: RC01; L24: PK02; L25: CK01; L26: ST02; L27: BR01; L28: Blank

Figure A3.2.8. Agarose gel electrophoresis of amplicons generated from E. faecalis DNA
utilising the cylM primer set. M: Molecular weight marker (HyperLadder 100bp); L1: DPC5237
L2: DPC1144; L3: ATCC29212; L4: DPC4787; L5: DPC4784; L6: DPC5154; L7: DPC5173;
L8: DPC4995; L9: DPC4996; L10: DPC5802; L11: DPC810; L12: DPC5083; L13: DPC5209;
L14: RC17; L15: RC11; L16: BF02; L17: TK02; L18: TK01; L19: M14; L20: M10; L21: PK07;
L22: ST01; L23: RC01; L24: PK02; L25: CK01; L26: ST02; L27: BR01; L28: Blank
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Figure A3.2.9. Agarose gel electrophoresis of amplicons generated from E. faecalis DNA
utilising the esp primer set. M: Molecular weight marker (HyperLadder 100bp); L1: PK07 L2:
ST01; L3: RC01; L4: RC11; L5: RC17; L6: TK01; L7: TK02; L8: ST02; L9: DPC5237; L10:
DPC4995; L11: BF02; L12: PK02; L13: BR01; L14: CK01; L15: M14; L16: M10; L17:
DPC5209; L18: DPC4996; L19: DPC5802; L20: DPC4784; L21: DPC4787; L22: DPC5154;
L23: DPC810; L24: DPC5083; L25: DPC5173; L26: G7; L27: F19190.

Figure A3.2.10. Agarose gel electrophoresis of amplicons generated from E. faecalis DNA
utilising the agg primer set. M: Molecular weight marker (HyperLadder 100bp); L1: PK07 L2:
ST01; L3: RC01; L4: RC11; L5: RC17; L6: TK01; L7: TK02; L8: ST02; L9: DPC5237; L10:
DPC4995; L11: BF02; L12: PK02; L13: BR01; L14: CK01; L15: M14; L16: M10; L17:
DPC5209; L18: DPC4996; L19: DPC5802; L20: DPC4784; L21: DPC4787; L22: DPC5154;
L23: DPC810; L24: DPC5083; L25: DPC5173; L26: V583; L27: ATCC29212; L28: Blank.
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Figure A3.2.11. Agarose gel electrophoresis of amplicons generated from E. faecalis DNA
utilising the hyl primer set. M: Marker (HyperLadder 25bp); L1: PK07 L2: ST01; L3: RC01;
L4: RC11; L5: RC17; L6: TK01; L7: TK02; L8: ST02; L9: DPC5237; L10: DPC4995; L11:
BF02; L12: PK02; L13: BR01; L14: CK01; L15: M14; L16: M10; L17: DPC5209; L18:
DPC4996; L19: DPC5802; L20: DPC4784; L21: DPC4787; L22: DPC5154; L23: DPC810; L24:
DPC5083; L25: DPC5173; L26: G7; L27: ATCC29212; L28: C68; L29: Blank.

Figure A3.2.12. Agarose gel electrophoresis of amplicons generated from E. faecalis DNA
utilising the vanA primer set. M: Molecular weight marker (HyperLadder 100bp); L1: PK07 L2:
ST01; L3: RC01; L4: RC11; L5: RC17; L6: TK01; L7: TK02; L8: ST02; L9: DPC5237; L10:
DPC4995; L11: BF02; L12: PK02; L13: BR01; L14: CK01; L15: M14; L16: M10; L17:
DPC5209; L18: DPC4996; L19: DPC5802; L20: DPC4784; L21: DPC4787; L22: DPC5154;
L23: DPC810; L24: DPC5083; L25: DPC5173; L26: G8; L27: Blank.
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Figure A3.2.13. Agarose gel electrophoresis of amplicons generated from E. faecalis DNA
utilising the vanB primer set. M: Molecular weight marker (HyperLadder 100bp); L1: PK07 L2:
ST01; L3: RC01; L4: RC11; L5: RC17; L6: TK01; L7: TK02; L8: ST02; L9: DPC5237; L10:
DPC4995; L11: BF02; L12: PK02; L13: BR01; L14: CK01; L15: M14; L16: M10; L17:
DPC5209; L18: DPC4996; L19: DPC5802; L20: DPC4784; L21: DPC4787; L22: DPC5154;
L23: DPC810; L24: DPC5083; L25: DPC5173; L26: G7; L27: C68; L28: Blank.
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Assessment of the antimicrobial properties of
Enterococcus faecalis fermented bovine skim milk
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INTRODUCTION
The work in this thesis lends towards the application of E. faecalis isolates in the
development of functional food products. An important consideration in the use of
enterococci in fermented food applications is their role in food preservation, particularly
during cheese production. Therefore, in addition to the bioassays performed in Chapter
IV, the E. faecalis milk fermentates were also assessed for antimicrobial activity to
examine the potential of the 25 isolates to be utilised as protective cultures in food biopreservation.
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MATERIALS AND METHODS
Determination of antimicrobial activity
The antimicrobial activity of the milk fermentates was assessed using an agar well
diffusion assay as previously described (Begley et al., 2009). Briefly, 60ml of agar was
seeded with 150 µl of a culture of the indicator strain grown overnight. Seeded agar was
poured into petri dishes and when set, 8 mm holes were bored with the end of a sterile
glass pipette. 10 µl of sloppy agar (0.75% w/v) was added to each well to prevent
supernatants from seeping underneath the agar base. Once solidified, 80 µl of the E.
faecalis fermented milk supernatant was added to the wells in the agar. Plates were
incubated overnight at 37°C for Escherichia coli ATCC25922, Staphylococcus aureus
CITCCK03, Salmonella enterica CITCCK02, Streptococcus mutans CITCCK15,
Bacillus cereus CITCCK08, Bacillus subtilis ATCC6633 and Listeria innocua
CITCCK16 and 30°C for Lactococcus lactis ATCC19257. Nisin from Lactococcus lactis
(Sigma-Aldrich, Arklow, Co. Wicklow, Ireland) was used as a positive control.
Experiments were performed in triplicate and the mean and standard deviation were
calculated using Microsoft Excel.
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RESULTS AND DISCUSSION
Antimicrobial activity
The antimicrobial activity of the E. faecalis milk fermentates is summarised in Table
A4.1. A narrow inhibitory spectrum towards the indicator organisms was observed
amongst the 25 isolates used in the study. None of the E. faecalis milk fermentates
displayed inhibitory activity towards E. coli, S. aureus, S. enterica, S. mutans, B. cereus
or B. subtilis. Of the 25 isolates analysed, the fermentate of 12 isolates displayed
inhibitory activity against at least one indicator organism. The fermentate of two isolates,
E. faecalis PK07 and E. faecalis DPC5083, demonstrated inhibitory activity towards both
L. innocua and L. lactis. Inhibitory activity ranged from 6.5mm to 15.83mm while the
highest zones of inhibition, 15.33mm and 15.83mm, were observed for the fermentate of
E. faecalis DPC5083 against L. lactis ATCC19257 and L. innocua CITCCK16,
respectively. Because the milk fermentates of the E. faecalis isolates were used to assess
the inhibitory activity towards the indicator microorganisms, it is possible that inhibitory
activity observed in this study may be due to the liberation of antimicrobial milk peptides
during fermentation. However, it may also be attributed to the production of enterococcal
bacteriocins, known as enterocins (outlined in Chapter I), which may have been secreted
during growth resulting in the subsequent presence of these bacteriocins in the milk
fermentates. The supernatant of the E. faecalis milk fermentates was neutralised to a pH
of 7.0 to assess the role of acid production on the observed inhibitory activity. The
inhibitory spectrum of the E. faecalis milk fermentates remained the same (data not
shown), thereby ruling out an acid effect on the inhibition of growth of the indicator
microorganisms.
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Table A4.1. Antimicrobial activity of milk supernatants against indicator strains L. innocua
CITCCK16 and L. lactis ATCC19257.
Inhibition zone (mm)*
Strain

L. innocua CITCCK16

E. faecalis M14
E. faecalis PK07

L. lactis ATCC19257
7.83 ± 0.29

9.67 ± 0.29

9.00 ± 0.00

E. faecalis ST02

6.50 ± 0.00

E. faecalis RC01

8.17 ± 0.29

E. faecalis ST01

8.00 ± 0.50

E. faecalis M10

7.83 ± 1.04

E. faecalis DPC5083

15.83 ± 0.29

15.33 ± 0.29

E. faecalis DPC5209

9.17 ± 0.29

E. faecalis DPC5802

7.83 ± 0.29

E. faecalis DPC4996

9.33 ± 0.29

E. faecalis DPC4787

8.33 ± 0.29

E. faecalis DPC4995

8.67 ± 0.29

*Results represent the mean ± standard deviation of three independent experiments.
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CONCLUSION
The inhibitory activity observed in this study is likely to be peptide in nature, either from
the milk derived fermentates or by bacteriocins produced by the enterococcal strains
during growth. Indeed, the overall aim of Chapter IV was to identify peptides which
displayed health-promoting properties and could subsequently be considered for use in
functional food development. Therefore, the antimicrobial properties of the E. faecalis
milk fermentates were not studied further beyond the supplementary work presented here.
However, while the primary application of bacteriocins has always been in food
preservation, their application in healthcare products is gaining increasing interest and
offers new opportunities for exploration due to antimicrobial resistance towards
conventional antibiotics. Therefore, the antimicrobial properties of E. faecalis milk
fermentates represents an interesting and worthwhile avenue for future research.
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